

Supplementary Information

Lung: Spontaneous

Ahrendt, S.A., Yang, S.C., Wu, L., Westra, W.H., Jen, J., Califano, J.A., and Sidransky, D. (1997) Comparison of oncogene mutation detection and telomerase activity for the molecular staging of non-small cell lung cancer. *Clin Cancer Res*, **3**, 1207-14.

Baksh, F.K., Dacic, S., Finkelstein, S.D., Swalsky, P.A., Raja, S., Sasatomi, E., Luketich, J.D., Fernando, H.C., and Yousem, S.A. (2003) Widespread molecular alterations present in stage I non-small cell lung carcinoma fail to predict tumor recurrence. *Mod Pathol*, **16**, 28-34.

Behn, M., Qun, S., Pankow, W., Havemann, K., and Schuermann, M. (1998) Frequent detection of ras and p53 mutations in brush cytology samples from lung cancer patients by a restriction fragment length polymorphism-based +ACI-enriched PCR+ACI- technique. *Clin Cancer Res*, **4**, 361-71.

Bepler, G. and Garcia-Blanco, M.A. (1994) Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small-cell lung cancer. *Proc Natl Acad Sci U S A*, **91**, 5513-7.

Boldrini, L., Faviana, P., Gisfredi, S., Di Quirico, D., Lucchi, M., Mussi, A., Angeletti, C.A., Baldinotti, F., Fogli, A., Simi, P., Basolo, F., Pingitore, F., and Fontanini, G. (2002) Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer. *Int J Oncol*, **20**, 155-9.

Boyle, J.O., Lonardo, F., Chang, J.H., Klimstra, D., Rusch, V., and Dmitrovsky, E. (2001) Multiple high-grade bronchial dysplasia and squamous cell carcinoma: concordant and discordant mutations. *Clin Cancer Res*, **7**, 259-66.

Brose, M.S., Volpe, P., Feldman, M., Kumar, M., Rishi, I., Guerrero, R., Einhorn, E., Herlyn, M., Minna, J., Nicholson, A., Roth, J.A., Albelda, S.M., Davies, H., Cox, C., Brignell, G., Stephens, P., Futreal, P.A., Wooster, R., Stratton, M.R., and Weber, B.L. (2002) BRAF and RAS mutations in human lung cancer and melanoma. *Cancer Res*, **62**, 6997-7000.

Casey, G., Lopez, M.E., Ramos, J.C., Plummer, S.J., Arboleda, M.J., Shaughnessy, M., Karlan, B., and Slamon, D.J. (1996) DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. *Oncogene*, **13**, 1971-81.

Cline, M.J. and Battifora, H. (1987) Abnormalities of protooncogenes in non-small cell lung cancer. Correlations with tumor type and clinical characteristics. *Cancer*, **60**, 2669-74.

Cooper, C.A., Bubb, V.J., Smithson, N., Carter, R.L., Gledhill, S., Lamb, D., Wyllie, A.H., and Carey, F.A. (1996) Loss of heterozygosity at 5q21 in non-small cell lung cancer: a frequent event but without evidence of apc mutation. *J Pathol*, **180**, 33-7.

Cooper, C.A., Carby, F.A., Bubb, V.J., Lamb, D., Kerr, K.M., and Wyllie, A.H. (1997) The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. *J Pathol*, **181**, 401-4.

D'Amico, D., Carbone, D.P., Johnson, B.E., Meltzer, S.J., and Minna, J.D. (1992) Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer. *Cancer Res*, **52**, 1996-9.

Dai, Y., Morishita, Y., Mase, K., Sato, N., Akaogi, E., Mitsui, T., and Noguchi, M. (2000) Application of the p53 and K-ras gene mutation patterns for cytologic diagnosis of recurrent lung carcinomas. *Cancer*, **90**, 258-63.

Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B.A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.J., Bigner, D.D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J.W., Leung, S.Y., Yuen, S.T., Weber, B.L., Seigler, H.F., Darrow, T.L., Paterson, H., Marais, R., Marshall, C.J., Wooster, R., Stratton, M.R., and Futreal, P.A. (2002) Mutations of the BRAF gene in human cancer. *Nature*, **417**, 949-54.

de Vos, S., Miller, C.W., Takeuchi, S., Gombart, A.F., Cho, S.K., and Koeffler, H.P. (1995) Alterations of CDKN2 (p16) in non-small cell lung cancer. *Genes Chromosomes Cancer*, **14**, 164-70.

Fong, K.M., Biesterveld, E.J., Virmani, A., Wistuba, I., Sekido, Y., Bader, S.A., Ahmadian, M., Ong, S.T., Rassool, F.V., Zimmerman, P.V., Giaccone, G., Gazdar, A.F., and Minna, J.D. (1997) FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. *Cancer Res*, **57**, 2256-67.

Gazzeri, S., Gouyer, V., Vour'ch, C., Brambilla, C., and Brambilla, E. (1998) Mechanisms of p16INK4A inactivation in non small-cell lung cancers. *Oncogene*, **16**, 497-504.

Gouyer, V., Gazzeri, S., Brambilla, E., Bolon, I., Moro, D., Perron, P., Benabid, A.L., and Brambilla, C. (1994) Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrine lung carcinomas. *Int J Cancer*, **58**, 818-24.

Hayashi, N., Sugimoto, Y., Tsuchiya, E., Ogawa, M., and Nakamura, Y. (1994) Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. *Biochem Biophys Res Commun*, **202**, 1426-30.

Hilbe, W., Dlaska, M., Duba, H.C., Dirnhofer, S., Eisterer, W., Oberwasserlechner, F., Mildner, A., Schmid, T., Kuhr, T., and Woll, E. (2003) Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: comparison with immunohistochemistry and clinico-pathological features. *Int J Oncol*, **23**, 1121-6.

Hiyama, K., Ishioka, S., Shirotani, Y., Inai, K., Hiyama, E., Murakami, I., Isobe, T., Inamizu, T., and Yamakido, M. (1995) Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and Rb. *Oncogene*, **10**, 937-44.

Horii, A., Nakatsuru, S., Miyoshi, Y., Ichii, S., Nagase, H., Ando, H., Yanagisawa, A., Tsuchiya, E., Kato, Y., and Nakamura, Y. (1992) Frequent somatic mutations of the APC gene in human pancreatic cancer. *Cancer Res*, **52**, 6696-8.

Husgafvel-Pursiainen, K., Boffetta, P., Kannio, A., Nyberg, F., Pershagen, G., Mukeria, A., Constantinescu, V., Fortes, C., and Benhamou, S. (2000) p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. *Cancer Res*, **60**, 2906-11.

Imai, M.A., Oda, Y., Oda, M., Nakanishi, I., and Kawahara, E. (2004) Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma. *J Cancer Res Clin Oncol*, **130**, 320-6.

Keohavong, P., Mady, H.H., Gao, W.M., Siegfried, J.M., Luketich, J.D., and Melhem, M.F. (2001) Topographic analysis of K- ras mutations in histologically normal lung tissues and tumours of lung cancer patients. *Br J Cancer*, **85**, 235-41.

Kishimoto, Y., Murakami, Y., Shiraishi, M., Hayashi, K., and Sekiya, T. (1992) Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. *Cancer Res*, **52**, 4799-804.

Kotsinas, A., Evangelou, K., Zacharatos, P., Kittas, C., and Gorgoulis, V.G. (2002) Proliferation, but not apoptosis, is associated with distinct beta-catenin expression patterns in non-small-cell lung carcinomas: relationship with adenomatous polyposis coli and G(1)-to S-phase cell-cycle regulators. *Am J Pathol*, **161**, 1619-34.

Kotsinas, A., Gorgoulis, V.G., Zacharatos, P., Mariatos, G., Kokotas, S., Liloglou, T., Ikonomopoulos, J., Zoumpourlis, V., Kyroudi, A., Field, J.K., Asimacopoulos, P.J., and Kittas, C. (2001) Additional characterization of a hexanucleotide polymorphic site in the first intron of human H-ras gene: comparative study of its alterations in non-small cell lung carcinomas and sporadic invasive breast carcinomas. *Cancer Genet Cytogenet*, **126**, 147-54.

Kropveld, A., Rozemuller, E.H., Leppers, F.G., Scheidel, K.C., de Weger, R.A., Koole, R., Hordijk, G.J., Slootweg, P.J., and Tilanus, M.G. (1999) Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100+ACU- of head and neck squamous cell cancers. *Lab Invest*, **79**, 347-53.

Le Calvez, F., Mukeria, A., Hunt, J.D., Kelm, O., Hung, R.J., Taniere, P., Brennan, P., Boffetta, P., Zaridze, D.G., and Hainaut, P. (2005) TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. *Cancer Res*, **65**, 5076-83.

Maeshima, A., Miyagi, A., Hirai, T., and Nakajima, T. (1997) Mucin-producing adenocarcinoma of the lung, with special reference to goblet cell type adenocarcinoma: immunohistochemical observation and Ki-ras gene mutation. *Pathol Int*, **47**, 454-60.

Maeshima, A., Sakamoto, M., and Hirohashi, S. (2002) Mixed mucinous-type and non-mucinous-type adenocarcinoma of the lung: immunohistochemical examination and K-ras gene mutation. *Virchows Arch*, **440**, 598-603.

Mao, L., Hruban, R.H., Boyle, J.O., Tockman, M., and Sidransky, D. (1994) Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. *Cancer Res*, **54**, 1634-7.

Marchetti, A., Buttitta, F., Pellegrini, S., Bertacca, G., Chella, A., Carnicelli, V., Tognoni, V., Filardo, A., Angeletti, C.A., and Bevilacqua, G. (1997) Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. *J Pathol*, **181**, 178-82.

Miller, C.W., Simon, K., Aslo, A., Kok, K., Yokota, J., Buys, C.H., Terada, M., and Koeffler, H.P. (1992) p53 mutations in human lung tumors. *Cancer Res*, **52**, 1695-8.

Murakami, I., Fujiwara, Y., Yamaoka, N., Hiyama, K., Ishioka, S., and Yamakido, M. (1996) Detection of p53 gene mutations in cytopathology and biopsy specimens from patients with lung cancer. *Am J Respir Crit Care Med*, **154**, 1117-23.

Naito, M., Satake, M., Sakai, E., Hirano, Y., Tsuchida, N., Kanzaki, H., Ito, Y., and Mori, T. (1992) Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. *Jpn J Cancer Res*, **83**, 1030-6.

Nakagawa, K., Conrad, N.K., Williams, J.P., Johnson, B.E., and Kelley, M.J. (1995) Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. *Oncogene*, **11**, 1843-51.

Naoki, K., Chen, T.H., Richards, W.G., Sugarbaker, D.J., and Meyerson, M. (2002) Missense mutations of the BRAF gene in human lung adenocarcinoma. *Cancer Res*, **62**, 7001-3.

Neville, E.M., Ellison, G., Kiaris, H., Stewart, M.P., Spandidos, D.A., Fox, J.C., and Field, J.K. (1995) Detection of K-ras mutations in non-small cell lung carcinoma. *Int J Oncol*, **7**, 511-514.

Niklinska, W., Burzykowski, T., Chyczewski, L., Rusin, M.R., Furman, M., Laudanski, J., Chyczewska, E., Sulik, M., and Niklinski, J. (2000) p53 gene mutation and protein expression in operable non-small cell lung cancer in Poland. *Eur J Cancer Prev*, **9**, 81-7.

Ohgaki, H., Kros, J.M., Okamoto, Y., Gaspert, A., Huang, H., and Kurrer, M.O. (2004) APC mutations are infrequent but present in human lung cancer. *Cancer Lett*, **207**, 197-203.

Okamoto, A., Demetrick, D.J., Spillare, E.A., Hagiwara, K., Hussain, S.P., Bennett, W.P., Forrester, K., Gerwin, B., Greenblatt, M.S., Serrano, M., and et al. (1994) p16INK4 mutations and altered expression in human tumors and cell lines. *Cold Spring Harb Symp Quant Biol*, **59**, 49-57.

Okamoto, A., Hussain, S.P., Hagiwara, K., Spillare, E.A., Rusin, M.R., Demetrick, D.J., Serrano, M., Hannon, G.J., Shiseki, M., Zariwala, M., and et, a.l. (1995) Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. *Cancer Res*, **55**, 1448-51.

Onuki, N., Wistuba, I.I., Travis, W.D., Virmani, A.K., Yashima, K., Brambilla, E., Hasleton, P., and Gazdar, A.F. (1999) Genetic changes in the spectrum of neuroendocrine lung tumors. *Cancer*, **85**, 600-7.

Packenham, J.P., Taylor, J.A., White, C.M., Anna, C.H., Barrett, J.C., and Devereux, T.R. (1995) Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers. *Clin Cancer Res*, **1**, 687-90.

Pao, W., Wang, T.Y., Riely, G.J., Miller, V.A., Pan, Q., Ladanyi, M., Zakowski, M.F., Heelan, R.T., Kris, M.G., and Varmus, H.E. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Med*, **2**, 57-61.

Petursdottir, T.E., Hafsteinsdottir, S.H., Jonasson, J.G., Moller, P.H., Thorsteinsdottir, U., Huiping, C., Egilsson, V., and Ingvarsson, S. (2002) Loss of heterozygosity at the FHIT gene in different solid human tumours and its association with survival in colorectal cancer patients. *Anticancer Res*, **22**, 3205-12.

Redondo, M., Rodriguez, F., Hortas, M.L., Concha, A., Morell, M., Garrido, F., and Ruiz-Cabello, F. (1997) Lack of correlation between codon 12 K-ras mutations and major histocompatibility complex antigens in bronchogenic carcinomas. *Cancer Detect Prev*, **21**, 412-7.

Reichel, M.B., Ohgaki, H., Petersen, I., and Kleihues, P. (1994) p53 mutations in primary human lung tumors and their metastases. *Mol Carcinog*, **9**, 105-9.

Ridanpaa, M., Anttila, S., and Husgafvel-Pursiainen, K. (1995) Detection of loss of heterozygosity in the p53 tumor suppressor gene using a PCR-based assay. *Pathol Res Pract*, **191**, 399-402.

Rodenhuis, S., van de Wetering, M.L., Mooi, W.J. , Evers, S.G., van Zandwijk, N., and Bos, J.L. (1987) Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. *N Engl J Med*, **317**, 929-35.

Rosell, R., Molina, F., Moreno, I., Martinez, E., Pifarre, A., Font, A., Li, S., Skacel, Z., Gomez-Codina, J., Camps, C., and et al. (1995) Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. *Lung Cancer*, **12 Suppl 1**, S59-70.

Rosell, R., Monzo, M., Molina, F., Martinez, E., Pifarre, A., Moreno, I., Mate, J.L., de Anta, J.M., Sanchez, M., and Font, A. (1995) K-ras genotypes and prognosis in non-small-cell lung cancer. *Ann Oncol*, **6 Suppl 3**, S15-20.

Rosell, R., Monzo, M., Pifarre, A., Ariza, A., Sanchez, J.J., Moreno, I., Maurel, J., Lopez, M.P., Abad, A., and de Anta, J.M. (1996) Molecular staging of non-small cell lung cancer according to K-ras genotypes.

Clin Cancer Res, **2**, 1083-6.

Rosell, R., Pifarre, A., Monzo, M., Astudillo, J., Lopez-Cabrerizo, M.P., Calvo, R., Moreno, I., Sanchez-Cespedes, M., Font, A., and Navas-Palacios, J.J. (1997) Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors. *Int J Cancer*, **74**, 330-4.

Rosell, R.L.S.A.A.e.al. (1993) Prognostic value of K-ras 12 genotypes in patients with advanced non-small cell lung cancer receiving carboplatin with either intravenous or chronic oral dose etoposide. *Int J Oncol*, **5**, 169-76.

Rusin, M.R., Okamoto, A., Chorazy, M., Czyzewski, K., Harasim, J., Spillare, E.A., Hagiwara, K., Hussain, S.P., Xiong, Y., Demetrick, D.J., and Harris, C.C. (1996) Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. *Int J Cancer*, **65**, 734-9.

Sameshima, Y., Matsuno, Y., Hirohashi, S., Shimosato, Y., Mizoguchi, H., Sugimura, T., Terada, M., and Yokota, J. (1992) Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. *Oncogene*, **7**, 451-7.

Sanchez-Cespedes, M., Decker, P.A., Doffek, K.M., Esteller, M., Westra, W.H., Alawi, E.A., Herman, J.G., Demeure, M.J., Sidransky, D., and Ahrendt, S.A. (2001) Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. *Cancer Res*, **61**, 2092-6.

Sanchez-Cespedes, M., Reed, A.L., Buta, M., Wu, L., Westra, W.H., Herman, J.G., Yang, S.C., Jen, J., and Sidransky, D. (1999) Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. *Oncogene*, **18**, 5843-9.

Sarkar, F.H., Valdivieso, M., Borders, J., Yao, K.L., Raval, M.M., Madan, S.K., Sreepathi, P., Shimoyama, R., Steiger, Z., Visscher, D.W., and et, a.l. (1995) A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue. *Diagn Mol Pathol*, **4**, 266-73.

Sato, H., Hiyama, K., Ishioka, S., Maeda, H., and Yamakido, M. (1999) Alternative splicing, but not allelic loss, of the FHIT gene increases with development of lung cancer. *Int J Oncol*, **15**, 81-8.

Schneider, P.M., Praeuer, H.W., Stoeltzing, O., Boehm, J., Manning, J., Metzger, R., Fink, U., Wegerer, S., Hoelscher, A.H., and Roth, J.A. (2000) Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. *Br J Cancer*, **83**, 473-9.

Shimizu, T. and Sekiya, T. (1995) Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers. *Int J Cancer*, **63**, 616-20.

Shipman, R., Schraml, P., Colombi, M., Raefle, G., Dalquen, P., and Ludwig, C. (1996) Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung cancer. *Eur J Cancer*, **32A**, 335-41.

Siegfried, J.M., Gillespie, A.T., Mera, R., Casey, T.J., Keohavong, P., Testa, J.R., and Hunt, J.D. (1997) Prognostic value of specific KRAS mutations in lung adenocarcinomas. *Cancer Epidemiol Biomarkers Prev*, **6**, 841-7.

Silini, E.M., Bosi, F., Pellegata, N.S., Volpato, G., Romano, A., Nazari, S., Tinelli, C., Ranzani, G.N., Solcia, E., and Fiocca, R. (1994) K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma. *Virchows Arch*, **424**, 367-73.

Slebos, R.J., Habets, G.G., Evers, S.G., Mooi, W.J., and Rodenhuis, S. (1991) Allele-specific detection of

K-ras oncogene expression in human non-small-cell lung carcinomas. *Int J Cancer*, **48**, 51-6.

Slebos, R.J., Kibbelaar, R.E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C.J., Wagenaar, S.S., Vanderschueren, R.G., van Zandwijk, N., Mooi, W.J., and et, a.l. (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. *N Engl J Med*, **323**, 561-5.

Somers, V.A., Leimbach, D.A., Theunissen, P.H., Murtagh, J.J. Jr, Holloway, B., Amberg, A.W. , and Thunnissen, F.B. (1998) Validation of the Point-EXACCT method in non-small cell lung carcinomas. *Clin Chem*, **44**, 1404-9.

Song, L., Yan, W., Deng, M., Song, S., Zhang, J. , and Zhao, T. (2004) Aberrations in the fragile histidine triad(FHIT) gene may be involved in lung carcinogenesis in patients with chronic pulmonary tuberculosis. *Tumour Biol*, **25**, 270-5.

Sozzi, G., Musso, K., Ratcliffe, C., Goldstraw, P., Pierotti, M.A., and Pastorino, U. (1999) Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. *Clin Cancer Res*, **5**, 2689-92.

Sugio, K., Fukuyama, Y., Sakada, T., Nishioka, K., Yamazaki, K., Ushijima, C., Tsukamoto, S., Ishida, T., and Sugimachi, K. (1998) Second primary cancers after resection of lung adenocarcinoma with ras gene mutation. *Anticancer Res*, **18**, 3395-8.

Sunaga, N., Kohno, T., Kolligs, F.T., Fearon, E.R., Saito, R., and Yokota, J. (2001) Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. *Genes Chromosomes Cancer*, **30**, 316-21.

Sundaresan, V., Ganly, P., Hasleton, P., Rudd, R., Sinha, G., Bleehen, N.M., and Rabbitts, P. (1992) p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. *Oncogene*, **7**, 1989-97.

Suzuki, Y., Orita, M., Shiraishi, M., Hayashi, K., and Sekiya, T. (1990) Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. *Oncogene*, **5**, 1037-43.

Takahashi, T., Takahashi, T., Suzuki, H., Hida, T., Sekido, Y., Ariyoshi, Y., and Ueda, R. (1991) The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. *Oncogene*, **6**, 1775-8.

Takebayashi, Y., Nakayama, K., Kanzaki, A., Miyashita, H., Ogura, O., Mori, S., Mutoh, M., Miyazaki, K., Fukumoto, M., and Pommier, Y. (2001) Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors. *Cancer Lett*, **174**, 115-25.

Taniguchi, Y., Gemma, A., Takeda, Y., Takenaka, K., Niitani, H., Kudoh, S., and Shimada, T. (1996) Stability of p53 tumor suppressor gene mutations during the process of metastasis and during chemotherapy. *Lung Cancer*, **14**, 219-28.

Tomizawa, Y., Kohno, T., Fujita, T., Kiyama, M., Saito, R., Noguchi, M., Matsuno, Y., Hirohashi, S., Yamaguchi, N., Nakajima, T., and Yokota, J. (1999) Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. *Oncogene*, **18**, 1007-14.

Top, B., Mooi, W.J., Klaver, S.G., Boerrigter, L., Wisman, P., Elbers, H.R., Visser, S., and Rodenhuis, S. (1995) Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. *Int J Cancer*, **64**, 83-91.

Toyooka, S., Tsukuda, K., Ouchida, M., Tanino, M., Inaki, Y., Kobayashi, K., Yano, M., Soh, J., Kobatake, T., Shimizu, N., and Shimizu, K. (2003) Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. *Oncol Rep*, **10**, 1455-9.

Vachtenheim, J., Horakova, I., and Novotna, H. (1994) Hypomethylation of CCGG sites in the 3' region of H-ras protooncogene is frequent and is associated with H-ras allele loss in non-small cell lung cancer. *Cancer Res*, **54**, 1145-8.

Vachtenheim, J., Horakova, I., Novotna, H., Opaalka, P., and Roubkova, H. (1995) Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. *Clin Cancer Res*, **1**, 359-65.

Vahakangas, K.H., Bennett, W.P., Castren, K., Welsh, J.A., Khan, M.A., Blomeke, B., Alavanja, M.C., and Harris, C.C. (2001) p53 and K-ras mutations in lung cancers from former and never-smoking women. *Cancer Res*, **61**, 4350-6.

van der Sijp, J.R., van Meerbeeck, J.P., Maat, A.P., Zondervan, P.E., Sleddens, H.F., van Geel, A.N., Eggermont, A.M., and Dinjens, W.N. (2002) Determination of the molecular relationship between multiple tumors within one patient is of clinical importance. *J Clin Oncol*, **20**, 1105-14.

van Oijen, M.G., Leppers Vd Straat, F.G., Tilanus, M.G., and Slootweg, P.J. (2000) The origins of multiple squamous cell carcinomas in the aerodigestive tract. *Cancer*, **88**, 884-93.

van Rens, M.T., Eijken, E.J., Elbers, J.R., Lammers, J.W., Tilanus, M.G., and Slootweg, P.J. (2002) p53 mutation analysis for definite diagnosis of multiple primary lung carcinoma. *Cancer*, **94**, 188-96.

Vega, F.J., Iniesta, P., Caldes, T., Sanchez, A., Lopez, J.A., de Juan, C., Diaz-Rubio, E., Torres, A., Balibrea, J.L., and Benito, M. (1997) p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer. *Br J Cancer*, **76**, 44-51.

Wieland, I. and Bohm, M. (1994) Frequent allelic deletion at a novel locus on chromosome 5 in human lung cancer. *Cancer Res*, **54**, 1772-4.

Witschi, H., Oreffo, V.I., and Pinkerton, K.E. (1995) Six-month exposure of strain A/J mice to cigarette sidestream smoke: cell kinetics and lung tumor data. *Fundam Appl Toxicol*, **26**, 32-40.

Yamasaki, M., Takeshima, Y., Fujii, S., Matsuura, M., Tagawa, K., and Inai, K. (2000) Correlation between morphological heterogeneity and genetic alteration within one tumor in adenocarcinomas of the lung. *Pathol Int*, **50**, 891-6.

Yanez, L., Groffen, J., and Valenzuela, D.M. (1987) c-K-ras mutations in human carcinomas occur preferentially in codon 12. *Oncogene*, **1**, 315-8.

Zheng, J., Shu, Q., Li, Z.H., Tsao, J.I., Weiss, L.M., and Shibata, D. (1994) Patterns of p53 mutations in squamous cell carcinoma of the lung. Acquisition at a relatively early age. *Am J Pathol*, **145**, 1444-9.

Lung: Tobacco (smoke)

Ahrendt, S.A., Decker, P.A., Alawi, E.A., Zhu Yr, Y.R., Sanchez-Cespedes, M., Yang, S.C., Haasler, G.B., Kajdacsy-Balla, A., Demeure, M.J., and Sidransky, D. (2001) Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. *Cancer*, **92**, 1525-30.

Andriani, F., Conte, D., Mastrangelo, T., Leon, M., Ratcliffe, C., Roz, L., Pelosi, G., Goldstraw, P., Sozzi, G., and Pastorino, U. (2004) Detecting lung cancer in plasma with the use of multiple genetic markers. *Int J Cancer*, **108**, 91-6.

- Behrens, C., Travis, L.B., Wistuba, I., Davis, S., Maitra, A., Clarke, E.A., Lynch, C.F., Glimelius, B., Wiklund, T., Tarone, R., and Gazdar, A.F. (2000) Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease. *Cancer Epidemiol Biomarkers Prev*, **9**, 1027-35.
- Bongiorno, P.F., Whyte, R.I., Lesser, E.J., Moore, J.H., Orringer, M.B., and Beer, D.G. (1994) Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. *J Thorac Cardiovasc Surg*, **107**, 590-5.
- Brattstrom, D., Bergqvist, M., Lamberg, K., Kraaz, W., Scheibenflug, L., Gustafsson, G., Inganas, M., Wagenius, G., and Brodin, O. (1998) Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry. *Med Oncol*, **15**, 255-61.
- Burke, L., Khan, M.A., Freedman, A.N., Gemma, A., Rusin, M., Guinee, D.G., Bennett, W.P., Caporaso, N.E., Fleming, M.V., Travis, W.D., Colby, T.V., Trastek, V., Pairolero, P.C., Tazelaar, H.D., Midthun, D.E., Liotta, L.A., and Harris, C.C. (1998) Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. *Cancer Res*, **58**, 2533-6.
- Chen, J.T., Chen, Y.C., Wang, Y.C., Tseng, R.C., Chen, C.Y., and Wang, Y.C. (2002) Alterations of the p16(ink4a) gene in resected nonsmall cell lung tumors and exfoliated cells within sputum. *Int J Cancer*, **98**, 724-31.
- Clements, N.C. Jr, Nelson, M.A., Wymer, J.A., Savage, C., Aguirre, M., and Garewal, H. (1995) Analysis of K-ras gene mutations in malignant and nonmalignant endobronchial tissue obtained by fiberoptic bronchoscopy. *Am J Respir Crit Care Med*, **152**, 1374-8.
- de Anta, J.M., Jassem, E., Rosell, R., Martinez-Roca, M., Jassem, J., Martinez-Lopez, E., Monzo, M., Sanchez-Hernandez, J.J., Moreno, I., and Sanchez-Cespedes, M. (1997) TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. *Oncogene*, **15**, 2951-8.
- De Benedetti, V.M., Travis, L.B., Welsh, J.A., van Leeuwen, F.E., Stovall, M., Clarke, E.A., Boice, J.D. Jr, and Bennett, W.P. (1996) p53 mutations in lung cancer following radiation therapy for Hodgkin's disease. *Cancer Epidemiol Biomarkers Prev*, **5**, 93-8.
- De Gregorio, L., Manenti, G., Incarbone, M., Pilotti, S., Pastorino, U., Pierotti, M.A., and Dragani, T.A. (1998) Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma. *Int J Cancer*, **79**, 269-72.
- Eberhard, D.A., Johnson, B.E., Amler, L.C., Goddard, A.D., Heldens, S.L., Herbst, R.S., Ince, W.L., Janne, P.A., Januario, T., Johnson, D.H., Klein, P., Miller, V.A., Ostland, M.A., Ramies, D.A., Sebisjanovic, D., Stinson, J.A., Zhang, Y.R., Seshagiri, S., and Hillan, K.J. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *J Clin Oncol*, **23**, 5900-9.
- Fong, K.M., Zimmerman, P.V., and Smith, P.J. (1995) Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. *Cancer Res*, **55**, 220-3.
- Fong, K.M., Zimmerman, P.V., and Smith, P.J. (1995) Microsatellite instability and other molecular abnormalities in non-small cell lung cancer. *Cancer Res*, **55**, 28-30.
- Fong, K.M., Zimmerman, P.V., and Smith, P.J. (1998) KRAS codon 12 mutations in Australian non-small cell lung cancer. *Aust N Z J Med*, **28**, 184-9.
- Gao, H.G., Chen, J.K., Stewart, J., Song, B., Rayappa, C., Whong, W.Z., and Ong, T. (1997) Distribution of p53 and K-ras mutations in human lung cancer tissues. *Carcinogenesis*, **18**, 473-8.

- Garinis, G.A., Gorgoulis, V.G., Mariatos, G., Zacharatos, P., Kotsinas, A., Liloglou, T., Foukas, P., Kanavaros, P., Kastrinakis, N.G., Vassilakopoulos, T., Vogiatzi, T., Field, J.K., and Kittas, C. (2001) Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs). *J Pathol*, **193**, 55-65.
- Gealy, R., Zhang, L., Siegfried, J.M., Luketich, J.D., and Keohavong, P. (1999) Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. *Cancer Epidemiol Biomarkers Prev*, **8**, 297-302.
- Gessner, C., Kuhn, H., Toepfer, K., Hammerschmidt, S., Schauer, J., and Wirtz, H. (2004) Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients. *Lung Cancer*, **43**, 215-22.
- Gorgoulis, V.G., Zacharatos, P., Kotsinas, A., Liloglou, T., Kyroudi, A., Veslemes, M., Rassidakis, A., Halazonetis, T.D., Field, J.K., and Kittas, C. (1998) Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. *Am J Pathol*, **153**, 1749-65.
- Gorgoulis, V.G., Zacharatos, P., Kotsinas, A., Mariatos, G., Liloglou, T., Vogiatzi, T., Foukas, P., Rassidakis, G., Garinis, G., Ioannides, T., Zoumpourlis, V., Bramis, J., Michail, P.O., Asimacopoulos, P.J., Field, J.K., and Kittas, C. (2000) Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergistic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs). *Mol Med*, **6**, 208-37.
- Graziano, S.L., Gamble, G.P., Newman, N.B., Abbott, L.Z., Rooney, M., Mookherjee, S., Lamb, M.L., Kohman, L.J., and Poiesz, B.J. (1999) Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. *J Clin Oncol*, **17**, 668-75.
- Hashimoto, T., Tokuchi, Y., Hayashi, M., Kobayashi, Y., Nishida, K., Hayashi, S., Ishikawa, Y., Nakagawa, K., Hayashi, J., and Tsuchiya, E. (2000) Different subtypes of human lung adenocarcinoma caused by different etiological factors. Evidence from p53 mutational spectra. *Am J Pathol*, **157**, 2133-41.
- Ho, W.L., Chang, J.W., Tseng, R.C., Chen, J.T., Chen, C.Y., Jou, Y.S., and Wang, Y.C. (2002) Loss of heterozygosity at loci of candidate tumor suppressor genes in microdissected primary non-small cell lung cancer. *Cancer Detect Prev*, **26**, 343-9.
- Holst, V.A., Finkelstein, S., and Yousem, S.A. (1998) Bronchioloalveolar adenocarcinoma of lung: monoclonal origin for multifocal disease. *Am J Surg Pathol*, **22**, 1343-50.
- Hsu, N.Y., Chen, C.Y., Wu, C.H., Liu, T.J., Kwan, P.C., Hsu, C.P., Hsia, J.Y., and Chang, W.T. (1996) Detection of k-ras point mutations in codons 12 and 13 in non-small cell lung cancers. *J Formos Med Assoc*, **95**, 741-5.
- Huang, C., Taki, T., Adachi, M., Konishi, T., Higashiyama, M., and Miyake, M. (1998) Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. *Oncogene*, **16**, 2469-77.
- Huang, C.L., Taki, T., Adachi, M., Konishi, T., Higashiyama, M., Kinoshita, M., Hadama, T., and Miyake, M. (1998) Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. *Int J Oncol*, **12**, 553-63.
- Husgafvel-Pursiainen, K., Boffetta, P., Kannio, A., Nyberg, F., Pershagen, G., Mukeria, A., Constantinescu, V., Fortes, C., and Benhamou, S. (2000) p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. *Cancer Res*, **60**, 2906-11.

- Kawasaki, H., Ogura, T., Yokose, T., Nagai, K., Nishiwaki, Y., and Esumi, H. (2001) p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis. *Hum Pathol*, **32**, 1043-9.
- Kelley, M.J., Nakagawa, K., Conrad, N.K., LeRiche, J., Murray, N., Lee, J.S., Ro, J.Y., Shaw, E.G., Tucker, M.A., and Johnson, B.E. (1996) Genetic analysis of second primary lung cancers in patients surviving small cell lung cancer. *Clin Cancer Res*, **2**, 1103-5.
- Keohavong, P., DeMichele, M.A., Melacrinos, A.C., Landreneau, R.J., Weyant, R.J., and Siegfried, J.M. (1996) Detection of K-ras mutations in lung carcinomas: relationship to prognosis. *Clin Cancer Res*, **2**, 411-8.
- Kern, J.A., Slebos, R.J., Top, B., Rodenhuis, S., Lager, D., Robinson, R.A., Weiner, D., and Schwartz, D.A. (1994) C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. *J Clin Invest*, **93**, 516-20.
- Kondo, K., Umemoto, A., Akimoto, S., Uyama, T., Hayashi, K., Ohnishi, Y., and Monden, Y. (1992) Mutations in the P53 tumour suppressor gene in primary lung cancer in Japan. *Biochem Biophys Res Commun*, **183**, 1139-46.
- Lau, D.H., Yang, B., Hu, R., and Benfield, J.R. (1997) Clonal origin of multiple lung cancers: K-ras and p53 mutations determined by nonradioisotopic single-strand conformation polymorphism analysis. *Diagn Mol Pathol*, **6**, 179-84.
- Law, J.C., Whiteside, T.L., Gollin, S.M., Weissfeld, J., El-Ashmawy, L., Srivastava, S., Landreneau, R.J., Johnson, J.T., and Ferrell, R.E. (1995) Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract. *Clin Cancer Res*, **1**, 763-8.
- Le Calvez, F., Mukeria, A., Hunt, J.D., Kelm, O., Hung, R.J., Taniere, P., Brennan, P., Boffetta, P., Zaridze, D.G., and Hainaut, P. (2005) TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. *Cancer Res*, **65**, 5076-83.
- Lee, L.N., Shew, J.Y., Sheu, J.C., Lee, Y.C., Lee, W.C., Fang, M.T., Chang, H.F., Yu, C.J., Yang, P.C., and Luh, K.T. (1994) Exon 8 mutation of p53 gene associated with nodal metastasis in non-small-cell lung cancer. *Am J Respir Crit Care Med*, **150**, 1667-71.
- Li, S., Rosell, R., Urban, A., Font, A., Ariza, A., Armengol, P., Abad, A., Navas, J.J., and Monzo, M. (1994) K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma. *Lung Cancer*, **11**, 19-27.
- Liloglou, T., Ross, H., Prime, W., Donnelly, R.J., Spandidos, D.A., Gosney, J.R., and Field, J.K. (1997) p53 gene aberrations in non-small-cell lung carcinomas from a smoking population. *Br J Cancer*, **75**, 1119-24.
- Liu, D., Huang, C.L., Kameyama, K., Hayashi, E., Yamauchi, A., Sumitomo, S., and Yokomise, H. (2002) Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients. *Cancer*, **94**, 2239-47.
- Lohmann, D., Putz, B., Reich, U., Bohm, J., Prauer, H., and Hofler, H. (1993) Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. *Am J Pathol*, **142**, 907-15.
- Lung, M.L., Wong, M., Lam, W.K., Lau, K.S., Kwan, S., Fu, K.H., Cheung, H., and Yew, W.W. (1992) Incidence of ras oncogene activation in lung carcinomas in Hong Kong. *Cancer*, **70**, 760-3.

Lung, M.L., Wong, M.P., Skaanild, M.T., Fok, C.L., Lam, W.K., and Yew, W.W. (1996) p53 mutations in non-small cell lung carcinomas in Hong Kong. *Chest*, **109**, 718-26.

Marchetti, A., Buttitta, F., Pellegrini, S., Chella, A., Bertacca, G., Filardo, A., Tognoni, V., Ferrelli, F., Signorini, E., Angeletti, C.A., and Bevilacqua, G. (1996) Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. *J Pathol*, **179**, 254-9.

Marchetti, A., Pellegrini, S., Bertacca, G., Buttitta, F., Gaeta, P., Carnicelli, V., Nardini, V., Griseri, P., Chella, A., Angeletti, C.A., and Bevilacqua, G. (1998) FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations. *J Pathol*, **184**, 240-6.

Marchetti, A., Pellegrini, S., Sozzi, G., Bertacca, G., Gaeta, P., Buttitta, F., Carnicelli, V., Griseri, P., Chella, A., Angeletti, C.A., Pierotti, M., and Bevilacqua, G. (1998) Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. *Br J Cancer*, **78**, 73-8.

Matsuzoe, D., Hidemitsu, T., Iwasaki, A., Yoneda, S., Kawahara, K., Shirakusa, T., and Kimura, A. (2001) Glutathione S-transferase mu1 null genotype is associated with K-ras gene mutation in lung adenocarcinoma among smokers. *Carcinogenesis*, **22**, 1327-30.

Mitsudomi, T., Lam, S., Shirakusa, T., and Gazdar, A.F. (1993) Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. *Chest*, **104**, 362-5.

Nelson, H.H., Christiani, D.C., Mark, E.J., Wiencke, J.K., Wain, J.C., and Kelsey, K.T. (1999) Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. *J Natl Cancer Inst*, **91**, 2032-8.

Noda, N., Matsuzoe, D., Konno, T., Kawahara, K., Yamashita, Y., and Shirakusa, T. (2001) K-ras gene mutations in non-small cell lung cancer in Japanese. *Oncol Rep*, **8**, 889-92.

Noda, N., Matsuzoe, D., Konno, T., Kawahara, K., Yamashita, Y., and Shirakusa, T. (2004) Risk for K-ras gene mutations in smoking-induced lung cancer is associated with cytochrome P4501A1 and glutathione S-transferase micro1 polymorphisms. *Oncol Rep*, **12**, 773-9.

Ohshima, S. and Xu, Y. (1997) p53 gene mutations, and CYP1A1 and GSTM1 genotypes in pulmonary squamous cell carcinomas. *Mol Pathol*, **50**, 108-10.

Pellegrini, S., Bertacca, G., Buttitta, F., Bevilacqua, G., and Marchetti, A. (1999) Lung tumours from non-smoking subjects: A p53-related genetic instability in a subset of cases. *Int J Mol Med*, **4**, 419-24.

Ramirez, J.L., Sarries, C., de Castro, P.L., Roig, B., Queralt, C., Escuin, D., de Aguirre, I., Sanchez, J.M., Manzano, J.L., Margeli, M., Sanchez, J.J., Astudillo, J., Taron, M., and Rosell, R. (2003) Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. *Cancer Lett*, **193**, 207-16.

Ribeiro, U., Safatle-Ribeiro, A.V., Posner, M.C., Rosendale, B., Bakker, A., Swalsky, P.A., Kim, R., Reynolds, J.C., and Finkelstein, S.D. (1996) Comparative p53 mutational analysis of multiple primary cancers of the upper aerodigestive tract. *Surgery*, **120**, 45-53.

Ridanpaa, M., Karjalainen, A., Anttila, S., Vainio, H., and Husgafvel-Pursianinen, K. (1994) Genetic alterations in p53 and K-ras in lung cancer in relation to histopathology of the tumor and smoking history of the patient. *Int J Oncol*, **5**, 1109-1117.

Rodenhuis, S., Slebos, R.J., Boot, A.J., Evers, S.G., Mooi, W.J., Wagenaar, S.S., van Bodegom, P.C., and

- Bos, J.L. (1988) Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. *Cancer Res*, **48**, 5738-41.
- Rodenhuis, S., van de Wetering, M.L., Mooi, W.J., Evers, S.G., van Zandwijk, N., and Bos, J.L. (1987) Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. *N Engl J Med*, **317**, 929-35.
- Rosell, R., Li, S., Skacel, Z., Mate, J.L., Maestre, J., Canela, M., Tolosa, E., Armengol, P., Barnadas, A., and Ariza, A. (1993) Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. *Oncogene*, **8**, 2407-12.
- Rusch, V.W., Reuter, V.E., Kris, M.G., Kurie, J., Miller, W.H. Jr, Nanus, D.M., Albino, A.P., and Dmitrovsky, E. (1992) Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. *J Thorac Cardiovasc Surg*, **104**, 1465-9.
- Sanchez-Cespedes, M., Decker, P.A., Doffek, K.M., Esteller, M., Westra, W.H., Alawi, E.A., Herman, J.G., Demeure, M.J., Sidransky, D., and Ahrendt, S.A. (2001) Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. *Cancer Res*, **61**, 2092-6.
- Sanz-Ortega, J., Saez, M.C., Sierra, E., Torres, A., Balibrea, J.L., Hernando, F., Sanz-Espónera, J., and Merino, M.J. (2001) 3p21, 5q21, and 9p21 allelic deletions are frequently found in normal bronchial cells adjacent to non-small-cell lung cancer, while they are unusual in patients with no evidence of malignancy. *J Pathol*, **195**, 429-34.
- Schlegel, U., Rosenfeld, M.R., Volkenandt, M., Rosenblum, M., Dalmau, J., and Furneaux, H. (1992) p53 gene mutations in primary lung tumors are conserved in brain metastases. *J Neurooncol*, **14**, 93-100.
- Shin, S.W., Breathnach, O.S., Linnoila, R.I., Williams, J., Gillespie, J.W., Kelley, M.J., and Johnson, B.E. (2001) Genetic changes in contralateral bronchioloalveolar carcinomas of the lung. *Oncology*, **60**, 81-7.
- Shiono, S., Omoe, K., and Endo, A. (1996) K-ras gene mutation in sputum samples containing atypical cells and adenocarcinoma cells in the lung. *Carcinogenesis*, **17**, 1683-6.
- Slebos, R.J., Hruban, R.H., Dalesio, O., Mooi, W.J., Offerhaus, G.J., and Rodenhuis, S. (1991) Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. *J Natl Cancer Inst*, **83**, 1024-7.
- Somers, V.A., van Henten, A.M., ten Velde, G.P., Arends, J.W., and Thunnissen, F.B. (1999) Additional value of K-ras point mutations in bronchial wash fluids for diagnosis of peripheral lung tumours. *Eur Respir J*, **13**, 1120-4.
- Sozzi, G., Miozzo, M., Pastorino, U., Pilotto, S., Donghi, R., Giarola, M., De Gregorio, L., Manenti, G., Radice, P., Minoletti, F., and et al. (1995) Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. *Cancer Res*, **55**, 135-40.
- Sozzi, G., Sard, L., De Gregorio, L., Marchetti, A., Musso, K., Buttitta, F., Tornielli, S., Pellegrini, S., Veronese, M.L., Manenti, G., Incarbone, M., Chella, A., Angeletti, C.A., Pastorino, U., Huebner, K., Bevilacqua, G., Pilotto, S., Croce, C.M., and Pierotti, M.A. (1997) Association between cigarette smoking and FHIT gene alterations in lung cancer. *Cancer Res*, **57**, 2121-3.
- Spasova, I., Novotna, H., Vachtenheim, J., Bartosova, H., Patek, J., Hosserova, V., Zatloukal, P., and Kinkor, Z. (2005) Low mutational rate of K-ras codon 12 in singular bronchoscopy specimens in suspected lung cancer. *Neoplasma*, **52**, 255-9.
- Takagi, Y., Koo, L.C., Osada, H., Ueda, R., Kyaw, K., Ma, C.C., Suyama, M., Saji, S., Takahashi, T.,

Tominaga, S., and et, a.l. (1995) Distinct mutational spectrum of the p53 gene in lung cancers from Chinese women in Hong Kong. *Cancer Res*, **55**, 5354-7.

Tokuchi, Y., Hashimoto, T., Kobayashi, Y., Hayashi, M., Nishida, K., Hayashi, S., Imai, K., Nakachi, K., Ishikawa, Y., Nakagawa, K., Kawakami, Y., and Tsuchiya, E. (1999) The expression of p73 is increased in lung cancer, independent of p53 gene alteration. *Br J Cancer*, **80**, 1623-9.

Tokuchi, Y., Kobayashi, Y., Hayashi, S., Hayashi, M., Tanimoto, K., Hashimoto, T., Nishida, K., Ishikawa, Y., Nakagawa, K., Satoh, Y., Yamamoto, M., and Tsuchiya, E. (1999) Abnormal FHIT transcripts found in both lung cancer and normal lung tissue. *Genes Chromosomes Cancer*, **24**, 105-11.

Toledo, G., Sola, J.J., Lozano, M.D., Soria, E., and Pardo, J. (2004) Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer. *Mod Pathol*, **17**, 440-8.

Tseng, J.E., Kemp, B.L., Khuri, F.R., Kurie, J.M., Lee, J.S., Zhou, X., Liu, D., Hong, W.K., and Mao, L. (1999) Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. *Cancer Res*, **59**, 4798-803.

Tzao, C., Tsai, H.Y., Chen, J.T., Chen, C.Y., and Wang, Y.C. (2004) 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer. *Eur J Cancer*, **40**, 2175-83.

Urban, T., Ricci, S., Danel, C., Antoine, M., Kambouchner, M., Godard, V., Lacave, R., and Bernaudin, J.F. (2000) Detection of codon 12 K-ras mutations in non-neoplastic mucosa from bronchial carina in patients with lung adenocarcinomas. *Br J Cancer*, **82**, 412-7.

Urban, T., Ricci, S., Lacave, R., Antoine, M., Kambouchner, M., Capron, F., and Bernaudin, J.F. (1996) Codon 12 Ki-ras mutation in non-small-cell lung cancer: comparative evaluation in tumoural and non-tumoural lung. *Br J Cancer*, **74**, 1051-5.

Vahakangas, K.H., Bennett, W.P., Castren, K., Welsh, J.A., Khan, M.A., Blomeke, B., Alavanja, M.C., and Harris, C.C. (2001) p53 and K-ras mutations in lung cancers from former and never-smoking women. *Cancer Res*, **61**, 4350-6.

van Rees, B.P., Cleton-Jansen, A.M., Cense, H.A. , Polak, M.M., Clement, M.J., Drillenburg, P., van Lanschot, J.J., and Offerhaus, G.J. (2000) Molecular evidence of field cancerization in a patient with 7 tumors of the aerodigestive tract. *Hum Pathol*, **31**, 269-71.

Wang, X., Christiani, D.C., Wiencke, J.K., Fischbein, M., Xu, X., Cheng, T.J., Mark, E., Wain, J.C., and Kelsey, K.T. (1995) Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. *Cancer Epidemiol Biomarkers Prev*, **4**, 543-8.

Wang, Y.C., Chen, C.Y., Chen, S.K., Cherng, S.H., Ho, W.L., and Lee, H. (1998) High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. *Cancer Res*, **58**, 328-33.

Wang, Y.C., Lee, H.S., Chen, S.K., Yang, S.C., and Chen, C.Y. (1998) Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome. *J Cancer Res Clin Oncol*, **124**, 517-22.

Westra, W.H., Baas, I.O., Hruban, R.H., Askin, F.B., Wilson, K., Offerhaus, G.J., and Slebos, R.J. (1996) K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. *Cancer Res*, **56**, 2224-8.

Westra, W.H., Slebos, R.J., Offerhaus, G.J., Goodman, S.N., Evers, S.G., Kensler, T.W., Askin, F.B.,

Rodenhuis, S., and Hruban, R.H. (1993) K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. *Cancer*, **72**, 432-8.

Xinarianos, G., Liloglou, T., Prime, W., Sourvinos, G., Karachristos, A., Gosney, J.R., Spandidos, D.A., and Field, J.K. (2002) p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma. *Int J Cancer*, **101**, 248-52.

Yanagawa, N., Tamura, G., Oizumi, H., Takahashi, N., Shimazaki, Y., and Motoyama, T. (2002) Frequent epigenetic silencing of the p16 gene in non-small cell lung cancers of tobacco smokers. *Jpn J Cancer Res*, **93**, 1107-13.

Yatabe, Y., Konishi, H., Mitsudomi, T., Nakamura, S., and Takahashi, T. (2000) Topographical distributions of allelic loss in individual non-small-cell lung cancers. *Am J Pathol*, **157**, 985-93.

Lung: Unexposed (tobacco)

Ahrendt, S.A., Decker, P.A., Alawi, E.A., Zhu Yr, Y.R., Sanchez-Cespedes, M., Yang, S.C., Haasler, G.B., Kajdacsy-Balla, A., Demeure, M.J., and Sidransky, D. (2001) Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. *Cancer*, **92**, 1525-30.

Bongiorno, P.F., Whyte, R.I., Lesser, E.J., Moore, J.H., Orringer, M.B., and Beer, D.G. (1994) Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. *J Thorac Cardiovasc Surg*, **107**, 590-5.

Brattstrom, D., Bergqvist, M., Lamberg, K., Kraaz, W., Scheibenflug, L., Gustafsson, G., Inganas, M., Wagenius, G., and Brodin, O. (1998) Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry. *Med Oncol*, **15**, 255-61.

Chen, J.T., Chen, Y.C., Wang, Y.C., Tseng, R.C., Chen, C.Y., and Wang, Y.C. (2002) Alterations of the p16(ink4a) gene in resected nonsmall cell lung tumors and exfoliated cells within sputum. *Int J Cancer*, **98**, 724-31.

De Gregorio, L., Manenti, G., Incarbone, M., Pilotti, S., Pastorino, U., Pierotti, M.A., and Dragani, T.A. (1998) Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma. *Int J Cancer*, **79**, 269-72.

Eberhard, D.A., Johnson, B.E., Amler, L.C., Goddard, A.D., Heldens, S.L., Herbst, R.S., Ince, W.L., Janne, P.A., Januario, T., Johnson, D.H., Klein, P., Miller, V.A., Ostland, M.A., Ramies, D.A., Sebisjanovic, D., Stinson, J.A., Zhang, Y.R., Seshagiri, S., and Hillan, K.J. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *J Clin Oncol*, **23**, 5900-9.

Fong, K.M., Zimmerman, P.V., and Smith, P.J. (1995) Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. *Cancer Res*, **55**, 220-3.

Fong, K.M., Zimmerman, P.V., and Smith, P.J. (1998) KRAS codon 12 mutations in Australian non-small cell lung cancer. *Aust N Z J Med*, **28**, 184-9.

Gao, H.G., Chen, J.K., Stewart, J., Song, B., Rayappa, C., Whong, W.Z., and Ong, T. (1997) Distribution of p53 and K-ras mutations in human lung cancer tissues. *Carcinogenesis*, **18**, 473-8.

Garinis, G.A., Gorgoulis, V.G., Mariatos, G., Zacharatos, P., Kotsinas, A., Liloglou, T., Foukas, P., Kanavaros, P., Kastrinakis, N.G., Vassilakopoulos, T., Vogiatzi, T., Field, J.K., and Kittas, C. (2001) Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs). *J Pathol*, **193**, 55-65.

Gealy, R., Zhang, L., Siegfried, J.M., Luketich, J.D., and Keohavong, P. (1999) Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. *Cancer Epidemiol Biomarkers Prev*, **8**, 297-302.

Gorgoulis, V.G., Zacharatos, P., Kotsinas, A., Liloglou, T., Kyroudi, A., Veslemes, M., Rassidakis, A., Halazonetis, T.D., Field, J.K., and Kittas, C. (1998) Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. *Am J Pathol*, **153**, 1749-65.

Gorgoulis, V.G., Zacharatos, P., Kotsinas, A., Mariatos, G., Liloglou, T., Vogiatzi, T., Foukas, P., Rassidakis, G., Garinis, G., Ioannides, T., Zoumpourlis, V., Bramis, J., Michail, P.O., Asimacopoulos, P.J., Field, J.K., and Kittas, C. (2000) Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergistic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs). *Mol Med*, **6**, 208-37.

Hashimoto, T., Tokuchi, Y., Hayashi, M., Kobayashi, Y., Nishida, K., Hayashi, S., Ishikawa, Y., Nakagawa, K., Hayashi, J., and Tsuchiya, E. (2000) Different subtypes of human lung adenocarcinoma caused by different etiological factors. Evidence from p53 mutational spectra. *Am J Pathol*, **157**, 2133-41.

Ho, W.L., Chang, J.W., Tseng, R.C., Chen, J.T., Chen, C.Y., Jou, Y.S., and Wang, Y.C. (2002) Loss of heterozygosity at loci of candidate tumor suppressor genes in microdissected primary non-small cell lung cancer. *Cancer Detect Prev*, **26**, 343-9.

Holst, V.A., Finkelstein, S., and Yousem, S.A. (1998) Bronchioloalveolar adenocarcinoma of lung: monoclonal origin for multifocal disease. *Am J Surg Pathol*, **22**, 1343-50.

Hsu, N.Y., Chen, C.Y., Wu, C.H., Liu, T.J., Kwan, P.C., Hsu, C.P., Hsia, J.Y., and Chang, W.T. (1996) Detection of k-ras point mutations in codons 12 and 13 in non-small cell lung cancers. *J Formos Med Assoc*, **95**, 741-5.

Huang, C., Taki, T., Adachi, M., Konishi, T., Higashiyama, M., and Miyake, M. (1998) Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. *Oncogene*, **16**, 2469-77.

Huang, C.L., Taki, T., Adachi, M., Konishi, T., Higashiyama, M., Kinoshita, M., Hadama, T., and Miyake, M. (1998) Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. *Int J Oncol*, **12**, 553-63.

Kondo, K., Umemoto, A., Akimoto, S., Uyama, T., Hayashi, K., Ohnishi, Y., and Monden, Y. (1992) Mutations in the P53 tumour suppressor gene in primary lung cancer in Japan. *Biochem Biophys Res Commun*, **183**, 1139-46.

Law, J.C., Whiteside, T.L., Gollin, S.M., Weissfeld, J., El-Ashmawy, L., Srivastava, S., Landreneau, R.J., Johnson, J.T., and Ferrell, R.E. (1995) Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract. *Clin Cancer Res*, **1**, 763-8.

Lee, L.N., Shew, J.Y., Sheu, J.C., Lee, Y.C., Lee, W.C., Fang, M.T., Chang, H.F., Yu, C.J., Yang, P.C., and Luh, K.T. (1994) Exon 8 mutation of p53 gene associated with nodal metastasis in non-small-cell lung cancer. *Am J Respir Crit Care Med*, **150**, 1667-71.

Liloglou, T., Ross, H., Prime, W., Donnelly, R.J., Spandidos, D.A., Gosney, J.R., and Field, J.K. (1997) p53 gene aberrations in non-small-cell lung carcinomas from a smoking population. *Br J Cancer*, **75**, 1119-24.

Liu, D., Huang, C.L., Kameyama, K., Hayashi, E., Yamauchi, A., Sumitomo, S., and Yokomise, H. (2002)

Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients. *Cancer*, **94**, 2239-47.

Lung, M.L., Wong, M., Lam, W.K., Lau, K.S., Kwan, S., Fu, K.H., Cheung, H., and Yew, W.W. (1992) Incidence of ras oncogene activation in lung carcinomas in Hong Kong. *Cancer*, **70**, 760-3.

Lung, M.L., Wong, M.P., Skaanild, M.T., Fok, C.L., Lam, W.K., and Yew, W.W. (1996) p53 mutations in non-small cell lung carcinomas in Hong Kong. *Chest*, **109**, 718-26.

Marchetti, A., Buttitta, F., Pellegrini, S., Chella, A., Bertacca, G., Filardo, A., Tognoni, V., Ferreli, F., Signorini, E., Angeletti, C.A., and Bevilacqua, G. (1996) Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. *J Pathol*, **179**, 254-9.

Marchetti, A., Pellegrini, S., Bertacca, G., Buttitta, F., Gaeta, P., Carnicelli, V., Nardini, V., Griseri, P., Chella, A., Angeletti, C.A., and Bevilacqua, G. (1998) FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations. *J Pathol*, **184**, 240-6.

Marchetti, A., Pellegrini, S., Sozzi, G., Bertacca, G., Gaeta, P., Buttitta, F., Carnicelli, V., Griseri, P., Chella, A., Angeletti, C.A., Pierotti, M., and Bevilacqua, G. (1998) Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. *Br J Cancer*, **78**, 73-8.

Matsuzoe, D., Hidemitsu, T., Iwasaki, A., Yoneda, S., Kawahara, K., Shirakusa, T., and Kimura, A. (2001) Glutathione S-transferase mu1 null genotype is associated with K-ras gene mutation in lung adenocarcinoma among smokers. *Carcinogenesis*, **22**, 1327-30.

Nelson, H.H., Christiani, D.C., Mark, E.J., Wiencke, J.K., Wain, J.C., and Kelsey, K.T. (1999) Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. *J Natl Cancer Inst*, **91**, 2032-8.

Noda, N., Matsuzoe, D., Konno, T., Kawahara, K., Yamashita, Y., and Shirakusa, T. (2001) K-ras gene mutations in non-small cell lung cancer in Japanese. *Oncol Rep*, **8**, 889-92.

Noda, N., Matsuzoe, D., Konno, T., Kawahara, K., Yamashita, Y., and Shirakusa, T. (2004) Risk for K-ras gene mutations in smoking-induced lung cancer is associated with cytochrome P4501A1 and glutathione S-transferase micro1 polymorphisms. *Oncol Rep*, **12**, 773-9.

Pellegrini, S., Bertacca, G., Buttitta, F., Bevilacqua, G., and Marchetti, A. (1999) Lung tumours from non-smoking subjects: A p53-related genetic instability in a subset of cases. *Int J Mol Med*, **4**, 419-24.

Ridanpaa, M.Karjalainen, A., Anttila, S., Vainio, H., and Husgafvel-Pursianinen, K. (1994) Genetic alterations in p53 and K-ras in lung cancer in relation to histopathology of the tumor and smoking history of the patient. *Int J Oncol*, **5**, 1109-1117.

Rodenhuis, S., Slebos, R.J., Boot, A.J., Evers, S.G., Mooi, W.J., Wagenaar, S.S., van Bodegom, P.C., and Bos, J.L. (1988) Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. *Cancer Res*, **48**, 5738-41.

Rodenhuis, S., van de Wetering, M.L., Mooi, W.J. , Evers, S.G., van Zandwijk, N., and Bos, J.L. (1987) Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. *N Engl J Med*, **317**, 929-35.

Rusch, V.W., Reuter, V.E., Kris, M.G., Kurie, J., Miller, W.H. Jr, Nanus, D.M., Albino, A.P., and Dmitrovsky, E. (1992) Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. *J*

Thorac Cardiovasc Surg, **104**, 1465-9.

Sanz-Ortega, J., Saez, M.C., Sierra, E., Torres, A., Balibrea, J.L., Hernando, F., Sanz-Espiner, J., and Merino, M.J. (2001) 3p21, 5q21, and 9p21 allelic deletions are frequently found in normal bronchial cells adjacent to non-small-cell lung cancer, while they are unusual in patients with no evidence of malignancy. *J Pathol*, **195**, 429-34.

Shiono, S., Omoe, K., and Endo, A. (1996) K-ras gene mutation in sputum samples containing atypical cells and adenocarcinoma cells in the lung. *Carcinogenesis*, **17**, 1683-6.

Slebos, R.J., Hruban, R.H., Dalesio, O., Mooi, W.J., Offerhaus, G.J., and Rodenhuis, S. (1991) Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. *J Natl Cancer Inst*, **83**, 1024-7.

Sozzi, G., Sard, L., De Gregorio, L., Marchetti, A., Musso, K., Buttitta, F., Tornielli, S., Pellegrini, S., Veronese, M.L., Manenti, G., Incarbone, M., Chella, A., Angeletti, C.A., Pastorino, U., Huebner, K., Bevilaqua, G., Pilotti, S., Croce, C.M., and Pierotti, M.A. (1997) Association between cigarette smoking and FHIT gene alterations in lung cancer. *Cancer Res*, **57**, 2121-3.

Spasova, I., Novotna, H., Vachtenheim, J., Bartosova, H., Patek, J., Hosserova, V., Zatloukal, P., and Kinkor, Z. (2005) Low mutational rate of K-ras codon 12 in singular bronchoscopy specimens in suspected lung cancer. *Neoplasma*, **52**, 255-9.

Takagi, Y., Koo, L.C., Osada, H., Ueda, R., Kyaw, K., Ma, C.C., Suyama, M., Saji, S., Takahashi, T., Tominaga, S., and et, a.l. (1995) Distinct mutational spectrum of the p53 gene in lung cancers from Chinese women in Hong Kong. *Cancer Res*, **55**, 5354-7.

Takeshima, Y., Nishisaka, T., Kawano, R., Kishizuchi, K., Fujii, S., Kitaguchi, S., and Inai, K. (1996) p16/CDKN2 gene and p53 gene alterations in Japanese non-smoking female lung adenocarcinoma. *Jpn J Cancer Res*, **87**, 134-40.

Tokuchi, Y., Hashimoto, T., Kobayashi, Y., Hayashi, M., Nishida, K., Hayashi, S., Imai, K., Nakachi, K., Ishikawa, Y., Nakagawa, K., Kawakami, Y., and Tsuchiya, E. (1999) The expression of p73 is increased in lung cancer, independent of p53 gene alteration. *Br J Cancer*, **80**, 1623-9.

Toledo, G., Sola, J.J., Lozano, M.D., Soria, E., and Pardo, J. (2004) Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer. *Mod Pathol*, **17**, 440-8.

Tzao, C., Tsai, H.Y., Chen, J.T., Chen, C.Y., and Wang, Y.C. (2004) 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer. *Eur J Cancer*, **40**, 2175-83.

Urban, T., Ricci, S., Danel, C., Antoine, M., Kambouchner, M., Godard, V., Lacave, R., and Bernaudin, J.F. (2000) Detection of codon 12 K-ras mutations in non-neoplastic mucosa from bronchial carina in patients with lung adenocarcinomas. *Br J Cancer*, **82**, 412-7.

Wang, X., Christiani, D.C., Wiencke, J.K., Fischbein, M., Xu, X., Cheng, T.J., Mark, E., Wain, J.C., and Kelsey, K.T. (1995) Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. *Cancer Epidemiol Biomarkers Prev*, **4**, 543-8.

Wang, Y.C., Chen, C.Y., Chen, S.K., Cherng, S.H., Ho, W.L., and Lee, H. (1998) High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. *Cancer Res*, **58**, 328-33.

Wang, Y.C., Lee, H.S., Chen, S.K., Yang, S.C., and Chen, C.Y. (1998) Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome. *J Cancer Res Clin Oncol*, **124**, 517-22.

Xinarianos, G., Liloglou, T., Prime, W., Sourvinos, G., Karachristos, A., Gosney, J.R., Spandidos, D.A., and Field, J.K. (2002) p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma. *Int J Cancer*, **101**, 248-52.

Yanagawa, N., Tamura, G., Oizumi, H., Takahashi, N., Shimazaki, Y., and Motoyama, T. (2002) Frequent epigenetic silencing of the p16 gene in non-small cell lung cancers of tobacco smokers. *Jpn J Cancer Res*, **93**, 1107-13.

Yatabe, Y., Konishi, H., Mitsudomi, T., Nakamura, S., and Takahashi, T. (2000) Topographical distributions of allelic loss in individual non-small-cell lung cancers. *Am J Pathol*, **157**, 985-93.

Oral: Spontaneous

Alsner, J., Sorensen, S.B., and Overgaard, J. (2001) TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. *Radiother Oncol*, **59**, 179-85.

Chang, S.E., Bhatia, P., Johnson, N.W., Morgan, P.R., McCormick, F., Young, B., and Hiorns, L. (1991) Ras mutations in United Kingdom examples of oral malignancies are infrequent. *Int J Cancer*, **48**, 409-12.

Chang, Y.S., Lin, Y.J., Tsai, C.N., Shu, C.H., Tsai, M.S., Choo, K.B., and Liu, S.T. (1992) Detection of mutations in the p53 gene in human head and neck carcinomas by single strand conformation polymorphism analysis. *Cancer Lett*, **67**, 167-74.

Chen, Q., Samaranayake, L.P., Zhou, H., and Xiao, L. (2000) Homozygous deletion of the PTEN tumor-suppressor gene is not a feature in oral squamous cell carcinoma. *Oral Oncol*, **36**, 95-9.

Dahse, R., Fiedler, W., von Eggeling, F., Schimmel, B., Koscielny, S., Beleites, E., Claussen, U., and Ernst, G. (1999) P53 genotyping - an effective concept for molecular testing of head and neck cancer? *Int J Mol Med*, **4**, 279-83.

Das, N., Majumder, J., and DasGupta, U.B. (2000) ras gene mutations in oral cancer in eastern India. *Oral Oncol*, **36**, 76-80.

Dawson, C.D., Chang, K.W., and Solt, D.B. (1996) MTS1 gene mutations in archival oral squamous cell carcinomas. *J Oral Pathol Med*, **25**, 541-6.

Erber, R., Conradt, C., Homann, N., Enders, C., Finckh, M., Dietz, A., Weidauer, H., and Bosch, F.X. (1998) TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. *Oncogene*, **16**, 1671-9.

Ganly, I., Soutar, D.S., Brown, R., and Kaye, S.B. (2000) p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy. *Br J Cancer*, **82**, 392-8.

Gasparotto, D., Maestro, R., Barzan, L., Vukosavljevic, T., Doglioni, C., Sulfaro, S., Piccinin, S., and Boiocchi, M. (1995) Recurrences and second primary tumours in the head and neck region: differentiation by p53 mutation analysis. *Ann Oncol*, **6**, 933-9.

Gonzalez, M.V., Pello, M.F., Ablanedo, P., Suarez, C., Alvarez, V., and Coto, E. (1998) Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in squamous cell carcinoma of the head and neck. *J Clin Pathol*, **51**, 520-4.

- Gotte, K., Riedel, F., Neubauer, J., Schafer, C., Coy, J.F., and Hormann, K. (2001) The relationship between allelic imbalance on 17p, p53 mutation and p53 overexpression in head and neck cancer. *Int J Oncol*, **19**, 331-6.
- Guo, Z., Yamaguchi, K., Sanchez-Cespedes, M., Westra, W.H., Koch, W.M., and Sidransky, D. (2001) Allelic losses in OraTest-directed biopsies of patients with prior upper aerodigestive tract malignancy. *Clin Cancer Res*, **7**, 1963-8.
- Hirano, T., Steele, P.E., and Gluckman, J.L. (1991) Low incidence of point mutation at codon 12 of K-ras proto-oncogene in squamous cell carcinoma of the upper aerodigestive tract. *Ann Otol Rhinol Laryngol*, **100**, 597-9.
- Huang, M.F., Chang, Y.C., Liao, P.S., Huang, T.H., Tsay, C.H., and Chou, M.Y. (1999) Loss of heterozygosity of p53 gene of oral cancer detected by exfoliative cytology. *Oral Oncol*, **35**, 296-301.
- Irish, J.C. and Bernstein, A. (1993) Oncogenes in head and neck cancer. *Laryngoscope*, **103**, 42-52.
- Kashiwazaki, H., Tonoki, H., Tada, M., Chiba, I., Shindoh, M., Totsuka, Y., Iggo, R., and Moriuchi, T. (1997) High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. *Oncogene*, **15**, 2667-74.
- Kiaris, H., Spandidos, D.A., Jones, A.S., and Field, J.K. (1994) Loss of heterozygosity and microsatellite instability of the H-ras gene in cancer of the head and neck. *Int J Oncol*, **5**, 579-582.
- Kisielewski, A.E., Xiao, G.H., Liu, S.C., Klein-Szanto, A.J., Novara, M., Sina, J., Bleicher, K., Yeung, R.S., and Goodrow, T.L. (1998) Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck. *Oncogene*, **17**, 83-91.
- Kropveld, A., Rozemuller, E.H., Leppers, F.G., Scheidel, K.C., de Weger, R.A., Koole, R., Hordijk, G.J., Slootweg, P.J., and Tilanus, M.G. (1999) Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100+ACU- of head and neck squamous cell cancers. *Lab Invest*, **79**, 347-53.
- Lazarus, P., Stern, J., Zwiebel, N., Fair, A., Richie, J.P. Jr, and Schantz, S. (1996) Relationship between p53 mutation incidence in oral cavity squamous cell carcinomas and patient tobacco use. *Carcinogenesis*, **17**, 733-9.
- Lee, N.K., Ye, Y.W., Li, X., Schweitzer, C., and Nisen, P.D. (1994) Allelic loss on chromosome 13 can precede histological changes in head and neck cancer. *Int J Oncol*, **5**, 205-210.
- Li, X.J., Murai, M., Koyama, T., Wang, D.Y., and Hashimoto, K. (2000) MDM2 overexpression with alteration of the p53 protein and gene status in oral carcinogenesis. *Jpn J Cancer Res*, **91**, 492-8.
- Mineta, H., Borg, A., Dictor, M., Wahlberg, P., and Wennerberg, J. (1997) Correlation between p53 mutation and cyclin D1 amplification in head and neck squamous cell carcinoma. *Oral Oncol*, **33**, 42-6.
- Nakahara, Y., Shintani, S., Mihara, M., Ueyama, Y., and Matsumura, T. (2001) High frequency of homozygous deletion and methylation of p16(INK4A) gene in oral squamous cell carcinomas. *Cancer Lett*, **163**, 221-8.
- Nunez, F., Dominguez, O., Coto, E., Suarez-Nieto, C., Perez, P., and Lopez-Larrea, C. (1992) Analysis of ras oncogene mutations in human squamous cell carcinoma of the head and neck. *Surg Oncol*, **1**, 405-11.
- Olshan, A.F., Weissler, M.C., Pei, H., Conway, K., Anderson, S., Fried, D.B., and Yarbrough, W.G. (1997) Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and

HPV. *Oncogene*, **14**, 811-8.

Pateromichelakis, S., Lee, G., Langdon, J.D., and Partridge, M. (2000) The FHIT gene in oral squamous cell carcinoma: allelic imbalance is frequent but cDNA aberrations are uncommon. *Oral Oncol*, **36**, 180-8.

Penhallow, J., Steingrimsdottir, H., Elamin, F., Warnakulasuriya, S., Farzaneh, F., Johnson, N., and Tavassoli, M. (1998) p53 alterations and HPV infections are common in oral SCC: p53 gene mutations correlate with the absence of HPV 16-E6 DNA. *Int J Oncol*, **12**, 59-68.

Poi, M.J., Yen, T., Li, J., Song, H., Lang, J.C., Schuller, D.E., Pearl, D.K., Casto, B.C., Tsai, M.D., and Weghorst, C.M. (2001) Somatic INK4a-ARF locus mutations: a significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck. *Mol Carcinog*, **30**, 26-36.

Riedel, F., Gotte, K., Schwalb, J., Schafer, C., and Hormann, K. (2000) Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck. *Acta Otolaryngol*, **120**, 105-11.

Ries, J.C., Schreiner, D., Steininger, H., and Girod, S.C. (1998) p53 mutation and detection of p53 protein expression in oral leukoplakia and oral squamous cell carcinoma. *Anticancer Res*, **18**, 2031-6.

Riese, U., Dahse, R., Fiedler, W., Theuer, C., Koscielny, S., Ernst, G., Beleites, E., Claussen, U., and von Eggeling, F. (1999) Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. *Int J Mol Med*, **4**, 61-5.

Rowley, H., Sherrington, P., Helliwell, T.R., Kinsella, A., and Jones, A.S. (1998) p53 expression and p53 gene mutation in oral cancer and dysplasia. *Otolaryngol Head Neck Surg*, **118**, 115-23.

Rumsby, G., Carter, R.L., and Gusterson, B.A. (1990) Low incidence of ras oncogene activation in human squamous cell carcinomas. *Br J Cancer*, **61**, 365-8.

Sakai, E., Rikimaru, K., Ueda, M., Matsumoto, Y., Ishii, N., Enomoto, S., Yamamoto, H., and Tsuchida, N. (1992) The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. *Int J Cancer*, **52**, 867-72.

Sakai, E. and Tsuchida, N. (1992) Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. *Oncogene*, **7**, 927-33.

Sakata, K. (1996) Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma. *J Oral Pathol Med*, **25**, 302-7.

Saranath, D., Bhoite, L.T., Mehta, A.R., Sanghavi, V., and Deo, M.G. (1991) Loss of allelic heterozygosity at the harvey ras locus in human oral carcinomas. *J Cancer Res Clin Oncol*, **117**, 484-8.

Sartor, M., Steingrimsdottir, H., Elamin, F., Gaken, J., Warnakulasuriya, S., Partridge, M., Thakker, N., Johnson, N.W., and Tavassoli, M. (1999) Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. *Br J Cancer*, **80**, 79-86.

Scholes, A.G., Liloglou, T., Snijders, P.J., Hart, C.A., Jones, A.S., Woolgar, J.A., Vaughan, E.D., Walboomers, J.M., and Field, J.K. (1997) p53 mutations in relation to human papillomavirus type 16 infection in squamous cell carcinomas of the head and neck. *Int J Cancer*, **71**, 796-9.

Shahnavaz, S.A., Bradley, G., Regezi, J.A., Thakker, N., Gao, L., Hogg, D., and Jordan, R.C. (2001) Patterns of CDKN2A gene loss in sequential oral epithelial dysplasias and carcinomas. *Cancer Res*, **61**, 2371-5.

- Shahnavaz, S.A., Regezi, J.A., Bradley, G., Dube, I.D., and Jordan, R.C. (2000) p53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas. *J Pathol*, **190**, 417-22.
- Shiga, K., Matsuura, K., Tateda, M., Saijo, S., Ogawa, T., Miyagi, T., and Kobayashi, T. (2004) Allelic loss correlated with tissue specificity in head and neck squamous cell carcinomas and the clinical features of patients. *Tohoku J Exp Med*, **204**, 163-72.
- Shiga, K., Ogawa, T., Yoshida, F., Matsuura, K., Tateda, M., Saijo, S., Miyagi, T., and Kobayashi, T. (2003) Multiple squamous cell carcinomas of the head and neck show different phenotypes of allelic loss patterns suggesting different clonal origin of carcinogenesis. *Anticancer Res*, **23**, 3911-5.
- Shintani, S., Nakahara, Y., Mihara, M., Ueyama, Y., and Matsumura, T. (2001) Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. *Oral Oncol*, **37**, 498-504.
- Tabor, M.P., Brakenhoff, R.H., Ruijter-Schippers, H.J., Kummer, J.A., Leemans, C.R., and Braakhuis, B.J. (2004) Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. *Clin Cancer Res*, **10**, 3607-13.
- Tabor, M.P., Brakenhoff, R.H., Ruijter-Schippers, H.J., Van Der Wal, J.E., Snow, G.B., Leemans, C.R., and Braakhuis, B.J. (2002) Multiple head and neck tumors frequently originate from a single preneoplastic lesion. *Am J Pathol*, **161**, 1051-60.
- Tabor, M.P., van Houten, V.M., Kummer, J.A., Vosjan, M.J., Vlasblom, R., Snow, G.B., Leemans, C.R., Braakhuis, B.J., and Brakenhoff, R.H. (2002) Discordance of genetic alterations between primary head and neck tumors and corresponding metastases associated with mutational status of the TP53 gene. *Genes Chromosomes Cancer*, **33**, 168-77.
- Tandle, A.T., Sanghvi, V., and Saranath, D. (2001) Determination of p53 genotypes in oral cancer patients from India. *Br J Cancer*, **84**, 739-42.
- Temam, S., Trassard, M., Leroux, G., Bosq, J., Luboinski, B., Lenoir, G., Benard, J., and Janot, F. (2003) Cytology vs molecular analysis for the detection of head and neck squamous cell carcinoma in oesopharyngeal brush samples: a prospective study in 56 patients. *Br J Cancer*, **88**, 1740-5.
- Tjebbes, G.W., Leppers vd Straat, F.G., Tilanus, M.G., Hordijk, G.J., and Slootweg, P.J. (1999) p53 tumor suppressor gene as a clonal marker in head and neck squamous cell carcinoma: p53 mutations in primary tumor and matched lymph node metastases. *Oral Oncol*, **35**, 384-9.
- Tsai, C.H., Yang, C.C., Chou, L.S., and Chou, M.Y. (2001) The correlation between alteration of p16 gene and clinical status in oral squamous cell carcinoma. *J Oral Pathol Med*, **30**, 527-31.
- Tsuchiya, R., Yamamoto, G., Nagoshi, Y., Aida, T., Irie, T., and Tachikawa, T. (2004) Expression of adenomatous polyposis coli (APC) in tumorigenesis of human oral squamous cell carcinoma. *Oral Oncol*, **40**, 932-40.
- Tsurusako, S., Tanaka, H., Hayashi, Y., Tohnai, I., Ueda, M., and Ishizaki, K. (2002) Low incidence of p53 mutations in well-differentiated tongue squamous cell carcinoma in Japan. *Jpn J Clin Oncol*, **32**, 327-31.
- Uzawa, K., Yoshida, H., Suzuki, H., Tanzawa, H., Shimazaki, J., Seino, S., and Sato, K. (1994) Abnormalities of the adenomatous polyposis coli gene in human oral squamous-cell carcinoma. *Int J Cancer*, **58**, 814-7.
- Uzawa, K., Suzuki, H., Yokoe, H., Tanzaura, H., and Sato, K. (1995) Mutational state of p16/CDKN2 and VHL genes in squamous cell carcinoma of the oral cavity. *Int J Oncology*, **7**, 895-899.

- van Rensburg, E.J., Engelbrecht, S., van Heerden, W.F., Kotze, M.J., and Raubenheimer, E.J. (1998) Detection of p53 gene mutations in oral squamous cell carcinomas of a black African population sample. *Hum Mutat*, **11**, 39-44.
- Viswanathan, M., Tsuchida, N., and Shanmugam, G. (2001) Selective deletion of p14(ARF) exon 1beta of the INK4a locus in oral squamous cell carcinomas of Indians. *Oral Oncol*, **37**, 341-4.
- Warnakulasuriya, K.A., Chang, S.E., and Johnson, N.W. (1992) Point mutations in the Ha-ras oncogene are detectable in formalin-fixed tissues of oral squamous cell carcinomas, but are infrequent in British cases. *J Oral Pathol Med*, **21**, 225-9.
- Weber, A., Bellmann, U., Bootz, F., Wittekind, C., and Tannapfel, A. (2002) INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck. *Virchows Arch*, **441**, 133-42.
- Weber, A., Langhanki, L., Sommerer, F., Markwarth, A., Wittekind, C., and Tannapfel, A. (2003) Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. *Oncogene*, **22**, 4757-9.
- Wiest, T., Schwarz, E., Enders, C., Flechtenmacher, C., and Bosch, F.X. (2002) Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. *Oncogene*, **21**, 1510-7.
- Yakushiji, T., Noma, H., Shibahara, T., Arai, K., Yamamoto, N., Tanaka, C., Uzawa, K., and Tanzawa, H. (2001) Analysis of a role for p16/CDKN2 expression and methylation patterns in human oral squamous cell carcinoma. *Bull Tokyo Dent Coll*, **42**, 159-68.
- Yamazaki, Y., Chiba, I., Hirai, A., Notani, K., Kashiwazaki, H., Tei, K., Totsuka, Y., Iizuka, T., Kohgo, T., and Fukuda, H. (2003) Radioresistance in oral squamous cell carcinoma with p53 DNA contact mutation. *Am J Clin Oncol*, **26**, e124-9.
- Yamazaki, Y., Chiba, I., Hirai, A., Satoh, C., Sakakibara, N., Notani, K., Iizuka, T., and Totsuka, Y. (2005) Clinical value of genetically diagnosed lymph node micrometastasis for patients with oral squamous cell carcinoma. *Head Neck*, **27**, 676-81.
- Yamazaki, Y., Chiba, I., Hirai, A., Sugiura, C., Notani, K., Kashiwazaki, H., Tei, K., Totsuka, Y., and Fukuda, H. (2003) Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma. *Oral Oncol*, **39**, 163-9.
- Yeh, K.T., Chang, J.G., Lin, T.H., Wang, Y.F., Chang, J.Y., Shih, M.C., and Lin, C.C. (2003) Correlation between protein expression and epigenetic and mutation changes of Wnt pathway-related genes in oral cancer. *Int J Oncol*, **23**, 1001-7.
- Yeadall, W.A., Torrance, L.K., Elsegood, K.A., Speight, P., Scully, C., and Prime, S.S. (1993) Ras gene point mutation is a rare event in premalignant tissues and malignant cells and tissues from oral mucosal lesions . *Eur J Cancer B Oral Oncol*, **1**, 63-7.
- Yokoyama, J., Shiga, K., Sasano, H., Suzuki, M., and Takasaka, T. (1996) Abnormalities and the implication of retinoblastoma locus and its protein product in head and neck cancers. *Anticancer Res*, **16**, 641-4.
- Oral: Tobacco (smoke)**
- Chaves, A.C., Cherubini, K., Herter, N., Furian, R., Santos, D.S., Squier, C., and Domann, F.E. (2004) Characterization of p53 gene mutations in a Brazilian population with oral squamous cell carcinomas. *Int J Oncol*, **24**, 295-303.

Dai, M., Clifford, G.M., le Calvez, F., Castellsague, X., Snijders, P.J., Pawlita, M., Herrero, R., Hainaut, P., and Franceschi, S. (2004) Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. *Cancer Res*, **64**, 468-71.

el-Naggar, A.K., Lai, S., Luna, M.A., Zhou, X.D., Weber, R.S., Goepfert, H., and Batsakis, J.G. (1995) Sequential p53 mutation analysis of pre-invasive and invasive head and neck squamous carcinoma. *Int J Cancer*, **64**, 196-201.

Ibrahim, S.O., Lillehaug, J.R., Johannessen, A.C., Liavaag, P.G., Nilsen, R., and Vasstrand, E.N. (1999) Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigen) in oropharyngeal squamous cell carcinomas. *Oral Oncol*, **35**, 302-13.

Koch, W.M., Boyle, J.O., Mao, L., Hakim, J., Hruban, R.H., and Sidransky, D. (1994) p53 gene mutations as markers of tumor spread in synchronous oral cancers. *Arch Otolaryngol Head Neck Surg*, **120**, 943-7.

Lazarus, P., Stern, J., Zwiebel, N., Fair, A., Richie, J.P. Jr, and Schantz, S. (1996) Relationship between p53 mutation incidence in oral cavity squamous cell carcinomas and patient tobacco use. *Carcinogenesis*, **17**, 733-9.

Matsuda, H., Konishi, N., Hiasa, Y., Hayashi, I., Tsuzuki, T., Tao, M., Kitahori, Y., Yoshioka, N., Kirita, T., and Sugimura, M. (1996) Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. *J Oral Pathol Med*, **25**, 232-8.

Schneider-Stock, R., Mawrin, C., Motsch, C., Boltze, C., Peters, B., Hartig, R., Buhtz, P., Giers, A., Rohrbeck, A., Freigang, B., and Roessner, A. (2004) Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. *Am J Pathol*, **164**, 1233-41.

Sisk, E.A., Soltys, S.G., Zhu, S., Fisher, S.G., Carey, T.E., and Bradford, C.R. (2002) Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. *Head Neck*, **24**, 841-9.

Sorensen, D.M., Lewark, T.M., Haney, J.L., Meyers, A.D., Krause, G., and Franklin, W.A. (1997) Absence of p53 mutations in squamous carcinomas of the tongue in nonsmoking and nondrinking patients younger than 40 years. *Arch Otolaryngol Head Neck Surg*, **123**, 503-6.

Tabor, M.P., Brakenhoff, R.H., van Houten, V.M., Kummer, J.A., Snel, M.H., Snijders, P.J., Snow, G.B., Leemans, C.R., and Braakhuis, B.J. (2001) Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. *Clin Cancer Res*, **7**, 1523-32.

Xu, J., Gimenez-Conti, I.B., Cunningham, J.E., Collet, A.M., Luna, M.A., Lanfranchi, H.E., Spitz, M.R., and Conti, C.J. (1998) Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. *Cancer*, **83**, 204-12.

Oral: Unexposed (tobacco)

Chaves, A.C., Cherubini, K., Herter, N., Furian, R., Santos, D.S., Squier, C., and Domann, F.E. (2004) Characterization of p53 gene mutations in a Brazilian population with oral squamous cell carcinomas. *Int J Oncol*, **24**, 295-303.

Dai, M., Clifford, G.M., le Calvez, F., Castellsague, X., Snijders, P.J., Pawlita, M., Herrero, R., Hainaut, P., and Franceschi, S. (2004) Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. *Cancer Res*, **64**, 468-71.

el-Naggar, A.K., Lai, S., Luna, M.A., Zhou, X.D., Weber, R.S., Goepfert, H., and Batsakis, J.G. (1995)

Sequential p53 mutation analysis of pre-invasive and invasive head and neck squamous carcinoma. *Int J Cancer*, **64**, 196-201.

Ibrahim, S.O., Vasstrand, E.N., Johannessen, A.C., Idris, A.M., Magnusson, B., Nilsen, R., and Lillehaug, J.R. (1999) Mutations of the p53 gene in oral squamous-cell carcinomas from Sudanese dippers of nitrosamine-rich toombak and non-snuff-dippers from the Sudan and Scandinavia. *Int J Cancer*, **81**, 527-34.

Matsuda, H., Konishi, N., Hiasa, Y., Hayashi, I., Tsuzuki, T., Tao, M., Kitahori, Y., Yoshioka, N., Kirita, T., and Sugimura, M. (1996) Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. *J Oral Pathol Med*, **25**, 232-8.

Partridge, M., Kiguwa, S., Emilion, G., Pateromichelakis, S., A'Hern, R., and Langdon, J.D. (1999) New insights into p53 protein stabilisation in oral squamous cell carcinoma. *Oral Oncol*, **35**, 45-55.

Sisk, E.A., Soltys, S.G., Zhu, S., Fisher, S.G., Carey, T.E., and Bradford, C.R. (2002) Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. *Head Neck*, **24**, 841-9.

Tabor, M.P., Brakenhoff, R.H., van Houten, V.M., Kummer, J.A., Snel, M.H., Snijders, P.J., Snow, G.B., Leemans, C.R., and Braakhuis, B.J. (2001) Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. *Clin Cancer Res*, **7**, 1523-32.

Larynx: Tobacco (smoke)

Barnard, D., Lehmann, K., Hoal, E.G., van Helden, P.D., and Victor, T.C. (2003) The spectrum of mutations in TP53 in laryngeal cancer patients from a high-incidence population shows similarities to many of the known mutational hotspots. *Cancer Genet Cytogenet*, **145**, 126-32.

el-Naggar, A.K., Lai, S., Luna, M.A., Zhou, X.D., Weber, R.S., Goepfert, H., and Batsakis, J.G. (1995) Sequential p53 mutation analysis of pre-invasive and invasive head and neck squamous carcinoma. *Int J Cancer*, **64**, 196-201.

Gallo, O., Franchi, A., Chiarelli, I., Porfirio, B., Grande, A., Simonetti, L., Bocciolini, C., and Fini-Storch, O. (1997) Potential biomarkers in predicting progression of epithelial hyperplastic lesions of the larynx. *Acta Otolaryngol Suppl*, **527**, 30-8.

Gottschlich, S., Maune, S., Preugschat, J., Hoffmann, M., Werner, J.A., Maass, J.D., Gorogh, T., Heidorn, K., and Rudert, H. (2000) p53 analysis of laryngeal cancer in exon 4 to 9. *Anticancer Res*, **20**, 2613-6.

Ibrahim, S.O., Lillehaug, J.R., Johannessen, A.C., Liavaag, P.G., Nilsen, R., and Vasstrand, E.N. (1999) Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigen) in oropharyngeal squamous cell carcinomas. *Oral Oncol*, **35**, 302-13.

Maestro, R., Dolcetti, R., Gasparotto, D., Doglioni, C., Pelucchi, S., Barzan, L., Grandi, E., and Boiocchi, M. (1992) High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. *Oncogene*, **7**, 1159-66.

Pavelic, Z.P., Li, Y.Q., Stambrook, P.J., McDonald, J.S., Munck-Wikland, E., Pavelic, K., Dacic, S., Danilovic, Z., Pavelic, L., Mugge, R.E., and et, a.l. (1994) Overexpression of p53 protein is common in premalignant head and neck lesions. *Anticancer Res*, **14**, 2259-66.

Ribeiro, U., Safatle-Ribeiro, A.V., Posner, M.C., Rosendale, B., Bakker, A., Swalsky, P.A., Kim, R., Reynolds, J.C., and Finkelstein, S.D. (1996) Comparative p53 mutational analysis of multiple primary cancers of the upper aerodigestive tract. *Surgery*, **120**, 45-53.

- Ronchetti, D., Neglia, C.B., Cesana, B.M., Carboni, N., Neri, A., Pruner, G., and Pignataro, L. (2004) Association between p53 gene mutations and tobacco and alcohol exposure in laryngeal squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg*, **130**, 303-6.
- Schneider-Stock, R., Mawrin, C., Motsch, C., Boltze, C., Peters, B., Hartig, R., Buhtz, P., Giers, A., Rohrbeck, A., Freigang, B., and Roessner, A. (2004) Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. *Am J Pathol*, **164**, 1233-41.
- Scholes, A.G., Liloglou, T., Snijders, P.J., Hart, C.A., Jones, A.S., Woolgar, J.A., Vaughan, E.D., Walboomers, J.M., and Field, J.K. (1997) p53 mutations in relation to human papillomavirus type 16 infection in squamous cell carcinomas of the head and neck. *Int J Cancer*, **71**, 796-9.
- Sisk, E.A., Soltys, S.G., Zhu, S., Fisher, S.G., Carey, T.E., and Bradford, C.R. (2002) Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. *Head Neck*, **24**, 841-9.
- Suzuki, T., Shidara, K., Hara, F., and Nakajima, T. (1994) High frequency of p53 abnormality in laryngeal cancers of heavy smokers and its relation to human papillomavirus infection. *Jpn J Cancer Res*, **85**, 1087-93.
- Esophagus: Spontaneous**
- An, J.Y., Fan, Z.M., Gao, S.S., Zhuang, Z.H., Qin, Y.R., Li, J.L., He, X., Tsao, G.S., and Wang, L.D. (2005) Loss of heterozygosity in multistage carcinogenesis of esophageal carcinoma at high-incidence area in Henan Province, China. *World J Gastroenterol*, **11**, 2055-60.
- Astori, G., Merluzzi, S., Arzese, A., Brosolo, P., de Pretis, G., Maier, R., Pipan, C., and Botta, G.A. (2001) Detection of human papillomavirus DNA and p53 gene mutations in esophageal cancer samples and adjacent normal mucosa. *Digestion*, **64**, 9-14.
- Audrezet, M.P., Robaszkiewicz, M., Mercier, B., Nousbaum, J.B., Bail, J.P., Hardy, E., Volant, A., Lozac'h, P., Charles, J.F., Goueron, H., and et, a.l. (1993) TP53 gene mutation profile in esophageal squamous cell carcinomas. *Cancer Res*, **53**, 5745-9.
- Audrezet, M.P., Robaszkiewicz, M., Mercier, B., Nousbaum, J.B., Hardy, E., Bail, J.P., Volant, A., Lozac'h, P., Gouerou, H., and Ferec, C. (1996) Molecular analysis of the TP53 gene in Barrett's adenocarcinoma. *Hum Mutat*, **7**, 109-13.
- Bahnassy, A.A., Zekri, A.R., Abdallah, S., El-Shehaby, A.M., and Sherif, G.M. (2005) Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival. *Pathol Int*, **55**, 53-62.
- Barrett, M.T., Sanchez, C.A., Galipeau, P.C., Neshat, K., Emond, M., and Reid, B.J. (1996) Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. *Oncogene*, **13**, 1867-73.
- Bektas, N., Donner, A., Wirtz, C., Heep, H., Gabbert, H.E., and Sarbia, M. (2000) Allelic loss involving the tumor suppressor genes APC and MCC and expression of the APC protein in the development of dysplasia and carcinoma in Barrett esophagus. *Am J Clin Pathol*, **114**, 890-5.
- Bennett, W.P., Hollstein, M.C., He, A., Zhu, S.M., Resau, J.H., Trump, B.F., Metcalf, R.A., Welsh, J.A., Midgley, C., Lane, D.P., and et, a.l. (1991) Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. *Oncogene*, **6**, 1779-84.
- Bennett, W.P., Hollstein, M.C., Metcalf, R.A., Welsh, J.A., He, A., Zhu, S.M., Kusters, I., Resau, J.H., Trump, B.F., Lane, D.P., and et, a.l. (1992) p53 mutation and protein accumulation during multistage

- human esophageal carcinogenesis. *Cancer Res*, **52**, 6092-7.
- Bennett, W.P., von Brevern, M.C., Zhu, S.M., Bartsch, H., Muehlbauer, K.R., and Hollstein, M.C. (1997) p53 mutations in esophageal tumors from a high incidence area of China in relation to patient diet and smoking history. *Cancer Epidemiol Biomarkers Prev*, **6**, 963-6.
- Bian, Y.S., Osterheld, M.C., Bosman, F.T., Benhantar, J., and Fontolliet, C. (2001) p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. *Mod Pathol*, **14**, 397-403.
- Bian, Y.S., Osterheld, M.C., Bosman, F.T., Fontolliet, C., and Benhantar, J. (2000) Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. *Am J Clin Pathol*, **114**, 583-90.
- Bian, Y.S., Osterheld, M.C., Fontolliet, C., Bosman, F.T., and Benhantar, J. (2002) p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. *Gastroenterology*, **122**, 1113-21.
- Biramijamal, F., Allameh, A., Mirbod, P., Groene, H.J., Koomagi, R., and Hollstein, M. (2001) Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran. *Cancer Res*, **61**, 3119-23.
- Blount, P.L., Meltzer, S.J., Yin, J., Huang, Y., Krasna, M.J., and Reid, B.J. (1993) Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. *Proc Natl Acad Sci U S A*, **90**, 3221-5.
- Boynton, R.F., Blount, P.L., Yin, J., Brown, V.L., Huang, Y., Tong, Y., McDaniel, T., Newkirk, C., Resau, J.H., Raskind, W.H., and et, a.l. (1992) Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. *Proc Natl Acad Sci U S A*, **89**, 3385-8.
- Boynton, R.F., Huang, Y., Blount, P.L., Reid, B.J., Raskind, W.H., Haggitt, R.C., Newkirk, C., Resau, J.H., Yin, J., and McDaniel, T. (1991) Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. *Cancer Res*, **51**, 5766-9.
- Breton, J., Sichel, F., Abbas, A., Marnay, J., Arsene, D., and Lechevrel, M. (2003) Simultaneous use of DGGE and DHPLC to screen TP53 mutations in cancers of the esophagus and cardia from a European high incidence area (Lower Normandy, France). *Mutagenesis*, **18**, 299-306.
- Busatto, G., Shiao, Y.H., Parenti, A.R., Baffa, R., Ruol, A., Plebani, M., Rugge, M., Bovo, D., Fawzy, S., Guido, M., Ancona, E., Ninfo, V., Correa, P., Lehmann, H.P., Scheer, W.D., Palli, D., Caporaso, N.E., Alvord, W.G., Amorosi, A., Nesi, G., Saieva, C., Masala, G., Fraumeni, J.F.Jr., and Rice, J.M. (1998) p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma. *Mol Pathol*, **51**, 80-4.
- Cai, Y.C., Yang, G.Y., Nie, Y., Wang, L.D., Zhao, X., Song, Y.L., Seril, D.N., Liao, J., Xing, E.P., and Yang, C.S. (2000) Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently+ADs- loss of imprinting and elevation of p73 expression may be related to defective p53. *Carcinogenesis*, **21**, 683-9.
- Cao, W., Chen, X., Dai, H., Wang, H., Shen, B., Chu, D., McAfee, T., and Zhang, Z.F. (2004) Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China. *Cancer*, **101**, 834-44.
- Casson, A.G., Evans, S.C., Gillis, A., Porter, G.A., Veugelers, P., Darnton, S.J., Guernsey, D.L., and Hainaut, P. (2003) Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. *J Thorac Cardiovasc Surg*, **125**, 1121-31.

- Casson, A.G., Mukhopadhyay, T., Cleary, K.R., Ro, J.Y., Levin, B., and Roth, J.A. (1991) p53 gene mutations in Barrett's epithelium and esophageal cancer. *Cancer Res*, **51**, 4495-9.
- Casson, A.G., Mukhopadhyay, T., Cleary, K.R., Ro, J.Y., Levin, B., and Roth, J.A. (1991) Oncogene activation in esophageal cancer. *J Thorac Cardiovasc Surg*, **102**, 707-9.
- Casson, A.G., Tammemagi, M., Eskandarian, S., Redston, M., McLaughlin, J., and Ozcelik, H. (1998) p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. *Mol Pathol*, **51**, 71-9.
- Casson, A.G., Wilson, S.M., McCart, J.A., O'Malley, F.P., Ozcelik, H., Tsao, M.S., and Chambers, A.F. (1997) ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. *Int J Cancer*, **72**, 739-45.
- Chan, W.C., Tang, C.M., Lau, K.W., and Lung, M.L. (1997) p16 tumor suppressor gene mutations in Chinese esophageal carcinomas in Hong Kong. *Cancer Lett*, **115**, 201-6.
- Choi, Y.W., Heath, E.I., Heitmiller, R., Forastiere, A.A., and Wu, T.T. (2000) Mutations in beta-catenin and APC genes are uncommon in esophageal and esophagogastric junction adenocarcinomas. *Mod Pathol*, **13**, 1055-9.
- Djalilvand, A., Pal, R., Goldman, H., Antonioli, D., and Kocher, O. (2004) Evaluation of p53 mutations in premalignant esophageal lesions and esophageal adenocarcinoma using laser capture microdissection. *Mod Pathol*, **17**, 1323-1327.
- Doak, S.H., Jenkins, G.J., Parry, E.M., Griffiths, A.P., Shah, V., Baxter, J.N., and Parry, J.M. (2003) Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma. *Br J Cancer*, **89**, 1729-35.
- Dolan, K., Garde, J., Walker, S.J., Sutton, R., Gosney, J., and Field, J.K. (1999) LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus. *Hum Pathol*, **30**, 1508-14.
- Dolan, K., Garde, J., Walker, S.J., Sutton, R., Gosney, J., and Field, J.K. (2000) Histological and molecular mapping of adenocarcinoma of the oesophagus and gastroesophageal junction: loss of heterozygosity occurs in histologically normal epithelium in the oesophagus and stomach. *Oncol Rep*, **7**, 521-8.
- Dolan, K., Walker, S.J., Gosney, J., Field, J.K., and Sutton, R. (2003) TP53 mutations in malignant and premalignant Barrett's esophagus. *Dis Esophagus*, **16**, 83-9.
- Esteve, A., Martel-Planche, G., Sylla, B.S., Hollstein, M., Hainaut, P., and Montesano, R. (1996) Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas. *Int J Cancer*, **66**, 301-4.
- Fujiki, T., Haraoka, S., Yoshioka, S., Ohshima, K., Iwashita, A., and Kikuchi, M. (2002) p53 Gene mutation and genetic instability in superficial multifocal esophageal squamous cell carcinoma. *Int J Oncol*, **20**, 669-79.
- Galiana, C., Lozano, J.C., Bancel, B., Nakazawa, H., and Yamasaki, H. (1995) High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus. *Mol Carcinog*, **14**, 286-93.
- Gamieldien, W., Victor, T.C., Mugwanya, D., Stepien, A., Gelderblom, W.C., Marasas, W.F., Geiger, D.H., and van Helden, P.D. (1998) p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa. *Int J Cancer*, **78**, 544-9.

- Gao, H., Wang, L.D., Zhou, Q., Hong, J.Y., Huang, T.Y., and Yang, C.S. (1994) p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. *Cancer Res*, **54**, 4342-6.
- Gates, C.E., Reed, C.E., Bromberg, J.S., Everett, E.T., and Baron, P.L. (1994) Prevalence of p53 mutations in patients with squamous cell carcinoma of the esophagus. *J Thorac Cardiovasc Surg*, **108**, 148-52.
- Giroux, M.A., Audrezet, M.P., Metges, J.P., Lozac'h, P., Volant, A., Nousbaum, J.B., Labat, J.P., Gouerou, H., Ferec, C., and Robaszkiewicz, M. (2002) Infrequent p16/CDKN2 alterations in squamous cell carcinoma of the oesophagus. *Eur J Gastroenterol Hepatol*, **14**, 15-8.
- Gleeson, C.M., Sloan, J.M., McGuigan, J.A., Ritchie, A.J., and Russell, S.E. (1995) Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. *Cancer Res*, **55**, 3406-11.
- Gleeson, C.M., Sloan, J.M., McManus, D.T., Maxwell, P., Arthur, K., McGuigan, J.A., Ritchie, A.J., and Russell, S.E. (1998) Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. *Br J Cancer*, **77**, 277-86.
- Gonzalez, M.V., Artinez, M.L., Rodrigo, L., Lopez-Larrea, C., Menendez, M.J., Alvarez, V., Perez, R., Fresno, M.F., Perez, M.J., Sampedro, A., and Coto, E. (1997) Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. *J Clin Pathol*, **50**, 212-7.
- Hamelin, R., Flejou, J.F., Muzeau, F., Potet, F., Laurent-Puig, P., Fekete, F., and Thomas, G. (1994) TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. *Gastroenterology*, **107**, 1012-8.
- Hardie, L.J., Darnton, S.J., Wallis, Y.L., Chauhan, A., Hainaut, P., Wild, C.P., and Casson, A.G. (2005) p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. *Cancer Lett*, **217**, 221-30.
- Hasegawa, M., Ohoka, I., Yamazaki, K., Hanami, K., Sugano, I., Nagao, T., Asoh, A., Wada, N., Nagao, K., and Ishida, Y. (2002) Expression of p21/WAF-1, status of apoptosis and p53 mutation in esophageal squamous cell carcinoma with HPV infection. *Pathol Int*, **52**, 442-50.
- Hattori, K., Kajiyama, Y., and Tsurumaru, M. (2003) Mutation of the p53 gene predicts lymph node metastases in Japanese patients with esophageal carcinoma: DNA and immunohistochemical analyses. *Dis Esophagus*, **16**, 301-6.
- Hayashi, K., Metzger, R., Salonga, D., Danenberg, K., Leichman, L.P., Fink, U., Sendler, A., Kelsen, D., Schwartz, G.K., Groshen, S., Lenz, H.J., and Danenberg, P.V. (1997) High frequency of simultaneous loss of p16 and p16beta gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach. *Oncogene*, **15**, 1481-8.
- Hollstein, M.C., Metcalf, R.A., Welsh, J.A., Montesano, R., and Harris, C.C. (1990) Frequent mutation of the p53 gene in human esophageal cancer. *Proc Natl Acad Sci U S A*, **87**, 9958-61.
- Hollstein, M.C., Peri, L., Mandar, A.M., Welsh, J.A., Montesano, R., Metcalf, R.A., Bak, M., and Harris, C.C. (1991) Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. *Cancer Res*, **51**, 4102-6.
- Hollstein, M.C., Smits, A.M., Galiana, C., Yamasaki, H., Bos, J.L., Mandar, A., Partensky, C., and Montesano, R. (1988) Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers. *Cancer Res*, **48**, 5119-23.
- Hori, H., Miyake, S., Akiyama, Y., Endo, M., and Yuasa, Y. (1996) Clonal heterogeneity in human

esophageal squamous cell carcinomas on DNA analysis. *Jpn J Cancer Res*, **87**, 923-9.

Hu, N., Huang, J., Emmert-Buck, M.R., Tang, Z.Z., Roth, M.J., Wang, C., Dawsey, S.M., Li, G., Li, W.J., Wang, Q.H., Han, X.Y., Ding, T., Giffen, C., Goldstein, A.M., and Taylor, P.R. (2001) Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a high-risk population in China. *Clin Cancer Res*, **7**, 883-91.

Hu, N., Wang, C., Su, H., Li, W.J., Emmert-Buck, M.R., Li, G., Roth, M.J., Tang, Z.Z., Lu, N., Giffen, C., Albert, P.S., Taylor, P.R., and Goldstein, A.M. (2004) High frequency of CDKN2A alterations in esophageal squamous cell carcinoma from a high-risk Chinese population. *Genes Chromosomes Cancer*, **39**, 205-16.

Huang, J., Hu, N., Goldstein, A.M., Emmert-Buck, M.R., Tang, Z.Z., Roth, M.J., Wang, Q.H., Dawsey, S.M., Han, X.Y., Ding, T., Li, G., Giffen, C., and Taylor, P.R. (2000) High frequency allelic loss on chromosome 17p13.3-p11.1 in esophageal squamous cell carcinomas from a high incidence area in northern China. *Carcinogenesis*, **21**, 2019-26.

Huang, Y., Boynton, R.F., Blount, P.L., Silverstein, R.J., Yin, J., Tong, Y., McDaniel, T.K., Newkirk, C., Resau, J.H., Sridhara, R., and et al. (1992) Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. *Cancer Res*, **52**, 6525-30.

Huang, Y., Meltzer, S.J., Yin, J., Tong, Y., Chang, E.H., Srivastava, S., McDaniel, T., Boynton, R.F., and Zou, Z.Q. (1993) Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. *Cancer Res*, **53**, 1889-94.

Igaki, H., Sasaki, H., Tachimori, Y., Kato, H., Watanabe, H., Kimura, T., Harada, Y., Sugimura, T., and Terada, M. (1995) Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. *Cancer Res*, **55**, 3421-3.

Imazeki, F., Omata, M., Nose, H., Ohto, M., and Isono, K. (1992) p53 gene mutations in gastric and esophageal cancers. *Gastroenterology*, **103**, 892-6.

Ito, S., Ohga, T., Saeki, H., Nakamura, T., Watanabe, M., Tanaka, S., Kakeji, Y., and Maehara, Y. (2005) p53 mutation profiling of multiple esophageal carcinoma using laser capture microdissection to demonstrate field carcinogenesis. *Int J Cancer*, **113**, 22-28.

Ito, T., Kaneko, K., Makino, R., Ito, H., Konishi, K., Kurahashi, T., Kitahara, T., and Mitamura, K. (2001) Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. *J Gastroenterol*, **36**, 303-11.

Iwaya, T., Maesawa, C., Nishizuka, S., Suzuki, Y., Sakata, K., Sato, N., Ikeda, K., Koeda, K., Ogasawara, S., Otsuka, K., Kimura, Y., Aoki, K., Ishida, K., Saito, K., and Tamura, G. (1998) Infrequent frameshift mutations of polynucleotide repeats in multiple primary cancers affecting the esophagus and other organs. *Genes Chromosomes Cancer*, **23**, 317-22.

Jiang, W., Kahn, S.M., Guillem, J.G., Lu, S.H., and Weinstein, I.B. (1989) Rapid detection of ras oncogenes in human tumors: applications to colon, esophageal, and gastric cancer. *Oncogene*, **4**, 923-8.

Katiyar, S., Hedau, S., Jain, N., Kar, P., Khuroo, M.S., Mohanta, J., Kumar, S., Gopalkrishna, V., Kumar, N., and Das, B.C. (2005) p53 gene mutation and human papillomavirus (HPV) infection in esophageal carcinoma from three different endemic geographic regions of India. *Cancer Lett*, **218**, 69-79.

Kihara, C., Seki, T., Furukawa, Y., Yamana, H., Kimura, Y., van Schaardenburgh, P., Hirata, K., and Nakamura, Y. (2000) Mutations in zinc-binding domains of p53 as a prognostic marker of esophageal cancer patients . *Jpn J Cancer Res*, **91**, 190-8.

Kobayashi, S., Koide, Y., Endo, M., Isono, K., and Ochiai, T. (1999) The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability. *Am J Surg*, **177**, 497-502.

Kuroki, T., Trapasso, F., Yendamuri, S., Matsuyama, A., Alder, H., Mori, M., and Croce, C.M. (2003) Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. *Cancer Res*, **63**, 3724-8.

Kuwabara, S., Ajioka, Y., Watanabe, H., Hitomi, J., Nishikura, K., and Hatakeyama, K. (1998) Heterogeneity of p53 mutational status in esophageal squamous cell carcinoma. *Jpn J Cancer Res*, **89**, 405-10.

Lam, K.Y., Tsao, S.W., Zhang, D., Law, S., He, D., Ma, L., and Wong, J. (1997) Prevalence and predictive value of p53 mutation in patients with oesophageal squamous cell carcinomas: a prospective clinico-pathological study and survival analysis of 70 patients. *Int J Cancer*, **74**, 212-9.

Li, L.Y., Tang, J.T., Jia, L.Q., and Li, P.W. (2005) Mutations of p53 gene exons 4-8 in human esophageal cancer. *World J Gastroenterol*, **11**, 2998-3001.

Liang, Y.Y., Esteve, A., Martel-Planche, G., Takahashi, S., Lu, S.H., Montesano, R., and Hollstein, M. (1995) p53 mutations in esophageal tumors from high-incidence areas of China. *Int J Cancer*, **61**, 611-4.

Lin, S.Y., Chen, P.H., Wang, C.K., Liu, J.D., Siauw, C.P., Chen, Y.J., Yang, M.J., Liu, M.H., Chen, T.C., and Chang, J.G. (1993) Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction sites method. *Am J Clin Pathol*, **100**, 686-9.

Lung, M.L., Chan, W.C., Zong, Y.S., Tang, C.M., Fok, C.L., Wong, K.T., Chan, L.K., and Lau, K.W. (1996) p53 mutational spectrum of esophageal carcinomas from five different geographical locales in China. *Cancer Epidemiol Biomarkers Prev*, **5**, 277-84.

Maesawa, C., Tamura, G., Nishizuka, S., Ogasawara, S., Ishida, K., Terashima, M., Sakata, K., Sato, N., Saito, K., and Satodate, R. (1996) Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. *Cancer Res*, **56**, 3875-8.

Maesawa, C., Tamura, G., Ogasawara, S., Suzuki, Y., Sakata, K., Sugimura, J., Nishizuka, S., Sato, N., Ishida, K., Saito, K., and Satodate, R. (1996) Loss of heterozygosity at the DCC gene locus is not crucial for the acquisition of metastatic potential in oesophageal squamous cell carcinoma. *Eur J Cancer*, **32A**, 896-8.

Maesawa, C., Tamura, G., Suzuki, Y., Ogasawara, S., Ishida, K., Saito, K., and Satodate, R. (1994) Aberrations of tumor-suppressor genes (p53, apc, mcc and Rb) in esophageal squamous-cell carcinoma. *Int J Cancer*, **57**, 21-5.

Makino, R., Kaneko, K., Kurahashi, T., Matsumura, T., and Mitamura, K. (2000) Detection of mutation of the p53 gene with high sensitivity by fluorescence-based PCR-SSCP analysis using low-pH buffer and an automated DNA sequencer in a large number of DNA samples. *Mutat Res*, **452**, 83-90.

Matsumoto, M., Furuhata, M., Kurabayashi, A., Araki, K., Sasaguri, S., and Ohtsuki, Y. (2003) Association between inducible nitric oxide synthase expression and p53 status in human esophageal squamous cell carcinoma. *Oncology*, **64**, 90-6.

Mayama, T., Mori, T., Abe, K., Sasano, H., Nishihira, T., Satomi, S., and Horii, A. (1997) Analysis of the p53 gene mutations in patients with multiple primary cancers of the oesophagus. *Eur J Surg Oncol*, **23**, 298-303.

Meltzer, S.J., Mane, S.M., Wood, P.K., Resau, J.H., Newkirk, C., Terzakis, J.A., Korelitz, B.I., Weinstein, W.M., and Needleman, S.W. (1990) Activation of c-Ki-ras in human gastrointestinal dysplasias determined by direct sequencing of polymerase chain reaction products. *Cancer Res*, **50**, 3627-30.

Meltzer, S.J., Yin, J., Huang, Y., McDaniel, T.K., Newkirk, C., Iseri, O., Vogelstein, B., and Resau, J.H. (1991) Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. *Proc Natl Acad Sci U S A*, **88**, 4976-80.

Menin, C., Santacatterina, M., Zambon, A., Montagna, M., Parenti, A., Ruol, A., and D'Andrea, E. (2000) Anomalous transcripts and allelic deletions of the FHIT gene in human esophageal cancer. *Cancer Genet Cytogenet*, **119**, 56-61.

Michael, D., Beer, D.G., Wilke, C.W., Miller, D.E., and Glover, T.W. (1997) Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas. *Oncogene*, **15**, 1653-9.

Mineta, H., Borg, A., Dictor, M., Wahlberg, P., and Wennerberg, J. (1997) Correlation between p53 mutation and cyclin D1 amplification in head and neck squamous cell carcinoma. *Oral Oncol*, **33**, 42-6.

Mir, M.M., Dar, N.A., Gochhait, S., Zargar, S.A., Ahangar, A.G., and Bamezai, R.N. (2005) p53 mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high-incidence area. *Int J Cancer*, **116**, 62-8.

Mizobuchi, S., Furuhata, M., Sonobe, H., Ohtsuki, Y., Ishikawa, T., Murakami, H., Kurabayashi, A., Ogoshi, S., and Sasaguri, S. (2000) Association between p53 immunostaining and cigarette smoking in squamous cell carcinoma of the esophagus. *Jpn J Clin Oncol*, **30**, 423-8.

Morgan, R.J., Newcomb, P.V., Bailey, M., Hardwick, R.H., and Alderson, D. (1998) Loss of heterozygosity at microsatellite marker sites for tumour suppressor genes in oesophageal adenocarcinoma. *Eur J Surg Oncol*, **24**, 34-7.

Mori, M., Mimori, K., Shiraishi, T., Alder, H., Inoue, H., Tanaka, Y., Sugimachi, K., Huebner, K., and Croce, C.M. (2000) Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. *Cancer Res*, **60**, 1177-82.

Muzeau, F., Flejou, J.F., Thomas, G., and Hamelin, R. (1997) Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers. *Int J Cancer*, **72**, 27-30.

Naidoo, R., Tarin, M., Reddi, A., and Chetty, R. (1999) Allelic imbalance and microsatellite instability in chromosomes 2p, 3p, 5q, and 18q in esophageal squamous carcinoma in patients from South Africa. *Diagn Mol Pathol*, **8**, 131-7.

Neshat, K., Sanchez, C.A., Galipeau, P.C., Blount, P.L., Levine, D.S., Joslyn, G., and Reid, B.J. (1994) p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. *Gastroenterology*, **106**, 1589-95.

Ninomiya, I., Endo, Y., Fushida, S., Sasagawa, T., Miyashita, T., Fujimura, T., Nishimura, G., Tani, T., Hashimoto, T., Yagi, M., Shimizu, K., Ohta, T., Yonemura, Y., Inoue, M., Sasaki, T., and Miwa, K. (2000) Alteration of beta-catenin expression in esophageal squamous-cell carcinoma. *Int J Cancer*, **85**, 757-61.

Ogasawara, S., Maesawa, C., Tamura, G., and Satodate, R. (1994) Lack of mutations of the adenomatous polyposis coli gene in oesophageal and gastric carcinomas. *Virchows Arch*, **424**, 607-11.

Ohta, M., Inoue, H., Cotticelli, M.G., Kastury, K., Baffa, R., Palazzo, J., Siprashvili, Z., Mori, M., McCue, P., Druck, T., and et, al. (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3+ADs-8) breakpoint, is abnormal in digestive tract cancers. *Cell*, **84**, 587-97.

- Okamoto, A., Demetrick, D.J., Spillare, E.A., Hagiwara, K., Hussain, S.P., Bennett, W.P., Forrester, K., Gerwin, B., Greenblatt, M.S., Serrano, M., and et al. (1994) p16INK4 mutations and altered expression in human tumors and cell lines. *Cold Spring Harb Symp Quant Biol*, **59**, 49-57.
- Owonikoko, T., Loberg, C., Gabbert, H.E., and Sarbia, M. (2001) Comparative analysis of basaloid and typical squamous cell carcinoma of the oesophagus: a molecular biological and immunohistochemical study. *J Pathol*, **193**, 155-61.
- Owonikoko, T., Rees, M., Gabbert, H.E., and Sarbia, M. (2002) Intratumoral genetic heterogeneity in Barrett adenocarcinoma. *Am J Clin Pathol*, **117**, 558-66.
- Petty, E.M., Kalikin, L.M., Orringer, M.B., and Beer, D.G. (1998) Distal chromosome 17q loss in Barrett's esophageal and gastric cardia adenocarcinomas: implications for tumorigenesis. *Mol Carcinog*, **22**, 222-8.
- Powell, S.M., Papadopoulos, N., Kinzler, K.W., Smolinski, K.N., and Meltzer, S.J. (1994) APC gene mutations in the mutation cluster region are rare in esophageal cancers. *Gastroenterology*, **107**, 1759-63.
- Putz, A., Hartmann, A.A., Fontes, P.R., Alexandre, C.O., Silveira, D.A., Klug, S.J., and Rabes, H.M. (2002) TP53 mutation pattern of esophageal squamous cell carcinomas in a high risk area (Southern Brazil): role of life style factors. *Int J Cancer*, **98**, 99-105.
- Ralhan, R., Arora, S., Chattopadhyay, T.K., Shukla, N.K., and Mathur, M. (2000) Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. *Int J Cancer*, **85**, 791-5.
- Ribeiro, U., Safatle-Ribeiro, A.V., Posner, M.C., Rosendale, B., Bakker, A., Swalsky, P.A., Kim, R., Reynolds, J.C., and Finkelstein, S.D. (1996) Comparative p53 mutational analysis of multiple primary cancers of the upper aerodigestive tract. *Surgery*, **120**, 45-53.
- Roncalli, M., Bosari, S., Marchetti, A., Buttitta, F., Bossi, P., Graziani, D., Peracchia, A., Bonavina, L., Viale, G., and Coggi, G. (1998) Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. *Lab Invest*, **78**, 1049-57.
- Rugge, M., Bovo, D., Busatto, G., Parenti, A.R., Fawzy, S., Guido, M., Ancona, E., Ninfo, V., Ruol, A., and Shiao, Y.H. (1997) p53 alterations but no human papillomavirus infection in preinvasive and advanced squamous esophageal cancer in Italy. *Cancer Epidemiol Biomarkers Prev*, **6**, 171-6.
- Sanz-Ortega, J., Hernandez, S., Saez, M.C., Sierra, E., Sanz-Ortega, G., Torres, A., Balibrea, J.L., Sanz-Espónera, J., and Merino, M.J. (2003) 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia. *Hepatogastroenterology*, **50**, 404-7.
- Sarbia, M., Tekin, U., Zeriouh, M., Donner, A., and Gabbert, H.E. (2001) Expression of the RB protein, allelic imbalance of the RB gene and amplification of the CDK4 gene in metaplasias, dysplasias and carcinomas in Barrett's oesophagus. *Anticancer Res*, **21**, 387-92.
- Schneider, P.M., Stoeltzing, O., Roth, J.A., Hoelscher, A.H., Wegerer, S., Mizumoto, S., Becker, K., Dittler, H.J., Fink, U., and Siewert, J.R. (2000) P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. *Clin Cancer Res*, **6**, 3153-8.
- Sepehr, A., Taniere, P., Martel-Planche, G., Zia'ee, A.A., Rastgar-Jazii, F., Yazdanbod, M., Etemad-Moghadam, G., Kamangar, F., Saidi, F., and Hainaut, P. (2001) Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran. *Oncogene*, **20**, 7368-74.
- Shi, S.T., Yang, G.Y., Wang, L.D., Xue, Z., Feng, B., Ding, W., Xing, E.P., and Yang, C.S. (1999) Role of

p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. *Carcinogenesis*, **20**, 591-7.

Shibagaki, I., Tanaka, H., Shimada, Y., Wagata, T., Ikenaga, M., Imamura, M., and Ishizaki, K. (1995) p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. *Clin Cancer Res*, **1**, 769-73.

Shiga, C., Shiga, K., Sasano, H., and Mori, S. (1992) A point mutation of c-Ki-ras gene was found in human esophageal carcinoma cell lines but not in primary esophageal carcinomas. *Biochem Biophys Res Commun*, **187**, 515-21.

Si, H.X., Tsao, S.W., Poon, C.S., and Cheung, A.L. (2004) Human papillomavirus infection and loss of heterozygosity in esophageal squamous cell carcinoma. *Cancer Lett*, **213**, 231-9.

Smeds, J., Berggren, P., Ma, X., Xu, Z., Hemminki, K., and Kumar, R. (2002) Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF)) and p53 genes are major targets for inactivation. *Carcinogenesis*, **23**, 645-55.

Sommerer, F., Vieth, M., Markwarth, A., Rohrich, K., Vomischloss, S., May, A., Ell, C., Stolte, M., Hengge, U.R., Wittekind, C., and Tannapfel, A. (2004) Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. *Oncogene*, **23**, 554-8.

Soslow, R.A., Altorki, N.K., Yang, G., Xie, D., and Yang, C.S. (1999) mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. *Mod Pathol*, **12**, 580-6.

Suwiwat, S., Oda, H., Shimizu, Y., and Ishikawa, T. (1997) Prevalence of p53 mutations and protein expression in esophageal cancers in southern Thailand. *Int J Cancer*, **72**, 23-6.

Suzuki, H., Zhou, X., Yin, J., Lei, J., Jiang, H.Y., Suzuki, Y., Chan, T., Hannon, G.J., Mergner, W.J., Abraham, J.M., and et, a.l. (1995) Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. *Hum Mol Genet*, **4**, 1883-7.

Swift, A., Risk, J.M., Kingsnorth, A.N., Wright, T.A., Myskow, M., and Field, J.K. (1995) Frequent loss of heterozygosity on chromosome 17 at 17q11.2-q12 in Barrett's adenocarcinoma. *Br J Cancer*, **71**, 995-8.

Taniere, P., Martel-Planche, G., Maurici, D., Lombard-Bohas, C., Scoazec, J.Y., Montesano, R., Berger, F., and Hainaut, P. (2001) Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. *Am J Pathol*, **158**, 33-40.

Taniere, P., Martel-Planche, G., Puttawibul, P., Casson, A., Montesano, R., Chanvitian, A., and Hainaut, P. (2000) TP53 mutations and MDM2 gene amplification in squamous-cell carcinomas of the esophagus in south Thailand. *Int J Cancer*, **88**, 223-7.

Taniere, P., Martel-Planche, G., Saurin, J.C., Lombard-Bohas, C., Berger, F., Scoazec, J.Y., and Hainaut, P. (2001) TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe. *Br J Cancer*, **85**, 721-6.

van Rees, B.P., Cleton-Jansen, A.M., Cense, H.A., Polak, M.M., Clement, M.J., Drillenburg, P., van Lanschot, J.J., and Offerhaus, G.J. (2000) Molecular evidence of field cancerization in a patient with 7 tumors of the aerodigestive tract. *Hum Pathol*, **31**, 269-71.

Victor, T., Du Toit, R., Jordaan, A.M., Bester, A.J., and van Helden, P.D. (1990) No evidence for point mutations in codons 12, 13, and 61 of the ras gene in a high-incidence area for esophageal and gastric cancers. *Cancer Res*, **50**, 4911-4.

Vieth, M., Schneider-Stock, R., Rohrich, K., May, A., Ell, C., Markwarth, A., Roessner, A., Stolte, M., and Tannapfel, A. (2004) INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma. *Virchows Arch*, **445**, 135-41.

Vos, M., Adams, C.H., Victor, T.C., and van Helden, P.D. (2003) Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. *Cancer Genet Cytogenet*, **140**, 23-30.

Wagata, T., Shibagaki, I., Immamura, M., Shimada, Y., Toguchida, J., Yandell, D.W., Ikenaga, M., Tobe, T., and Ishizaki, K. (1993) Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. *Cancer Res*, **53**, 846-50.

Wijnhoven, B.P., Nollet, F., De Both, N.J., Tilanus, H.W., and Dinjens, W.N. (2000) Genetic alterations involving exon 3 of the beta-catenin gene do not play a role in adenocarcinomas of the esophagus. *Int J Cancer*, **86**, 533-7.

Xing, E.P., Nie, Y., Song, Y., Yang, G.Y., Cai, Y.C., Wang, L.D., and Yang, C.S. (1999) Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. *Clin Cancer Res*, **5**, 2704-13.

Xing, E.P., Nie, Y., Wang, L.D., Yang, G.Y., and Yang, C.S. (1999) Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. *Carcinogenesis*, **20**, 77-84.

Xing, E.P., Yang, G.Y., Wang, L.D., Shi, S.T., and Yang, C.S. (1999) Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer. *Clin Cancer Res*, **5**, 1231-40.

Yamanoshita, O., Kubota, T., Hou, J., Ping, Y.M., Zhang, X.L., Li, X.P., Li, S.S., Li, X.X., Zhu, D.C., Fukushima, Y., and Nakajima, T. (2005) DHPLC is superior to SSCP in screening p53 mutations in esophageal cancer tissues. *Int J Cancer*, **114**, 74-9.

Yanagi, M., Keller, G., Mueller, J., Walch, A., Werner, M., Stein, H.J., Siewert, J.R., and Hofler, H. (2000) Comparison of loss of heterozygosity and microsatellite instability in adenocarcinomas of the distal esophagus and proximal stomach. *Virchows Arch*, **437**, 605-10.

Zou, T.T., Lei, J., Shi, Y.Q., Yin, J., Wang, S., Souza, R.F., Kong, D., Shimada, Y., Smolinski, K.N., Greenwald, B.D., Abraham, J.M., Harpaz, N., and Meltzer, S.J. (1997) FHIT gene alterations in esophageal cancer and ulcerative colitis (UC). *Oncogene*, **15**, 101-5.

Stomach: Spontaneous

Abraham, S.C., Nobukawa, B., Giardiello, F.M., Hamilton, S.R., and Wu, T.T. (2000) Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. *Am J Pathol*, **157**, 747-54.

Abraham, S.C., Park, S.J., Lee, J.H., Mugartegui, L., and Wu, T.T. (2003) Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes. *Mod Pathol*, **16**, 786-95.

Akiyama, S., Tamura, G., Endoh, Y., Fukushima, N., Ichihara, Y., Aizawa, K., Kawata, S., and Motoyama, T. (2003) Histogenesis of hepatoid adenocarcinoma of the stomach: molecular evidence of identical origin with coexistent tubular adenocarcinoma. *Int J Cancer*, **106**, 510-5.

Barletta, C., Scillato, F., Sega, F.M., and Mannella, E. (1993) Genetic alteration in gastrointestinal cancer. A molecular and cytogenetic study. *Anticancer Res*, **13**, 2325-9.

- Bataille, F., Rummele, P., Dietmaier, W., Gaag, D., Klebl, F., Reichle, A., Wild, P., Hofstadter, F., and Hartmann, A. (2003) Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. *Mol Pathol*, **56**, 286-92.
- Berloco, P., Russo, F., Cariola, F., Gentile, M., Giorgio, P., Caruso, M.L., Valentini, A.M., Di Matteo, G., and Di Leo, A. (2003) Low presence of p53 abnormalities in H pylori-infected gastric mucosa and in gastric adenocarcinoma. *J Gastroenterol*, **38**, 28-36.
- Blok, P., Craanen, M.E., Offerhaus, G.J., Dekker, W., Kuipers, E.J., Meuwissen, S.G., and Tytgat, G.N. (1999) Molecular alterations in early gastric carcinomas. No apparent correlation with Helicobacter pylori status. *Am J Clin Pathol*, **111**, 241-7.
- Breton, J., Sichel, F., Abbas, A., Marnay, J., Arsene, D., and Lechevrel, M. (2003) Simultaneous use of DGGE and DHPLC to screen TP53 mutations in cancers of the esophagus and cardia from a European high incidence area (Lower Normandy, France). *Mutagenesis*, **18**, 299-306.
- Candidus, S., Bischoff, P., Becker, K.F., and Hofler, H. (1996) No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas. *Cancer Res*, **56**, 49-52.
- Carvalho, R., Milne, A.N., van Rees, B.P., Caspers, E., Cirnes, L., Figueiredo, C., Offerhaus, G.J., and Weterman, M.A. (2004) Early-onset gastric carcinomas display molecular characteristics distinct from gastric carcinomas occurring at a later age. *J Pathol*, **204**, 75-83.
- Chen, P.H., Lin, S.Y., Wang, C.K., Chen, Y.J., Chen, T.C., and Chang, J.G. (1993) "Hot spots" mutation analysis of p53 gene in gastrointestinal cancers by amplification of naturally occurring and artificially created restriction sites. *Clin Chem*, **39**, 2186-91.
- Chen, Y.J., Chang, J.G., Shih, L.S., Chen, P.H., Endo, M., Whang-Peng, J., and Chen, Y.M. (1997) Frequent detection of aberrant RNA transcripts of the CDKN2 gene in human gastric adenocarcinoma. *Int J Cancer*, **71**, 350-4.
- Cheng, X.X., Sun, Y., Chen, X.Y., Zhang, K.L., Kong, Q.Y., Liu, J., and Li, H. (2004) Frequent translocalization of beta-catenin in gastric cancers and its relevance to tumor progression. *Oncol Rep*, **11**, 1201-7.
- Chetty, R., Naidoo, R., Tarin, M., and Sitti, C. (2002) Chromosome 2p, 3p, 5q and 18q status in sporadic gastric cancer. *Pathology*, **34**, 275-81.
- Cho, J.H., Noguchi, M., Ochiai, A., and Hirohashi, S. (1996) Loss of heterozygosity of multiple tumor suppressor genes in human gastric cancers by polymerase chain reaction. *Lab Invest*, **74**, 835-41.
- Chung, Y.J., Choi, J.R., Park, S.W., Kim, K.M., and Rhyu, M.G. (2001) Evidence for two modes of allelic loss: multifocal analysis on both early and advanced gastric carcinomas. *Virchows Arch*, **438**, 31-8.
- Chung, Y.J., Kim, K.M., Choi, J.R., Choi, S.W., and Rhyu, M.G. (1999) Relationship between intratumor histological heterogeneity and genetic abnormalities in gastric carcinoma with microsatellite instability. *Int J Cancer*, **82**, 782-8.
- Clements, W.M., Wang, J., Sarnaik, A., Kim, O.J., MacDonald, J., Fenoglio-Preiser, C., Groden, J., and Lowy, A.M. (2002) beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. *Cancer Res*, **62**, 3503-6.
- D'Andrea, E., Baffa, R., Menin, C., Montagna, M., Rugge, M., and Chieco-Bianchi, L. (1995) TP53 gene mutations in gastric carcinoma detected by polymerase chain reaction/single-strand conformation polymorphism analysis of archival material. *J Cancer Res Clin Oncol*, **121**, 79-83.

- Deguchi, R., Takagi, A., Kawata, H., Inoko, H., and Miwa, T. (2001) Association between CagA+ Helicobacter pylori infection and p53, bax and transforming growth factor-beta-RII gene mutations in gastric cancer patients. *Int J Cancer*, **91**, 481-5.
- Ebert, M.P., Fei, G., Kahmann, S., Muller, O., Yu, J., Sung, J.J., and Malfertheiner, P. (2002) Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. *Carcinogenesis*, **23**, 87-91.
- Ebert, M.P., Yu, J., Hoffmann, J., Rocco, A., Rocken, C., Kahmann, S., Muller, O., Korc, M., Sung, J.J., and Malfertheiner, P. (2003) Loss of beta-catenin expression in metastatic gastric cancer. *J Clin Oncol*, **21**, 1708-14.
- Endoh, Y., Sakata, K., Tamura, G., Ohmura, K., Ajioka, Y., Watanabe, H., and Motoyama, T. (2000) Cellular phenotypes of differentiated-type adenocarcinomas and precancerous lesions of the stomach are dependent on the genetic pathways. *J Pathol*, **191**, 257-63.
- Fang, D.C., Jass, J.R., and Wang, D.X. (1998) Loss of heterozygosity and loss of expression of the DCC gene in gastric cancer. *J Clin Pathol*, **51**, 593-6.
- Fang, D.C., Jass, J.R., Wang, D.X., Zhou, X.D., Luo, Y.H., and Young, J. (1999) Infrequent loss of heterozygosity of APC/MCC and DCC genes in gastric cancer showing DNA microsatellite instability. *J Clin Pathol*, **52**, 504-8.
- Fang, D.C., Luo, Y.H., Yang, S.M., Li, X.A., Ling, X.L., and Fang, L. (2002) Mutation analysis of APC gene in gastric cancer with microsatellite instability. *World J Gastroenterol*, **8**, 787-91.
- Fang, D.C., Yang, S.M., Zhou, X.D., Wang, D.X., and Luo, Y.H. (2001) Telomere erosion is independent of microsatellite instability but related to loss of heterozygosity in gastric cancer. *World J Gastroenterol*, **7**, 522-6.
- Fedriga, R., Calistri, D., Nanni, O., Cortesi, L., Saragoni, L., and Amadori, D. (2000) Relation between food habits and p53 mutational spectrum in gastric cancer patients. *Int J Oncol*, **17**, 127-33.
- Ficarella, C., Cannita, K., Ricevuto, E., Toniato, E., Fusco, C., Sinopoli, N.T., De Galitiis, F., Di Rocco, Z.C., Porzio, G., Frati, L., Gulino, A., Martinotti, S., and Marchetti, P. (2003) P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancer. *Oncol Rep*, **10**, 169-73.
- Flejou, J.F., Gratio, V., Muzeau, F., and Hamelin, R. (1999) p53 abnormalities in adenocarcinoma of the gastric cardia and antrum. *Mol Pathol*, **52**, 263-8.
- Fricke, E., Keller, G., Becker, I., Rosivatz, E., Schott, C., Plaschke, S., Rudelius, M., Hermannstadter, C., Busch, R., Hofler, H., Becker, K.F., and Luber, B. (2003) Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma. *Int J Cancer*, **104**, 60-5.
- Fujita, K., Ohuchi, N., Yao, T., Okumura, M., Fukushima, Y., Kanakura, Y., Kitamura, Y., and Fujita, J. (1987) Frequent overexpression, but not activation by point mutation, of ras genes in primary human gastric cancers. *Gastroenterology*, **93**, 1339-45.
- Fushida, S., Urano, T., Tsuruta, H., Yonemura, Y., Miyazaki, I., and Shiku, H. (1993) Frequent p53 mutations on exon 5 and exon 8 in human primary gastric cancer. *Int J Oncol*, **2**, 563-568.
- Gemma, A., Hagiwara, K., Ke, Y., Burke, L.M., Khan, M.A., Nagashima, M., Bennett, W.P., and Harris, C.C. (1997) FHIT mutations in human primary gastric cancer. *Cancer Res*, **57**, 1435-7.

Gleeson, C.M., Sloan, J.M., McManus, D.T., Maxwell, P., Arthur, K., McGuigan, J.A., Ritchie, A.J., and Russell, S.E. (1998) Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. *Br J Cancer*, **77**, 277-86.

Gunther, T., Schneider-Stock, R., Hackel, C., Kasper, H.U., Pross, M., Hackelsberger, A., Lippert, H., and Roessner, A. (2000) Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. *Mod Pathol*, **13**, 621-6.

Gunther, T., Schneider-Stock, R., Pross, M., Manger, T., Malfertheiner, P., Lippert, H., and Roessner, A. (1998) Alterations of the p16/MTS1-tumor suppressor gene in gastric cancer. *Pathol Res Pract*, **194**, 809-13.

Hao, Y., Zhang, J., Yi, C., and Qian, W. (1997) Abnormal change of p53 gene in gastric and precancerous lesions and APC gene deletion in gastric carcinoma and near tissues. *J Tongji Med Univ*, **17**, 75-8.

He, X.S., Su, Q., Chen, Z.C., He, X.T., Long, Z.F., Ling, H., and Zhang, L.R. (2001) Expression, deletion [was deleton] and mutation of p16 gene in human gastric cancer. *World J Gastroenterol*, **7**, 515-21.

Hiyama, T., Haruma, K., Kitadai, Y., Masuda, H., Miyamoto, M., Tanaka, S., Yoshihara, M., Shimamoto, F., and Chayama, K. (2002) K-ras mutation in helicobacter pylori-associated chronic gastritis in patients with and without gastric cancer. *Int J Cancer*, **97**, 562-6.

Hongyo, T., Buzard, G.S., Palli, D., Weghorst, C.M., Amorosi, A., Galli, M., Caporaso, N.E., Fraumeni, J.F.Jr., and Rice, J.M. (1995) Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. *Cancer Res*, **55**, 2665-72.

Horii, A., Nakatsuru, S., Miyoshi, Y., Ichii, S., Nagase, H., Kato, Y., Yanagisawa, A., and Nakamura, Y. (1992) The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. *Cancer Res*, **52**, 3231-3.

Hosoi, H., Hirosawa, S., Yamamoto, K., Ohkusa, T., and Aoki, N. (1995) Using biopsy materials to detect mutations in gastrointestinal tumors. *J Clin Gastroenterol*, **20**, 272-6.

Hsieh, L.L., Hsieh, J.T., Wang, L.Y., Fang, C.Y., Chang, S.H., and Chen, T.C. (1996) p53 mutations in gastric cancers from Taiwan. *Cancer Lett*, **100**, 107-13.

Hsieh, L.L. and Huang, Y.C. (1995) Loss of heterozygosity of APC/MCC gene in differentiated and undifferentiated gastric carcinomas in Taiwan. *Cancer Lett*, **96**, 169-74.

Huiping, C., Kristjansdottir, S., Bergthorsson, J.T., Jonasson, J.G., Magnusson, J., Egilsson, V., and Ingvarsson, S. (2002) High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. *Eur J Cancer*, **38**, 728-35.

Huiping, C., Kristjansdottir, S., Jonasson, J.G., Magnusson, J., Egilsson, V., and Ingvarsson, S. (2001) Alterations of E-cadherin and beta-catenin in gastric cancer. *BMC Cancer*, **1**, 16.

Igaki, H., Sasaki, H., Tachimori, Y., Kato, H., Watanabe, H., Kimura, T., Harada, Y., Sugimura, T., and Terada, M. (1995) Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. *Cancer Res*, **55**, 3421-3.

Imatani, A., Sasano, H., Asaki, S., Toyota, T., Saito, M., Masuda, T., and Nagura, H. (1996) Analysis of p53 abnormalities in endoscopic gastric biopsies. *Anticancer Res*, **16**, 2049-56.

Imazeki, F., Omata, M., Nose, H., Ohto, M., and Isono, K. (1992) p53 gene mutations in gastric and esophageal cancers. *Gastroenterology*, **103**, 892-6.

- Iwamatsu, H., Nishikura, K., Watanabe, H., Ajioka, Y., Hashidate, H., Kashimura, H., and Asakura, H. (2001) Heterogeneity of p53 mutational status in the superficial spreading type of early gastric carcinoma. *Gastric Cancer*, **4**, 20-6.
- Iwaya, T., Maesawa, C., Nishizuka, S., Suzuki, Y., Sakata, K., Sato, N., Ikeda, K., Koeda, K., Ogasawara, S., Otsuka, K., Kimura, Y., Aoki, K., Ishida, K., Saito, K., and Tamura, G. (1998) Infrequent frameshift mutations of polynucleotide repeats in multiple primary cancers affecting the esophagus and other organs. *Genes Chromosomes Cancer*, **23**, 317-22.
- Jiang, W., Kahn, S.M., Guillem, J.G., Lu, S.H., and Weinstein, I.B. (1989) Rapid detection of ras oncogenes in human tumors: applications to colon, esophageal, and gastric cancer. *Oncogene*, **4**, 923-8.
- Kanai, Y., Tsuda, H., Oda, T., Sakamoto, M., and Hirohashi, S. (1995) Analysis of the neurofibromatosis 2 gene in human breast and hepatocellular carcinomas. *Jpn J Clin Oncol*, **25**, 1-4.
- Kang, G.H., Kim, C.J., Kim, W.H., Kang, Y.K., Kim, H.O., and Kim, Y.I. (1997) Genetic evidence for the multicentric origin of synchronous multiple gastric carcinoma. *Lab Invest*, **76**, 407-17.
- Kasper, H.U., Schneider-Stock, R., Mellin, W., and Roessner, A. (1998) P21 protein expression and ras-oncogene mutations in gastric carcinoma: correlation with clinical data. *Int J Oncol*, **12**, 69-74.
- Kawamura, A., Adachi, K., Ishihara, S., Katsume, T., Takashima, T., Yuki, M., Amano, K., Fukuda, R., Yamashita, Y., and Kinoshita, Y. (2001) Correlation between microsatellite instability and metachronous disease recurrence after endoscopic mucosal resection in patients with early stage gastric carcinoma. *Cancer*, **91**, 339-45.
- Kihana, T., Tsuda, H., Hirota, T., Shimosato, Y., Sakamoto, H., Terada, M., and Hirohashi, S. (1991) Point mutation of c-Ki-ras oncogene in gastric adenoma and adenocarcinoma with tubular differentiation. *Jpn J Cancer Res*, **82**, 308-14.
- Kim, I.J., Park, J.H., Kang, H.C., Shin, Y., Park, H.W., Park, H.R., Ku, J.L., Lim, S.B., and Park, J.G. (2003) Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. *Hum Genet*, **114**, 118-20.
- Kim, J.H., Choi, J.J., Noh, S.H., Roh, J.K., Min, J.S., Youn, J.K., Yoo, N.C., Lim, H.Y., Carbone, D.P., and Gazdar, A.F. (1993) Comparison of p53 gene mutations in paired primary and metastatic gastric tumor tissues. *J Korean Med Sci*, **8**, 187-91.
- Kim, J.H., Takahashi, T., Chiba, I., Park, J.G., Birrer, M.J., Roh, J.K., De Lee, H., Kim, J.P., Minna, J.D., and Gazdar, A.F. (1991) Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. *J Natl Cancer Inst*, **83**, 938-43.
- Kim, S.S., Bhang, C.S., Min, K.O., Chae, H.S., Choi, S.W., Lee, C.D., Lim, K.W., Chung, I.S., and Park, D.H. (2002) p53 mutations and microsatellite instabilities in the subtype of intestinal metaplasia of the stomach. *J Korean Med Sci*, **17**, 490-6.
- Kim, T.Y., Bang, Y.J., Kim, W.S., Kang, S.H., Lee, K.U., Choe, K.J., and Kim, N.K. (1997) Mutation of ras oncogene in gastric adenocarcinoma: association with histological phenotype. *Anticancer Res*, **17**, 1335-9.
- Koh, E.H., Chung, H.C., Lee, K.B., Han, E.K., Oh, S.H., Min, J.S., Choi, E.M., Youn, J.K., and Kim, B.S. (1992) Point mutation at codon 12 of the c-Ha-ras gene in human gastric cancers. *J Korean Med Sci*, **7**, 110-5.
- Koshiba, M., Ogawa, O., Habuchi, T., Hamazaki, S., Shimada, T., Takahashi, R., and Sugiyama, T. (1993)

Infrequent ras mutation in human stomach cancers. *Jpn J Cancer Res*, **84**, 163-7.

Kubicka, S., Claas, C., Staab, S., Kuhnel, F., Zender, L., Trautwein, C., Wagner, S., Rudolph, K.L., and Manns, M. (2002) p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. *Dig Dis Sci*, **47**, 114-21.

Kushima, R. and Hattori, T. (1993) Histogenesis and characteristics of gastric-type adenocarcinomas in the stomach. *J Cancer Res Clin Oncol*, **120**, 103-11.

Lee, J.H., Abraham, S.C., Kim, H.S., Nam, J.H., Choi, C., Lee, M.C., Park, C.S., Juhng, S.W., Rashid, A., Hamilton, S.R., and Wu, T.T. (2002) Inverse relationship between APC gene mutation in gastric adenomas and development of adenocarcinoma. *Am J Pathol*, **161**, 611-8.

Lee, K.H., Lee, J.S., Suh, C., Kim, S.W., Kim, S.B., Lee, J.H., Lee, M.S., Park, M.Y., Sun, H.S., and Kim, S.H. (1995) Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. *Cancer*, **75**, 2794-801.

Lee, S.H., Kim, W.H., Kim, H.K., Woo, K.M., Nam, H.S., Kim, H.S., Kim, J.G., and Cho, M.H. (2001) Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas. *Biochem Biophys Res Commun*, **284**, 850-5.

Lee, S.H., Lee, J.W., Soung, Y.H., Kim, H.S., Park, W.S., Kim, S.Y., Lee, J.H., Park, J.Y., Cho, Y.G., Kim, C.J., Nam, S.W., Kim, S.H., Lee, J.Y., and Yoo, N.J. (2003) BRAF and KRAS mutations in stomach cancer. *Oncogene*, **22**, 6942-5.

Lee, Y.Y., Kang, S.H., Seo, J.Y., Jung, C.W., Lee, K.U., Choe, K.J., Kim, B.K., Kim, N.K., Koeffler, H.P., and Bang, Y.J. (1997) Alterations of p16INK4A and p15INK4B genes in gastric carcinomas. *Cancer*, **80**, 1889-96.

Liang, Y.Y., Esteve, A., Martel-Planche, G., Takahashi, S., Lu, S.H., Montesano, R., and Hollstein, M. (1995) p53 mutations in esophageal tumors from high-incidence areas of China. *Int J Cancer*, **61**, 611-4.

Lin, S.Y., Chen, P.H., Wang, C.K., Liu, J.D., Siauw, C.P., Chen, Y.J., Yang, M.J., Liu, M.H., Chen, T.C., and Chang, J.G. (1993) Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction sites method. *Am J Clin Pathol*, **100**, 686-9.

Lu, C., Xu, H.M., Ren, Q., Ao, Y., Wang, Z.N., Ao, X., Jiang, L., Luo, Y., and Zhang, X. (2003) Somatic mutation analysis of p53 and ST7 tumor suppressor genes in gastric carcinoma by DHPLC. *World J Gastroenterol*, **9**, 2662-5.

Machado, J.C., Soares, P., Carneiro, F., Rocha, A., Beck, S., Blin, N., Berx, G., and Sobrinho-Simoes, M. (1999) E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. *Lab Invest*, **79**, 459-65.

Maesawa, C., Tamura, G., Suzuki, Y., Ogasawara, S., Sakata, K., Kashiwaba, M., and Satodate, R. (1995) The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. *J Pathol*, **176**, 249-58.

Matozaki, T., Sakamoto, C., Suzuki, T., Matsuda, K., Uchida, T., Nakano, O., Wada, K., Nishisaki, H., Konda, Y., Nagao, M., and et al. (1992) p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells. *Cancer Res*, **52**, 4335-41.

Migliavacca, M., Ottini, L., Bazan, V., Agnese, V., Corsale, S., Macaluso, M., Lupi, R., Dardanoni, G., Valerio, M.R., Pantuso, G., Di Fede, G., Tomasino, R.M., Gebbia, N., Mariani-Costantini, R., and Russo, A. (2004) TP53 in gastric cancer: mutations in the I3 loop and LSH motif DNA-binding domains of TP53

predict poor outcome. *J Cell Physiol*, **200**, 476-85.

Miki, H., Ohmori, M., Perantoni, A.O., and Enomoto, T. (1991) K-ras activation in gastric epithelial tumors in Japanese. *Cancer Lett*, **58**, 107-13.

Mironov, N.M., Aguelon, M.A., Potapova, G.I., Omori, Y., Gorbunov, O.V., Klimenkov, A.A., and Yamasaki, H. (1994) Alterations of (CA)n DNA repeats and tumor suppressor genes in human gastric cancer. *Cancer Res*, **54**, 41-4.

Miyazawa, K., Iwaya, K., Kuroda, M., Harada, M., Serizawa, H., Koyanagi, Y., Sato, Y., Mizokami, Y., Matsuoka, T., and Mukai, K. (2000) Nuclear accumulation of beta-catenin in intestinal-type gastric carcinoma: correlation with early tumor invasion. *Virchows Arch*, **437**, 508-13.

Nabais, S., Machado, J.C., Lopes, C., Seruca, R., Carneiro, F., and Sobrinho-Simoes, M. (2003) Patterns of beta-catenin expression in gastric carcinoma: clinicopathological relevance and mutation analysis. *Int J Surg Pathol*, **11**, 1-9.

Nagata, Y., Abe, M., Kobayashi, K., Yoshida, K., Ishibashi, T., Naoe, T., Nakayama, E., and Shiku, H. (1990) Glycine to aspartic acid mutations at codon 13 of the c-Ki-ras gene in human gastrointestinal cancers. *Cancer Res*, **50**, 480-2.

Nagel, S., Borisch, B., Thein, S.L., Oestreicher, M., Nothiger, F., Birrer, S., Tobler, A., and Fey, M.F. (1995) Somatic mutations detected by mini- and microsatellite DNA markers reveal clonal intratumor heterogeneity in gastrointestinal cancers. *Cancer Res*, **55**, 2866-70.

Nakatsuru, S., Yanagisawa, A., Furukawa, Y., Ichii, S., Kato, Y., Nakamura, Y., and Horii, A. (1993) Somatic mutations of the APC gene in precancerous lesion of the stomach. *Hum Mol Genet*, **2**, 1463-5.

Nakatsuru, S., Yanagisawa, A., Ichii, S., Tahara, E., Kato, Y., Nakamura, Y., and Horii, A. (1992) Somatic mutation of the APC gene in gastric cancer: frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma. *Hum Mol Genet*, **1**, 559-63.

Nanus, D.M., Kelsen, D.P., Mentle, I.R., Altorki, N., and Albino, A.P. (1990) Infrequent point mutations of ras oncogenes in gastric cancers. *Gastroenterology*, **98**, 955-60.

Neuman, W.L., Waslylyshyn, M.L., Jacoby, R., Erroi, F., Angriman, I., Montag, A., Brasitus, T., Michelassi, F., and Westbrook, C.A. (1991) Evidence for a common molecular pathogenesis in colorectal, gastric, and pancreatic cancer. *Genes Chromosomes Cancer*, **3**, 468-73.

Nishizuka, S., Tamura, G., Maesawa, C., Sakata, K., Suzuki, Y., Iwaya, T., Terashima, M., Saito, K., and Satodate, R. (1997) Analysis of the DPC4 gene in gastric carcinoma. *Jpn J Cancer Res*, **88**, 335-9.

Noguchi, T., Muller, W., Wirtz, H.C., Willers, R., and Gabbert, H.E. (1999) FHIT gene in gastric cancer: association with tumour progression and prognosis. *J Pathol*, **188**, 378-81.

Ogasawara, S., Maesawa, C., Tamura, G., and Satodate, R. (1994) Lack of mutations of the adenomatous polyposis coli gene in oesophageal and gastric carcinomas. *Virchows Arch*, **424**, 607-11.

Ohta, M., Inoue, H., Cotticelli, M.G., Kastury, K., Baffa, R., Palazzo, J., Siprashvili, Z., Mori, M., McCue, P., Druck, T., and et, a.l. (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3+ADs-8) breakpoint, is abnormal in digestive tract cancers. *Cell*, **84**, 587-97.

Oliveira, C., Pinto, M., Duval, A., Bennetot, C., Domingo, E., Espin, E., Armengol, M., Yamamoto, H., Hamelin, R., Seruca, R., and Schwartz, S. Jr (2003) BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. *Oncogene*, **22**, 9192-6.

- Ott, K., Vogelsang, H., Mueller, J., Becker, K., Muller, M., Fink, U., Siewert, J.R., Hofler, H., and Keller, G. (2003) Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. *Clin Cancer Res*, **9**, 2307-15.
- Park, T.J., Han, S.U., Cho, Y.K., Paik, W.K., Kim, Y.B., and Lim, I.K. (2001) Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. *Cancer*, **92**, 2760-8.
- Park, W.S., Oh, R.R., Park, J.Y., Lee, S.H., Shin, M.S., Kim, Y.S., Kim, S.Y., Lee, H.K., Kim, P.J., Oh, S.T., Yoo, N.J., and Lee, J.Y. (1999) Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. *Cancer Res*, **59**, 4257-60.
- Petty, E.M., Kalikin, L.M., Orringer, M.B., and Beer, D.G. (1998) Distal chromosome 17q loss in Barrett's esophageal and gastric cardia adenocarcinomas: implications for tumorigenesis. *Mol Carcinog*, **22**, 222-8.
- Petursdottir, T.E., Hafsteinsdottir, S.H., Jonasson, J.G., Moller, P.H., Thorsteinsdottir, U., Huiping, C., Egilsson, V., and Ingvarsson, S. (2002) Loss of heterozygosity at the FHIT gene in different solid human tumours and its association with survival in colorectal cancer patients. *Anticancer Res*, **22**, 3205-12.
- Poremba, C., Yandell, D.W., Huang, Q., Little, J.B., Mellin, W., Schmid, K.W., Bocker, W., and Dockhorn-Dworniczak, B. (1995) Frequency and spectrum of p53 mutations in gastric cancer--a molecular genetic and immunohistochemical study. *Virchows Arch*, **426**, 447-55.
- Powell, S.M., Cummings, O.W., Mullen, J.A., Asghar, A., Fuga, G., Piva, P., Minacci, C., Megha, T., Tosi, P., and Jackson, C.E. (1996) Characterization of the APC gene in sporadic gastric adenocarcinomas. *Oncogene*, **12**, 1953-9.
- Ranzani, G.N., Luinetti, O., Padovan, L.S., Calistri, D., Renault, B., Burrel, M., Amadori, D., Fiocca, R., and Solcia, E. (1995) p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. *Cancer Epidemiol Biomarkers Prev*, **4**, 223-31.
- Ranzani, G.N., Renault, B., Pellegata, N.S., Fattorini, P., Magni, E., Bacci, F., and Amadori, D. (1993) Loss of heterozygosity and K-ras gene mutations in gastric cancer. *Hum Genet*, **92**, 244-9.
- Renault, B., Calistri, D., Buonsanti, G., Nanni, O., Amadori, D., and Ranzani, G.N. (1996) Microsatellite instability and mutations of p53 and TGF-beta RII genes in gastric cancer. *Hum Genet*, **98**, 601-7.
- Renault, B., van den Broek, M., Fodde, R., Wijnen, J., Pellegata, N.S., Amadori, D., Khan, P.M., and Ranzani, G.N. (1993) Base transitions are the most frequent genetic changes at P53 in gastric cancer. *Cancer Res*, **53**, 2614-7.
- Rhyu, M.G., Park, W.S., Jung, Y.J., Choi, S.W., and Meltzer, S.J. (1994) Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. *Gastroenterology*, **106**, 1584-8.
- Ricevuto, E., Ficarella, C., Fusco, C., Cannita, K., Tessitore, A., Toniato, E., Gabriele, A., Frati, L., Marchetti, P., Gulino, A., and Martinotti, S. (1996) Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparation. *Am J Pathol*, **148**, 405-13.
- Rugge, M., Shiao, Y.H., Busatto, G., Cassaro, M., Strobbe, C., Russo, V.M., Leo, G., Parenti, A.R., Scapinello, A., Arslan, P., Egarter-Vigl, E., Baffa, R., Ruol, A., Plebani, M., Bovo, D., Fawzy, S., Guido, M., Ancona, E., Ninfo, V., Correa, P., Lehmann, H.P., Scheer, W.D., Palli, D., Caporaso, N.E., Alvord, W.G., Amorosi, A., Nesi, G., Saieva, C., Masala, G., Fraumeni, J.F.Jr., and Rice, J.M. (2000) The p53 gene in patients under the age of 40 with gastric cancer: mutation rates are low but are associated with a cardiac location. *Mol Pathol*, **53**, 207-10.

- Saegusa, M., Takano, Y., Kamata, Y., and Okayasu, J. (1996) Bcl-2 expression and allelic loss of the p53 gene in gastric carcinomas. *J Cancer Res Clin Oncol*, **122**, 427-32.
- Safatle-Ribeiro, A.V., Ribeiro Junior, U., Reynolds, J.C., Gama-Rodrigues, J.J., Iriya, K., Kim, R., Bakker, A., Swalsky, P.A., Pinotti, H.W., and Finkelstein, S.D. (1996) Morphologic, histologic, and molecular similarities between adenocarcinomas arising in the gastric stump and the intact stomach. *Cancer*, **78**, 2288-99.
- Saito, A., Kanai, Y., Maesawa, C., Ochiai, A., Torii, A., and Hirohashi, S. (1999) Disruption of E-cadherin-mediated cell adhesion systems in gastric cancers in young patients. *Jpn J Cancer Res*, **90**, 993-9.
- Sakata, K., Tamura, G., Maesawa, C., Suzuki, Y., Terashima, M., Satoh, K., Eda, Y., Suzuki, A., Sekiyama, S., and Satodate, R. (1995) Loss of heterozygosity on the short arm of chromosome 9 without p16 gene mutation in gastric carcinomas. *Jpn J Cancer Res*, **86**, 333-5.
- Sakurai, S., Sano, T., and Nakajima, T. (1995) Clinicopathological and molecular biological studies of gastric adenomas with special reference to p53 abnormality. *Pathol Int*, **45**, 51-7.
- Sasaki, Y., Morimoto, I., Kusano, M., Hosokawa, M., Itoh, F., Yanagihara, K., Imai, K., and Tokino, T. (2001) Mutational analysis of the beta-catenin gene in gastric carcinomas. *Tumour Biol*, **22**, 123-30.
- Schneider, B.G., Hilsenbeck, S.G., Hensel, C.H., Pekkel, V., Shelton, C.H., Rodriguez-Martinez, H.A., Gutierrez-Diaz, M.E., Pulitzer, D.R., and Allred, D.C. (1994) p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. *Virchows Arch*, **424**, 187-93.
- Semba, S., Yokozaki, H., Yamamoto, S., Yasui, W., and Tahara, E. (1996) Microsatellite instability in precancerous lesions and adenocarcinomas of the stomach. *Cancer*, **77**, 1620-7.
- Seruca, R., David, L., Castedo, S., Veiga, I., Borresen, A.L., and Sobrinho-Simoes, M. (1994) p53 alterations in gastric carcinoma: a study of 56 primary tumors and 204 nodal metastases. *Cancer Genet Cytogenet*, **75**, 45-50.
- Seruca, R., David, L., Holm, R., Nesland, J.M., Fangan, B.M., Castedo, S., Sobrinho-Simoes, M., and Borresen, A.L. (1992) P53 mutations in gastric carcinomas. *Br J Cancer*, **65**, 708-10.
- Seta, T., Imazeki, F., Yokosuka, O., Saisho, H., Suzuki, T., Koide, Y., and Isono, K. (1998) Expression of p53 and p21WAF1/CIP1 proteins in gastric and esophageal cancers: comparison with mutations of the p53 gene. *Dig Dis Sci*, **43**, 279-89.
- Shen, C., Chang, J.G., Lee, L.S., Yang, M.J., Chen, T.C., Lin, K.Y., Lee, M.D., and Chen, P.H. (1991) Analysis of ras gene mutations in gastrointestinal cancers. *J Formos Med Assoc*, **90**, 1149-54.
- Shepherd, T., Tolbert, D., Benedetti, J., Macdonald, J., Stemmermann, G., Wiest, J., DeVoe, G., Miller, M.A., Wang, J., Noffsinger, A., and Fenoglio-Preiser, C. (2000) Alterations in exon 4 of the p53 gene in gastric carcinoma. *Gastroenterology*, **118**, 1039-44.
- Shiao, Y.H., Palli, D., Buzard, G.S., Caporaso, N.E., Amorosi, A., Saieva, C., Fraumeni, J.F.Jr., Anderson, L.M., and Rice, J.M. (1998) Implications of p53 mutation spectrum for cancer etiology in gastric cancers of various histologic types from a high-risk area of central Italy. *Carcinogenesis*, **19**, 2145-9.
- Shiao, Y.H., Rugge, M., Correa, P., Lehmann, H.P., Scheer, W.D., Palli, D., Caporaso, N.E., Alvord, W.G., Amorosi, A., Nesi, G., Saieva, C., Masala, G., Fraumeni, J.F.Jr., and Rice, J.M. (1994) p53 alteration in gastric precancerous lesions
Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers

Diet, Helicobacter pylori, and p53 mutations in gastric cancer: a molecular epidemiology study in Italy. *Am J Pathol*, **144**, 511-7.

Shibata, A., Parsonnet, J., Longacre, T.A., Garcia, M.I., Puligandla, B., Davis, R.E., Vogelman, J.H., Orentreich, N., and Habel, L.A. (2002) CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma. *Carcinogenesis*, **23**, 419-24.

Strickler, J.G., Zheng, J., Shu, Q., Burgart, L.J., Alberts, S.R., and Shibata, D. (1994) p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. *Cancer Res*, **54**, 4750-5.

Sud, R., Talbot, I.C., and Delhanty, J.D. (1996) Infrequent alterations of the APC and MCC genes in gastric cancers from British patients. *Br J Cancer*, **74**, 1104-8.

Sud, R., Wells, D., Talbot, I.C., and Delhanty, J.D. (2001) Genetic alterations in gastric cancers from British patients. *Cancer Genet Cytogenet*, **126**, 111-9.

Sugai, T., Habano, W., Nakamura, S., Yoshida, T., Uesugi, N., Suto, T., and Itoh, C. (1998) Correlation of histologic morphology and tumor stage with molecular genetic analysis using microdissection in gastric carcinomas. *Diagn Mol Pathol*, **7**, 235-40.

Suzuki, S., Muroishi, Y., Nakanishi, I., and Oda, Y. (2004) Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer. *J Gastroenterol*, **39**, 220-30.

Takaoka, A.S., Kakiuchi, H., Itoh, F., Hinoda, Y., Kusano, M., Ohara, M., Tsukakoshi, H., Hosokawa, M., and Imai, K. (1997) Infrequent alterations of the p16 (MTS-1) gene in human gastric cancer. *Tumour Biol*, **18**, 95-103.

Tamura, G., Kihana, T., Nomura, K., Terada, M., Sugimura, T., and Hirohashi, S. (1991) Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. *Cancer Res*, **51**, 3056-8.

Tamura, G., Maesawa, C., Suzuki, Y., Ogasawara, S., Terashima, M., Saito, K., and Satodate, R. (1993) Primary gastric carcinoma cells frequently lose heterozygosity at the APC and MCC genetic loci. *Jpn J Cancer Res*, **84**, 1015-8.

Tamura, G., Maesawa, C., Suzuki, Y., Tamada, H., Satoh, M., Ogasawara, S., Kashiwaba, M., and Satodate, R. (1994) Mutations of the APC gene occur during early stages of gastric adenoma development. *Cancer Res*, **54**, 1149-51.

Tamura, G., Sakata, K., Maesawa, C., Suzuki, Y., Terashima, M., Satoh, K., Sekiyama, S., Suzuki, A., Eda, Y., and Satodate, R. (1995) Microsatellite alterations in adenoma and differentiated adenocarcinoma of the stomach. *Cancer Res*, **55**, 1933-6.

Tamura, G., Sakata, K., Nishizuka, S., Maesawa, C., Suzuki, Y., Iwaya, T., Terashima, M., Saito, K., and Satodate, R. (1997) Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines. *Genes Chromosomes Cancer*, **20**, 98-102.

Tamura, G., Sato, K., Akiyama, S., Tsuchiya, T., Endoh, Y., Usuba, O., Kimura, W., Nishizuka, S., and Motoyama, T. (2001) Molecular characterization of undifferentiated-type gastric carcinoma. *Lab Invest*, **81**, 593-8.

Tang, S., Luo, H., Yu, J., Yang, D., and Shu, J. (2003) Relationship between alterations of p16(INK4a) and p14(ARF) genes of CDKN2A locus and gastric carcinogenesis. *Chin Med J (Engl)*, **116**, 1083-7.

Tannapfel, A., Schmelzer, S., Benicke, M., Klimpfinger, M., Kohlhaw, K., Mossner, J., Engeland, K., and Wittekind, C. (2001) Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer. *J Pathol*, **195**, 163-70.

Tohdo, H., Yokozaki, H., Haruma, K., Kajiyama, G., and Tahara, E. (1993) p53 gene mutations in gastric adenomas. *Virchows Arch B Cell Pathol Incl Mol Pathol*, **63**, 191-5.

Tolbert, D., Fenoglio-Preiser, C., Noffsinger, A., De Voe, G., MacDonald, J., Benedetti, J., and Stemmermann, G.N. (1999) The relation of p53 gene mutations to gastric cancer subsite and phenotype. *Cancer Causes Control*, **10**, 227-31.

Tolbert, D.M., Noffsinger, A.E., Miller, M.A., DeVoe, G.W., Stemmermann, G.N., Macdonald, J.S. , and Fenoglio-Preiser, C.M. (1999) p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. *Mod Pathol*, **12**, 54-60.

Tong, J.H., To, K.F., Ng, E.K., Lau, J.Y., Lee, T.L., Lo, K.W., Leung, W.K., Tang, N.L., Chan, F.K., Sung, J.J., and Chung, S.C. (2001) Somatic beta-catenin mutation in gastric carcinoma--an infrequent event that is not specific for microsatellite instability. *Cancer Lett*, **163**, 125-30.

Toyooka, M., Konishi, M., Kikuchi-Yanoshita, R., Iwama, T., and Miyaki, M. (1995) Somatic mutations of the adenomatous polyposis coli gene in gastroduodenal tumors from patients with familial adenomatous polyposis. *Cancer Res*, **55**, 3165-70.

Tsuchiya, C., Ohshima, S., and Takahama, M. (1997) Detection of c-Ki-ras oncogene mutation in gastric adenomas with formalin-fixed, paraffin-embedded biopsy materials. *J Gastroenterol*, **32**, 28-33.

Uchino, S., Noguchi, M., Ochiai, A., Saito, T., Kobayashi, M., and Hirohashi, S. (1993) p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. *Int J Cancer*, **54**, 759-64.

van Rees, B.P., Musler, A., Caspers, E., Drillenburg, P., Craanen, M.E., Polkowski, W., Chibowski, D., and Offerhaus, G.J. (1999) K-ras mutations in gastric stump carcinomas and in carcinomas from the non-operated stomach. *Hepatogastroenterology*, **46**, 2063-8.

Victor, T., Du Toit, R., Jordaan, A.M., Bester, A.J., and van Helden, P.D. (1990) No evidence for point mutations in codons 12, 13, and 61 of the ras gene in a high-incidence area for esophageal and gastric cancers. *Cancer Res*, **50**, 4911-4.

Wang, D., Fang, D., Luo, Y., Lu, R., and Liu, W. (1999) Study of loss of heterozygosity at DCC and APC/MCC genetic loci of gastric cancer. *Chin Med Sci J*, **14**, 107-11.

Wang, J.Y., Lin, S.R., Hsieh, J.S., Hsu, C.H., Huang, Y.S., and Huang, T.J. (2001) Mutations of p53 gene in gastric carcinoma in Taiwan. *Anticancer Res*, **21**, 513-20.

Wang, X.J., Yuan, S.L., Li, C.P., Iida, N., Oda, H., Aiso, S., and Ishikawa, T. (2000) Infrequent p53 gene mutation and expression of the cardia adenocarcinomas from a high-incidence area of Southwest China. *World J Gastroenterol*, **6**, 750-753.

Woo, D.K., Kim, H.S., Lee, H.S., Kang, Y.H., Yang, H.K., and Kim, W.H. (2001) Altered expression and mutation of beta-catenin gene in gastric carcinomas and cell lines. *Int J Cancer*, **95**, 108-13.

Wu, M., Semba, S., Li, D., and Yokozaki, H. (2004) Molecular pathological analysis of mucinous adenocarcinomas of the stomach. *Pathobiology*, **71**, 201-10.

Wu, M., Semba, S., Oue, N., Ikehara, N., Yasui, W., and Yokozaki, H. (2004) BRAF/K-ras mutation,

microsatellite instability, and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas. *Gastric Cancer*, **7**, 246-53.

Wu, M.S., Lin, Y.W., Sheu, J.C., Wang, H.P., Wang, J.T., Shun, C.T., Lee, W.J., Wang, T.H., and Lin, J.T. (1996) Intragenic homozygous deletions of MTS1 gene in gastric cancer in Taiwan. *Jpn J Cancer Res*, **87**, 1052-5.

Wu, M.S., Shun, C.T., Wang, H.P., Sheu, J.C., Lee, W.J., Wang, T.H., and Lin, J.T. (1997) Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. *Gastroenterology*, **112**, 1457-65.

Yamada, Y., Yoshida, T., Hayashi, K., Sekiya, T., Yokota, J., Hirohashi, S., Nakatani, K., Nakano, H., Sugimura, T., and Terada, M. (1991) p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. *Cancer Res*, **51**, 5800-5.

Yamamoto, H., Perez-Piteira, J., Yoshida, T., Terada, M., Itoh, F., Imai, K., and Perucho, M. (1999) Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. *Gastroenterology*, **116**, 1348-57.

Yanagi, M., Keller, G., Mueller, J., Walch, A., Werner, M., Stein, H.J., Siewert, J.R., and Hofler, H. (2000) Comparison of loss of heterozygosity and microsatellite instability in adenocarcinomas of the distal esophagus and proximal stomach. *Virchows Arch*, **437**, 605-10.

Yashiro, M., Nishioka, N., and Hirakawa, K. (2005) K-ras mutation influences macroscopic features of gastric carcinoma. *J Surg Res*, **124**, 74-8.

Yokozaki, H., Kuniyasu, H., Kitadai, Y., Nishimura, K., Todo, H., Ayhan, A., Yasui, W., Ito, H., and Tahara, E. (1992) p53 point mutations in primary human gastric carcinomas. *J Cancer Res Clin Oncol*, **119**, 67-70.

Yoo, J., Park, S.Y., Robinson, R.A., Kang, S.J., Ahn, W.S., and Kang, C.S. (2002) ras Gene mutations and expression of Ras signal transduction mediators in gastric adenocarcinomas. *Arch Pathol Lab Med*, **126**, 1096-100.

Zhao, G.H., Li, T.C., Shi, L.H., Xia, Y.B., Lu, L.M., Huang, W.B., Sun, H.L., and Zhang, Y.S. (2003) Relationship between inactivation of p16 gene and gastric carcinoma. *World J Gastroenterol*, **9**, 905-9.

Zhao, W., Chan, T.L., Chu, K.M., Chan, A.S., Stratton, M.R., Yuen, S.T., and Leung, S.Y. (2004) Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability. *Int J Cancer*, **108**, 167-9.

Colorectal: Spontaneous

Akiyama, Y., Arai, T., Nagasaki, H., Yagi, O.K., Nakahata, A., Nakajima, T., Ohkura, Y., Iwai, T., Saitoh, K., and Yuasa, Y. (1999) Frequent allelic imbalance on chromosome 18q21 in early superficial colorectal cancers. *Jpn J Cancer Res*, **90**, 1329-37.

Albanese, I., Scibetta, A.G., Migliavacca, M., Russo, A., Bazan, V., Tomasino, R.M., Colomba, P., Tagliavia, M., and La Farina, M. (2004) Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. *Biochem Biophys Res Commun*, **325**, 784-91.

Albuquerque, C., Breukel, C., van der Luijt, R., Fidalgo, P., Lage, P., Slors, F.J., Leitao, C.N., Fodde, R., and Smits, R. (2002) The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. *Hum Mol Genet*, **11**, 1549-60.

Andreyev, H.J., Tilsed, J.V., Cunningham, D., Sampson, S.A., Norman, A.R., Schneider, H.J., and Clarke, P.A. (1997) K-ras mutations in patients with early colorectal cancers. *Gut*, **41**, 323-9.

Aoki, T., Takeda, S., Yanagisawa, A., Kato, Y., Ajioka, Y., Watanabe, H., Kudo, S., and Nakamura, Y. (1994) APC and p53 mutations in de novo colorectal adenocarcinomas. *Hum Mutat*, **3**, 342-6.

Baisse, B., Bouzourene, H., Saraga, E.P., Bosman, F.T., and Benhettar, J. (2001) Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. *Int J Cancer*, **93**, 346-52.

Baker, S.J., Preisinger, A.C., Jessup, J.M., Paraskeva, C., Markowitz, S., Willson, J.K., Hamilton, S., and Vogelstein, B. (1990) p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. *Cancer Res*, **50**, 7717-22.

Barletta, C., Scillato, F., Sega, F.M., and Mannella, E. (1993) Genetic alteration in gastrointestinal cancer. A molecular and cytogenetic study. *Anticancer Res*, **13**, 2325-9.

Bautista, D., Obrador, A., Moreno, V., Cabeza, E., Canet, R., Benito, E., Bosch, X., and Costa, J. (1997) Ki-ras mutation modifies the protective effect of dietary monounsaturated fat and calcium on sporadic colorectal cancer. *Cancer Epidemiol Biomarkers Prev*, **6**, 57-61.

Bazan, V., Migliavacca, M., Tubiolo, C., Macaluso, M., Zanna, I., Corsale, S., Amato, A., Calo, V., Dardanoni, G., Morello, V., La Farina, M., Albanese, I., Tomasino, R.M., Gebbia, N., and Russo, A. (2002) Have p53 gene mutations and protein expression a different biological significance in colorectal cancer? *J Cell Physiol*, **191**, 237-46.

Benhettar, J., Cerottini, J.P., Saraga, E., Metthez, G., and Givel, J.C. (1996) p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. *Int J Cancer*, **69**, 190-2.

Benhettar, J., Losi, L., Chaubert, P., Givel, J.C., and Costa, J. (1993) Prognostic significance of K-ras mutations in colorectal carcinoma. *Gastroenterology*, **104**, 1044-8.

Bertorelle, R., Esposito, G., Del Mistro, A., Belluco, C., Nitti, D., Lise, M., and Chieco-Bianchi, L. (1995) Association of p53 gene and protein alterations with metastases in colorectal cancer. *Am J Surg Pathol*, **19**, 463-71.

Borresen-Dale, A.L., Lothe, R.A., Meling, G.I., Hainaut, P., Rognum, T.O., and Skovlund, E. (1998) TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. *Clin Cancer Res*, **4**, 203-10.

Boughdady, I.S., Kinsella, A.R., Haboubi, N.Y., and Schofield, P.F. (1992) K-ras gene mutation in colorectal adenomas and carcinomas from familial adenomatous polyposis patients. *Surg Oncol*, **1**, 269-74.

Boughdady, I.S., Kinsella, A.R., Haboubi, N.Y., and Schofield, P.F. (1992) K-ras gene mutations in adenomas and carcinomas of the colon. *Surg Oncol*, **1**, 275-82.

Breivik, J., Meling, G.I., Spurkland, A., Rognum, T.O., and Gaudernack, G. (1994) K-ras mutation in colorectal cancer: Relations to patient age, sex and tumour location. *Br J Cancer*, **69**, 367-71.

Burmer, G.C., Crispin, D.A., Kolli, V.R., Haggitt, R.C., Kulander, B.G., Rubin, C.E., and Rabinovitch, P.S. (1991) Frequent loss of a p53 allele in carcinomas and their precursors in ulcerative colitis. *Cancer Commun*, **3**, 167-72.

Burri, N., Shaw, P., Bouzourene, H., Sordat, I., Sordat, B., Gillet, M., Schorderet, D., Bosman, F.T., and Chaubert, P. (2001) Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. *Lab Invest*, **81**, 217-29.

- Calistri, D., Rengucci, C., Bocchini, R., Saragoni, L., Zoli, W., and Amadori, D. (2003) Fecal multiple molecular tests to detect colorectal cancer in stool. *Clin Gastroenterol Hepatol*, **1**, 377-83.
- Campo, E., de la Calle-Martin, O., Miquel, R., Palacin, A., Romero, M., Fabregat, V., Vives, J., Cardesa, A., and Yague, J. (1991) Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. *Cancer Res*, **51**, 4436-42.
- Campo, E., Miquel, R., Jares, P., Bosch, F., Juan, M., Leone, A., Vives, J., Cardesa, A., and Yague, J. (1994) Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal carcinomas. *Cancer*, **73**, 2913-21.
- Campomenosi, P., Asereto, P., Bogliolo, M., Fronza, G., Abbondandolo, A., Capasso, A., Bellomo, P.F., Monaco, R., Rapallo, A., Sciutto, A., Oreccchia, R., Geido, E., and Giaretti, W. (1998) p53 mutations and DNA ploidy in colorectal adenocarcinomas. *Anal Cell Pathol*, **17**, 1-12.
- Carethers, J.M., Hawn, M.T., Greenson, J.K., Hitchcock, C.L., and Boland, C.R. (1998) Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. *Gastroenterology*, **114**, 1188-95.
- Cerottini, J.P., Caplin, S., Saraga, E., Givel, J.C., and Benhatar, J. (1998) The type of K-ras mutation determines prognosis in colorectal cancer. *Am J Surg*, **175**, 198-202.
- Chang, S.C., Lin, J.K., Lin, T.C., and Liang, W.Y. (2005) Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. *Int J Oncol*, **26**, 65-75.
- Chang, S.C., Lin, J.K., Lin, T.C., and Liang, W.Y. (2005) Loss of heterozygosity: an independent prognostic factor of colorectal cancer. *World J Gastroenterol*, **11**, 778-84.
- Chen, P.H., Lin, S.Y., Wang, C.K., Chen, Y.J., Chen, T.C., and Chang, J.G. (1993) "Hot spots" mutation analysis of p53 gene in gastrointestinal cancers by amplification of naturally occurring and artificially created restriction sites. *Clin Chem*, **39**, 2186-91.
- Chetty, R., Naidoo, R., and Schneider, J. (1998) Allelic imbalance and microsatellite instability of the DCC gene in colorectal cancer in patients under the age of 35 using fluorescent DNA technology. *Mol Pathol*, **51**, 35-8.
- Chiang, J.M. (1998) Role of K-ras mutations in colorectal carcinoma. *Cancer Lett*, **126**, 179-85.
- Colomer, A., Erill, N., Verdu, M., Roman, R., Vidal, A., Cordon-Cardo, C., and Puig, X. (2003) Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas. *Appl Immunohistochem Mol Morphol*, **11**, 130-7.
- Crabtree, M., Sieber, O.M., Lipton, L., Hodgson, S.V., Lamlum, H., Thomas, H.J., Neale, K., Phillips, R.K., Heinemann, K., and Tomlinson, I.P. (2003) Refining the relation between 'first hits' and 'second hits' at the APC locus: the 'loose fit' model and evidence for differences in somatic mutation spectra among patients. *Oncogene*, **22**, 4257-65.
- Cripps, K.J., Purdie, C.A., Carder, P.J., White, S., Komine, K., Bird, C.C., and Wyllie, A.H. (1994) A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. *Oncogene*, **9**, 2739-43.
- Cunningham, J., Lust, J.A., Schaid, D.J., Bren, G.D., Carpenter, H.A., Rizza, E., Kovach, J.S., and Thibodeau, S.N. (1992) Expression of p53 and 17p allelic loss in colorectal carcinoma. *Cancer Res*, **52**, 1974-80.

Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B.A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.J., Bigner, D.D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J.W., Leung, S.Y., Yuen, S.T., Weber, B.L., Seigler, H.F., Darrow, T.L., Paterson, H., Marais, R., Marshall, C.J., Wooster, R., Stratton, M.R., and Futreal, P.A. (2002) Mutations of the BRAF gene in human cancer. *Nature*, **417**, 949-54.

De Angelis, P., Stokke, T., Smedshammer, L., and et al. (1993) P53 expression associated with high degree of tumor DNAaneuploidy and incidence of P53 gene mutations and is localized to the aneuploid component in colorectal carcinomas. *Int J Oncol*, **3**, 305-12.

De Benedetti, L., Sciallero, S., Gismondi, V., James, R., Bafico, A., Biticchi, R., Masetti, E., Bonelli, L., Heouaine, A., Picasso, M., and et, a.l. (1994) Association of APC gene mutations and histological characteristics of colorectal adenomas. *Cancer Res*, **54**, 3553-6.

De Benedetti, L., Varesco, L., Pellegata, N.S., Losi, L., Gismondi, V., Casarino, L., Sciallero, S., Bonelli, L., Biticchi, R., Bafico, A., and et, a.l. (1993) Genetic events in sporadic colorectal adenomas: K-ras and p53 heterozygous mutations are not sufficient for malignant progression. *Anticancer Res*, **13**, 667-70.

De Filippo, C., Luceri, C., Caderni, G., Pacini, M., Messerini, L., Biggeri, A., Mini, E., Tonelli, F., Cianchi, F., and Dolara, P. (2002) Mutations of the APC gene in human sporadic colorectal cancers. *Scand J Gastroenterol*, **37**, 1048-53.

Dehari, R. (2001) Infrequent APC mutations in serrated adenoma. *Tohoku J Exp Med*, **193**, 181-6.

Deng, G., Bell, I., Crawley, S., Gum, J., Terdiman, J.P., Allen, B.A., Truta, B., Slesinger, M.H., and Kim, Y.S. (2004) BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. *Clin Cancer Res*, **10**, 191-5.

Deuter, R., Linz, J., Pietsch, S., Winde, G., Hentsch, S., and Muller, O. (1996) DNA alterations in sporadic colorectal tumors do not correlate with tumor staging diagnosed by the TNM system. *Cancer Lett*, **109**, 161-9.

Dillon, D., Zheng, K., and Costa, J. (2001) Rapid, efficient genotyping of clinical tumor samples by laser-capture microdissection/PCR/SSCP. *Exp Mol Pathol*, **70**, 195-200.

Ding, S.F., Delhanty, J.D., Dooley, J.S., Bowles, L., Wood, C.B., and Habib, N.A. (1993) The putative tumor suppressor gene on chromosome 5q for hepatocellular carcinoma is distinct from the MCC and APC genes. *Cancer Detect Prev*, **17**, 405-9.

Dix, B., Robbins, P., Carrello, S., House, A., and Iacopetta, B. (1994) Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. *Br J Cancer*, **70**, 585-90.

Domingo, E., Laiho, P., Ollikainen, M., Pinto, M., Wang, L., French, A.J., Westra, J., Frebourg, T., Espin, E., Armengol, M., Hamelin, R., Yamamoto, H., Hofstra, R.M., Seruca, R., Lindblom, A., Peltomaki, P., Thibodeau, S.N., Aaltonen, L.A., and Schwartz, S.Jr. (2004) BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. *J Med Genet*, **41**, 664-8.

Dong, S.M., Traverso, G., Johnson, C., Geng, L., Favis, R., Boynton, K., Hibi, K., Goodman, S.N., D'Allessio, M., Paty, P., Hamilton, S.R., Sidransky, D., Barany, F., Levin, B., Shuber, A., Kinzler, K.W., Vogelstein, B., and Jen, J. (2001) Detecting colorectal cancer in stool with the use of multiple genetic targets. *J Natl Cancer Inst*, **93**, 858-65.

- Elnatan, J., Goh, H.S., and Smith, D.R. (1996) C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. *Eur J Cancer*, **32A**, 491-7.
- Esteller, M., Gonzalez, S., Risques, R.A., Marcuello, E., Mangues, R., Germa, J.R., Herman, J.G., Capella, G., and Peinado, M.A. (2001) K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. *J Clin Oncol*, **19**, 299-304.
- Etienne, M.C., Chazal, M., Laurent-Puig, P., Magne, N., Rosty, C., Formento, J.L., Francoual, M., Formento, P., Renee, N., Chamorey, E., Bourgeon, A., Seitz, J.F., Delpero, J.R., Letoublon, C., Pezet, D., and Milano, G. (2002) Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. *J Clin Oncol*, **20**, 2832-43.
- Finkelstein, S.D., Sayegh, R., Bakker, A., and Swalsky, P. (1993) Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. *Arch Surg*, **128**, 526-31; discussion 531-2.
- Finkelstein, S.D., Sayegh, R., Christensen, S., and Swalsky, P.A. (1993) Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. *Cancer*, **71**, 3827-38.
- Fogt, F., Zhuang, Z., Poremba, C., Dockhorn-Dworniczak, B., and Vortmeyer, A. (1998) Comparison of p53 immunoexpression with allelic loss of p53 in ulcerative colitis-associated dysplasia and carcinoma. *Oncol Rep*, **5**, 477-80.
- Font, A., Abad, A., Monzo, M., Sanchez, J.J., Guillot, M., Manzano, J.L., Pinol, M., Ojanguren, I., and Rosell, R. (2001) Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. *Dis Colon Rectum*, **44**, 549-57.
- Forslund, A., Kressner, U., Lonnroth, C., Andersson, M., Lindmark, G., and Lundholm, K. (2002) P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH. *Int J Oncol*, **21**, 409-15.
- Forslund, A., Lonnroth, C., Andersson, M., Brevinge, H., and Lundholm, K. (2001) Mutations and allelic loss of p53 in primary tumor DNA from potentially cured patients with colorectal carcinoma. *J Clin Oncol*, **19**, 2829-36.
- Froggatt, N.J., Leveson, S.H., and Garner, R.C. (1995) Low frequency and late occurrence of p53 and dcc aberrations in colorectal tumours. *J Cancer Res Clin Oncol*, **121**, 7-15.
- Fujimori, T., Satonaka, K., Yamamura-Idei, Y., Nagasako, K., and Maeda, S. (1994) Non-involvement of ras mutations in flat colorectal adenomas and carcinomas. *Int J Cancer*, **57**, 51-5.
- Fujiwara, T., Stolker, J.M., Watanabe, T., Rashid, A., Longo, P., Eshleman, J.R., Booker, S., Lynch, H.T., Jass, J.R., Green, J.S., Kim, H., Jen, J., Vogelstein, B., and Hamilton, S.R. (1998) Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. *Am J Pathol*, **153**, 1063-78.
- Garcia, J.M., Rodriguez, R., Dominguez, G., Silva, J.M., Provencio, M., Silva, J., Colmenarejo, A., Millan, I., Munoz, C., Salas, C., Coca, S., Espana, P., and Bonilla, F. (2003) Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer. *Gut*, **52**, 1756-63.
- Garcia, J.M., Rodriguez, R., Silva, J., Munoz, C., Dominguez, G., Silva, J.M., Carcereny, E., Provencio, M., Espana, P., and Bonilla, F. (2003) Intratumoral heterogeneity in microsatellite alterations in BRCA1 and PTEN regions in sporadic colorectal cancer. *Ann Surg Oncol*, **10**, 876-81.
- Garinis, G.A., Spanakis, N.E., Menounos, P.G., Manolis, E.N., and Peros, G. (2003) Transcriptional

impairment of beta-catenin/E-cadherin complex is not associated with beta-catenin mutations in colorectal carcinomas. *Br J Cancer*, **88**, 206-9.

Geido, E., Sciuotto, A., Rubagotti, A., Oliani, C., Monaco, R., Risio, M., and Giaretti, W. (2002) Combined DNA flow cytometry and sorting with k-ras2 mutation spectrum analysis and the prognosis of human sporadic colorectal cancer. *Cytometry*, **50**, 216-24.

Giaretti, W., Pujic, N., Rapallo, A., Nigro, S., Di Vinci, A., Geido, E., and Risio, M. (1995) K-ras-2 G-C and G-T transversions correlate with DNA aneuploidy in colorectal adenomas. *Gastroenterology*, **108**, 1040-7.

Giaretti, W., Rapallo, A., Geido, E., Sciuotto, A., Merlo, F., Risio, M., and Rossini, F.P. (1998) Specific K-ras2 mutations in human sporadic colorectal adenomas are associated with DNA near-diploid aneuploidy and inhibition of proliferation. *Am J Pathol*, **153**, 1201-9.

Giaretti, W., Rapallo, A., Sciuotto, A., Macciocu, B., Geido, E., Hermsen, M.A., Postma, C., Baak, J.P., Williams, R.A., and Meijer, G.A. (2000) Intratumor heterogeneity of k-ras and p53 mutations among human colorectal adenomas containing early cancer. *Anal Cell Pathol*, **21**, 49-57.

Giaretti, W., Venesio, T., Sciuotto, A., Prevosto, C., Geido, E., and Risio, M. (2003) Near-diploid and near-triploid human sporadic colorectal adenocarcinomas differ for KRAS2 and TP53 mutational status. *Genes Chromosomes Cancer*, **37**, 207-13.

Gonzalez-Aguilera, J.J., Oliart, S., Azcoita, M.M., and Fernandez-Peralta, A.M. (2004) Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer. *Am J Clin Oncol*, **27**, 39-45.

Greenwald, B.D., Harpaz, N., Yin, J., Huang, Y., Tong, Y., Brown, V.L., McDaniel, T., Newkirk, C., Resau, J.H., and Meltzer, S.J. (1992) Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. *Cancer Res*, **52**, 741-5.

Guanti, G., Resta, N., Simone, C., Cariola, F., Demma, I., Fiorente, P., and Gentile, M. (2000) Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis. *Hum Mol Genet*, **9**, 283-7.

Halatsch, M.E., Hirsch-Ernst, K.I., Weinel, R.J., and Kahl, G.F. (1998) Differential activation of the c-Ki-ras-2 proto-oncogene in human colorectal carcinoma. *Anticancer Res*, **18**, 2323-5.

Hamelin, R., Jegou, N., Laurent-Puig, P., Vidaud, M., and Thomas, G. (1993) Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. *Oncogene*, **8**, 2213-20.

Hayashi, N., Sugai, S., Ito, I., Nakamori, S., Ogawa, M., and Nakamura, Y. (1996) Ethnic difference in the pattern of K-ras oncogene mutations in human colorectal cancers. *Hum Mutat*, **8**, 258-61.

Hayes, V.M., Bleeker, W., Verlind, E., Timmer, T., Karrenbeld, A., Plukker, J.T., Marx, M.P., Hofstra, R.M., and Buys, C.H. (1999) Comprehensive TP53-denaturing gradient gel electrophoresis mutation detection assay also applicable to archival paraffin-embedded tissue. *Diagn Mol Pathol*, **8**, 2-10.

Heide, I., Thiede, C., Sonntag, T., de Kant, E., Neubauer, A., Jonas, S., Peter, F.J., Neuhaus, P., Herrmann, R., Huhn, D., and Rochlitz, C.F. (1997) The status of p53 in the metastatic progression of colorectal cancer. *Eur J Cancer*, **33**, 1314-22.

Hibi, K., Robinson, C.R., Booker, S., Wu, L., Hamilton, S.R., Sidransky, D., and Jen, J. (1998) Molecular detection of genetic alterations in the serum of colorectal cancer patients. *Cancer Res*, **58**, 1405-7.

Hildebrandt, B., Heide, I., Thiede, C., Nagel, S., Dieing, A., Jonas, S., Neuhaus, P., Rochlitz, C.F., Riess,

- H., and Neubauer, A. (2000) Lack of point mutations in exons 11-23 of the retinoblastoma susceptibility gene RB-1 in liver metastases of colorectal carcinoma. *Oncology*, **59**, 344-6.
- Hiyama, T., Yokozaki, H., Shimamoto, F., Haruma, K., Yasui, W., Kajiyama, G., and Tahara, E. (1998) Frequent p53 gene mutations in serrated adenomas of the colorectum. *J Pathol*, **186**, 131-9.
- Hosoi, H., Hirosawa, S., Yamamoto, K., Ohkusa, T., and Aoki, N. (1995) Using biopsy materials to detect mutations in gastrointestinal tumors. *J Clin Gastroenterol*, **20**, 272-6.
- Iacopetta, B., DiGrandi, S., Dix, B., Haig, C., Soong, R., and House, A. (1994) Loss of heterozygosity of tumour suppressor gene loci in human colorectal carcinoma. *Eur J Cancer*, **30A**, 664-70.
- Ichii, S., Takeda, S., Horii, A., Nakatsuru, S., Miyoshi, Y., Emi, M., Fujiwara, Y., Koyama, K., Furuyama, J., Utsunomiya, J., and et, al. (1993) Detailed analysis of genetic alterations in colorectal tumors from patients with and without familial adenomatous polyposis (FAP). *Oncogene*, **8**, 2399-405.
- Ikehara, N., Semba, S., Sakashita, M., Aoyama, N., Kasuga, M., and Yokozaki, H. (2005) BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. *Int J Cancer*, **115**, 943-50.
- Ishii, M., Sugai, T., Habano, W., and Nakamura, S. (2004) Analysis of Ki-ras gene mutations within the same tumor using a single tumor crypt in colorectal carcinomas. *J Gastroenterol*, **39**, 544-9.
- Ishioka, C., Sato, T., Gamoh, M., Suzuki, T., Shibata, H., Kanamaru, R., Wakui, A., and Yamazaki, T. (1991) Mutations of the P53 gene, including an intronic point mutation, in colorectal tumors. *Biochem Biophys Res Commun*, **177**, 901-6.
- Ito, Y., Kobayashi, S., Taniguchi, T., Kainuma, O., Hara, T., and Ochiai, T. (2002) Frequent detection of K-ras mutation in stool samples of colorectal carcinoma patients after improved DNA extraction: comparison with tissue samples. *Int J Oncol*, **20**, 1263-8.
- Iwao, K., Nakamori, S., Kameyama, M., Imaoka, S., Kinoshita, M., Fukui, T., Ishiguro, S., Nakamura, Y., and Miyoshi, Y. (1998) Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. *Cancer Res*, **58**, 1021-6.
- Iwaya, T., Maesawa, C., Nishizuka, S., Suzuki, Y., Sakata, K., Sato, N., Ikeda, K., Koeda, K., Ogasawara, S., Otsuka, K., Kimura, Y., Aoki, K., Ishida, K., Saito, K., and Tamura, G. (1998) Infrequent frameshift mutations of polynucleotide repeats in multiple primary cancers affecting the esophagus and other organs. *Genes Chromosomes Cancer*, **23**, 317-22.
- Jarry, A., Masson, D., Cassagnau, E., Parois, S., Laboisse, C., and Denis, M.G. (2004) Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. *Mol Cell Probes*, **18**, 349-52.
- Jass, J.R., Biden, K.G., Cummings, M.C., Simms, L.A., Walsh, M., Schoch, E., Meltzer, S.J., Wright, C., Searle, J., Young, J., and Leggett, B.A. (1999) Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. *J Clin Pathol*, **52**, 455-60.
- Kanamaru, R. and Ishioka, C. (1992) Mutations of the p53 gene and other genes involving in human colorectal carcinogenesis. *Tohoku J Exp Med*, **168**, 159-66.
- Kastrinakis, W.V., Ramchurren, N., Maggard, M., Steele, G.Jr., and Summerhayes, I.C. (1995) K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. *Arch Surg*, **130**, 9-14.
- Kastrinakis, W.V., Ramchurren, N., Rieger, K.M., Hess, D.T., Loda, M., Steele, G., and Summerhayes, I.C. (1995) Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. *Oncogene*, **11**, 647-52.

- Kern, A., Taubert, H., Scheele, J., Rudroff, C., Mothes, H., Kappler, M., Bartel, F., and Richter, K.K. (2002) Association of p53 mutations, microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases. *Int J Oncol*, **21**, 243-9.
- Khan, Z.A., Jonas, S.K., Feldmann, K.A., Patel, H., Wharton, R.Q., Tarragona, A., Ivison, A., and Allen-Mersh, T.G. (2001) P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases. *J Cancer Res Clin Oncol*, **127**, 675-80.
- Khan, Z.A., Jonas, S.K., Le-Marre, N., Patel, H., Wharton, R.Q., Tarragona, A., Ivison, A., and Allen-Mersh, T.G. (2000) P53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients. *Clin Cancer Res*, **6**, 3499-504.
- Kikuchi-Yanoshita, R., Konishi, M., Fukunari, H., Tanaka, K., and Miyaki, M. (1992) Loss of expression of the DCC gene during progression of colorectal carcinomas in familial adenomatous polyposis and non-familial adenomatous polyposis patients. *Cancer Res*, **52**, 3801-3.
- Kikuchi-Yanoshita, R., Konishi, M., Ito, S., Seki, M., Tanaka, K., Maeda, Y., Iino, H., Fukayama, M., Koike, M., Mori, T., and et al. (1992) Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. *Cancer Res*, **52**, 3965-71.
- Kim, I.J., Kang, H.C., Park, J.H., Shin, Y., Ku, J.L., Lim, S.B., Park, S.Y., Jung, S.Y., Kim, H.K., and Park, J.G. (2003) Development and applications of a beta-catenin oligonucleotide microarray: beta-catenin mutations are dominantly found in the proximal colon cancers with microsatellite instability. *Clin Cancer Res*, **9**, 2920-5.
- Ko, J.M., Cheung, M.H., Kwan, M.W., Wong, C.M., Lau, K.W., Tang, C.M., and Lung, M.L. (1999) Genomic instability and alterations in Apc, Mcc and Dcc in Hong Kong patients with colorectal carcinoma. *Int J Cancer*, **84**, 404-9.
- Koinuma, K., Shitoh, K., Miyakura, Y., Furukawa, T., Yamashita, Y., Ota, J., Ohki, R., Choi, Y.L., Wada, T., Konishi, F., Nagai, H., and Mano, H. (2004) Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. *Int J Cancer*, **108**, 237-42.
- Koness, R.J., King, T.C., Schechter, S., McLean, S.F., Lodowsky, C., and Wanebo, H.J. (1996) Synchronous colon carcinomas: molecular-genetic evidence for multicentricity. *Ann Surg Oncol*, **3**, 136-43.
- Konig, E.A., Koves, I., Rasinariu, A., Popp, A.R., Kusser, W.C., Soyomki, K., Kovacs, A., Glickman, B.W., Jeney, A., and Marcsek, Z.L. (2001) Alterations of K-ras and p53 mutations in colorectal cancer patients in Central Europe. *J Toxicol Environ Health A*, **62**, 333-47.
- Konishi, K., Takimoto, M., Kaneko, K., Makino, R., Hirayama, Y., Nozawa, H., Kurahashi, T., Kumekawa, Y., Yamamoto, T., Ito, H., Yoshikawa, N., Kusano, M., Nakayama, K., Rembacken, B.J., Ota, H., and Imawari, M. (2006) BRAF mutations and phosphorylation status of mitogen-activated protein kinases in the development of flat and depressed-type colorectal neoplasias. *Br J Cancer*, **94**, 311-7.
- Konishi, M., Kikuchi-Yanoshita, R., Tanaka, K., Muraoka, M., Onda, A., Okumura, Y., Kishi, N., Iwama, T., Mori, T., Koike, M., Ushio, K., Chiba, M., Nomizu, S., Konishi, F., Utsunomiya, J., and Miyaki, M. (1996) Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. *Gastroenterology*, **111**, 307-17.
- Lamlum, H., Ilyas, M., Rowan, A., Clark, S., Johnson, V., Bell, J., Frayling, I., Efstatouliou, J., Pack, K., Payne, S., Roylance, R., Gorman, P., Sheer, D., Neale, K., Phillips, R., Talbot, I., Bodmer, W., and Tomlinson, I. (1999) The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. *Nat Med*, **5**, 1071-5.

Lamlum, H., Papadopoulou, A., Ilyas, M., Rowan, A., Gillet, C., Hanby, A., Talbot, I., Bodmer, W., and Tomlinson, I. (2000) APC mutations are sufficient for the growth of early colorectal adenomas. *Proc Natl Acad Sci U S A*, **97**, 2225-8.

Laurent-Puig, P., Olschwang, S., Delattre, O., Validire, P., Melot, T., Mosseri, V., Salmon, R.J., and Thomas, G. (1991) Association of Ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma. *Int J Cancer*, **49**, 220-3.

Lee, J.C., Wang, S.T., Lai, M.D., Lin, Y.J., and Yang, H.B. (1996) K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. *Anticancer Res*, **16**, 3839-44.

Lees, N.P., Harrison, K.L., Hall, C.N., Margison, G.P., and Povey, A.C. (2004) Reduced MGMT activity in human colorectal adenomas is associated with K-ras GC->AT transition mutations in a population exposed to methylating agents. *Carcinogenesis*, **25**, 1243-7.

Lenz, H.J., Hayashi, K., Salonga, D., Danenberg, K.D., Danenberg, P.V., Metzger, R., Banerjee, D., Bertino, J.R., Groshen, S., Leichman, L.P., and Leichman, C.G. (1998) p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. *Clin Cancer Res*, **4**, 1243-50.

Leung, C.S., Cheung, M.H., Wong, C.M., Lau, K.W., Tang, C.M., and Lung, M.L. (1997) p53 mutations detected in colorectal carcinoma patients in Hong Kong. *Cancer Epidemiol Biomarkers Prev*, **6**, 925-30.

Liang, J.T., Chang, K.J., Chen, J.C., Lee, C.C., Cheng, Y.M., Hsu, H.C., Wu, M.S., Wang, S.M., Lin, J.T., and Cheng, A.L. (1999) Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. *Oncology*, **57**, 149-56.

Lin, J.K., Chang, S.C., Yang, Y.C., and Li, A.F. (2003) Loss of heterozygosity and DNA aneuploidy in colorectal adenocarcinoma. *Ann Surg Oncol*, **10**, 1086-94.

Lin, S.Y., Chen, P.H., Wang, C.K., Liu, J.D., Siauw, C.P., Chen, Y.J., Yang, M.J., Liu, M.H., Chen, T.C., and Chang, J.G. (1993) Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction sites method. *Am J Clin Pathol*, **100**, 686-9.

Lin, S.Y., Chen, P.H., Yang, M.J., Chen, T.C., Chang, C.P., and Chang, J.G. (1995) Ras oncogene and p53 gene hotspot mutations in colorectal cancers. *J Gastroenterol Hepatol*, **10**, 119-24.

Losi, L., Ponz de Leon, M., Jiricny, J., Di Gregorio, C., Benatti, P., Percesepe, A., Fante, R., Roncucci, L., Pedroni, M., and Benhattar, J. (1997) K-ras and p53 mutations in hereditary non-polyposis colorectal cancers. *Int J Cancer*, **74**, 94-6.

Lovig, T., Meling, G.I., Diep, C.B., Thorstensen, L., Norheim Andersen, S., Lothe, R.A., and Rognum, T.O. (2002) APC and CTNNB1 mutations in a large series of sporadic colorectal carcinomas stratified by the microsatellite instability status. *Scand J Gastroenterol*, **37**, 1184-93.

Luceri, C., Guglielmi, F., De Filippo, C., Caderni, G., Mini, E., Biggeri, A., Napoli, C., Tonelli, F., Cianchi, F., and Dolara, P. (2000) Clinicopathologic features and FHIT gene expression in sporadic colorectal adenocarcinomas. *Scand J Gastroenterol*, **35**, 637-41.

Maltzman, T., Knoll, K., Martinez, M.E., Byers, T., Stevens, B.R., Marshall, J.R., Reid, M.E., Einspahr, J., Hart, N., Bhattacharyya, A.K., Kramer, C.B., Sampliner, R., Alberts, D.S., and Ahnen, D.J. (2001) Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. *Gastroenterology*, **121**, 302-9.

Martinez-Garza, S.G., Nunez-Salazar, A., Calderon-Garciduenas, A.L., Bosques-Padilla, F.J. ,

Niderhauser-Garcia, A., and Barrera-Saldana, H.A. (1999) Frequency and clinicopathology associations of K-ras mutations in colorectal cancer in a northeast Mexican population. *Dig Dis*, **17**, 225-9.

Meling, G.I., Lothe, R.A., Borresen, A.L., Hauge, S., Graue, C., Clausen, O.P., and Rognum, T.O. (1991) Genetic alterations within the retinoblastoma locus in colorectal carcinomas. Relation to DNA ploidy pattern studied by flow cytometric analysis. *Br J Cancer*, **64**, 475-80.

Meltzer, S.J., Ahnen, D.J., Battifora, H., Yokota, J., and Cline, M.J. (1987) Protooncogene abnormalities in colon cancers and adenomatous polyps. *Gastroenterology*, **92**, 1174-80.

Mirabelli-Primdahl, L., Gryfe, R., Kim, H., Millar, A., Luceri, C., Dale, D., Holowaty, E., Bapat, B., Gallinger, S., and Redston, M. (1999) Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. *Cancer Res*, **59**, 3346-51.

Miyaki, M., Iijima, T., Ishii, R., Kita, Y., Koike, M., Kuroki, T., and Mori, T. (2002) Increased frequency of p53 mutation in sporadic colorectal cancer from cigarette smokers. *Jpn J Clin Oncol*, **32**, 196-201.

Miyaki, M., Iijima, T., Kimura, J., Yasuno, M., Mori, T., Hayashi, Y., Koike, M., Shitara, N., Iwama, T., and Kuroki, T. (1999) Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. *Cancer Res*, **59**, 4506-9.

Miyaki, M., Iijima, T., Yamaguchi, T., Kadofuku, T., Funata, N., and Mori, T. (2004) Both BRAF and KRAS mutations are rare in colorectal carcinomas from patients with hereditary nonpolyposis colorectal cancer. *Cancer Lett*, **211**, 105-9.

Miyaki, M., Iijima, T., Yasuno, M., Kita, Y., Hishima, T., Kuroki, T., and Mori, T. (2002) High incidence of protein-truncating mutations of the p53 gene in liver metastases of colorectal carcinomas. *Oncogene*, **21**, 6689-93.

Miyaki, M., Konishi, M., Kikuchi-Yanoshita, R., Enomoto, M., Igari, T., Tanaka, K., Muraoka, M., Takahashi, H., Amada, Y., Fukayama, M., and et, a.l. (1994) Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. *Cancer Res*, **54**, 3011-20.

Moerkerk, P., Arends, J.W., van Driel, M., de Bruine, A., de Goeij, A., and ten Kate, J. (1994) Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. *Cancer Res*, **54**, 3376-8.

Morin, P.J., Sparks, A.B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K.W. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. *Science*, **275**, 1787-90.

Morris, R.G., Curtis, L.J., Romanowski, P., Hardcastle, J.D., Jenkins, D.A., Robinson, M., Wyllie, A.H., and Bird, C.C. (1996) Ki-ras mutations in adenomas: a characteristic of cancer-bearing colorectal mucosa. *J Pathol*, **180**, 357-63.

Mulkens, J., Poncin, J., Arends, J.W., and De Goeij, A.F. (1998) APC mutations in human colorectal adenomas: analysis of the mutation cluster region with temperature gradient gel electrophoresis and clinicopathological features. *J Pathol*, **185**, 360-5.

Muller, O., Nimmrich, I., Finke, U., Friedl, W., and Hoffmann, I. (1998) A beta-catenin mutation in a sporadic colorectal tumor of the RER phenotype and absence of beta-catenin germline mutations in FAP patients. *Genes Chromosomes Cancer*, **22**, 37-41.

Murata, M., Iwao, K., Miyoshi, Y., Nagasawa, Y., Yabu, M., Himeno, S., Imanishi, K., Ohsawa, M., Wada, H., Tominaga, S., Shimano, T., Kobayashi, T., and Nakamura, Y. (2000) Activation of the beta-catenin

gene by interstitial deletions involving exon 3 as an early event in colorectal tumorigenesis. *Cancer Lett*, **159**, 73-8.

Nagasaka, T., Sasamoto, H., Notohara, K., Cullings, H.M., Takeda, M., Kimura, K., Kambara, T., MacPhee, D.G., Young, J., Leggett, B.A., Jass, J.R., Tanaka, N., and Matsubara, N. (2004) Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. *J Clin Oncol*, **22**, 4584-94.

Nagata, Y., Abe, M., Kobayashi, K., Yoshida, K., Ishibashi, T., Naoe, T., Nakayama, E., and Shiku, H. (1990) Glycine to aspartic acid mutations at codon 13 of the c-Ki-ras gene in human gastrointestinal cancers. *Cancer Res*, **50**, 480-2.

Neuman, W.L., Waslylyshyn, M.L., Jacoby, R., Erroi, F., Angriman, I., Montag, A., Brasitus, T., Michelassi, F., and Westbrook, C.A. (1991) Evidence for a common molecular pathogenesis in colorectal, gastric, and pancreatic cancer. *Genes Chromosomes Cancer*, **3**, 468-73.

Nishisho, I., Nakamura, Y., Miyoshi, Y., Miki, Y., Ando, H., Horii, A., Koyama, K., Utsunomiya, J., Baba, S., and Hedge, P. (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. *Science*, **253**, 665-9.

Norheim-Andersen, S., Lovig, T., Breivik, J., Lund, E., Gaudernack, G., Meling, G.I., and Rognum, T.O. (1997) K-ras mutations and prognosis in large-bowel carcinomas. *Scand J Gastroenterol*, **32**, 62-9.

Nusko, G., Sachse, R., Mansmann, U., Wittekind, C., and Hahn, E.G. (1997) K-RAS-2 gene mutations as predictors of metachronous colorectal adenomas. *Scand J Gastroenterol*, **32**, 1035-41.

Ogasawara, S., Maesawa, C., Tamura, G., and Satodate, R. (1994) Lack of mutations of the adenomatous polyposis coli gene in oesophageal and gastric carcinomas. *Virchows Arch*, **424**, 607-11.

Ogino, S., Meyerhardt, J.A., Cantor, M., Brahmandam, M., Clark, J.W., Namgyal, C., Kawasaki, T., Kinsella, K., Michelini, A.L., Enzinger, P.C., Kulke, M.H., Ryan, D.P., Loda, M., and Fuchs, C.S. (2005) Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. *Clin Cancer Res*, **11**, 6650-6.

Ohhara, M., Esumi, M., and Kurosu, Y. (1996) Activation but not inactivation of the MTS1 gene is associated with primary colorectal carcinomas. *Biochem Biophys Res Commun*, **226**, 791-5.

Ohki, S., Onda, M., Fukushima, T., Takita, K., Suzuki, S., Hoshino, M., Tsuchiya, A., Abe, R., and Takenoshita, S. (2003) Telomeric repeat-length alterations in colorectal carcinoma are associated with loss of heterozygosity and point mutation in p53 gene. *Int J Mol Med*, **11**, 485-90.

Ohtaki, N., Yamaguchi, A., Goi, T., Fukaya, T., Takeuchi, K., Katayama, K., Hirose, K., and Urano, T. (2001) Somatic alterations of the DPC4 and Madr2 genes in colorectal cancers and relationship to metastasis. *Int J Oncol*, **18**, 265-70.

Okada, K., Urano, T., Goi, T., Baba, H., Yamaguchi, A., Furukawa, K., and Shiku, H. (1994) Isolation of human nm23 genomes and analysis of loss of heterozygosity in primary colorectal carcinomas using a specific genomic probe. *Cancer Res*, **54**, 3979-82.

Oliva, M.R., Ripoll, F., Muniz, P., Iradi, A., Trullenque, R., Valls, V., Drehmer, E., and Saez, G.T. (1997) Genetic alterations and oxidative metabolism in sporadic colorectal tumors from a Spanish community. *Mol Carcinog*, **18**, 232-43.

Oliva, M.R., Saez, G.T., Latres, E., and Cordon-Cardo, C. (1995) A new polymorphic site in intron 2 of TP53 characterizes LOH in human tumors by PCR-SSCP. *Diagn Mol Pathol*, **4**, 54-8.

Oliveira, C., Westra, J.L., Arango, D., Ollikainen, M., Domingo, E., Ferreira, A., Velho, S., Niessen, R., Lagerstedt, K., Alhopuro, P., Laiho, P., Veiga, I., Teixeira, M.R., Ligtenberg, M., Kleibeuker, J.H., Sijmons, R.H., Plukker, J.T., Imai, K., Lage, P., Hamelin, R., Albuquerque, C., Schwartz, S. Jr, Lindblom, A., Peltomaki, P., Yamamoto, H., Aaltonen, L.A., Seruca, R., and Hofstra, R.M. (2004) Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. *Hum Mol Genet*, **13**, 2303-11.

Olschwang, S., Hamelin, R., Laurent-Puig, P., Thuille, B., De Rycke, Y., Li, Y.J., Muzeau, F., Girodet, J., Salmon, R.J., and Thomas, G. (1997) Alternative genetic pathways in colorectal carcinogenesis. *Proc Natl Acad Sci U S A*, **94**, 12122-7.

Olschwang, S., Slezak, P., Roze, M., Jaramillo, E., Nakano, H., Koizumi, K., Rubio, C.A., Laurent-Puig, P., and Thomas, G. (1998) Somatically acquired genetic alterations in flat colorectal neoplasias. *Int J Cancer*, **77**, 366-9.

Onda, M., Abe, R., Tsuchiya, A., Fukushima, T., Ando, Y., and Yoshida, T. (1997) K-ras and p53 gene mutations in colorectal cancer in 57 Japanese patients. *Fukushima J Med Sci*, **43**, 29-39.

Oudejans, J.J., Slebos, R.J., Zoetmulder, F.A., Mooi, W.J., and Rodenhuis, S. (1991) Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. *Int J Cancer*, **49**, 875-9.

Park, J.H., Kim, I.J., Kang, H.C., Shin, Y., Park, H.W., Jang, S.G., Ku, J.L., Lim, S.B., Jeong, S.Y., and Park, J.G. (2004) Oligonucleotide microarray-based mutation detection of the K-ras gene in colorectal cancers with use of competitive DNA hybridization. *Clin Chem*, **50**, 1688-91.

Peinado, M.A., Fernandez-Renart, M., Capella, G., Wilson, L., and Peruch, M. (1993) Mutations in the p53 suppressor gene do not correlate with c-K-ras oncogene mutations in colorectal cancer. *Int. J. Oncology*, **2**, 123-134.

Peller, S., Halevy, A., Slutzki, S., Kopilova, Y., and Rotter, V. (1995) p53 mutations in matched primary and metastatic human tumors. *Mol Carcinog*, **13**, 166-72.

Petrowsky, H., Sturm, I., Graubitz, O., Kooby, D.A., Staib-Sebler, E., Gog, C., Kohne, C.H., Hillebrand, T., Daniel, P.T., Fong, Y., and Lorenz, M. (2001) Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. *Eur J Surg Oncol*, **27**, 80-7.

Petursdottir, T.E., Hafsteinsdottir, S.H., Jonasson, J.G., Moller, P.H., Thorsteinsdottir, U., Huiping, C., Egilsson, V., and Ingvarsson, S. (2002) Loss of heterozygosity at the FHIT gene in different solid human tumours and its association with survival in colorectal cancer patients. *Anticancer Res*, **22**, 3205-12.

Powell, S.M., Zilz, N., Beazer-Barclay, Y., Bryan, T.M., Hamilton, S.R., Thibodeau, S.N., Vogelstein, B., and Kinzler, K.W. (1992) APC mutations occur early during colorectal tumorigenesis. *Nature*, **359**, 235-7.

Prior, T.W., Chadwick, R.B., Papp, A.C., Arcot, A.N., Isa, A.M., Pearl, D.K., Stemmermann, G., Percesepe, A., Loukola, A., Aaltonen, L.A., and De La Chapelle, A. (1999) The I1307K polymorphism of the APC gene in colorectal cancer. *Gastroenterology*, **116**, 58-63.

Puig, P., Urgell, E., Capella, G., Sancho, F.J., Pujol, J., Boadas, J., Farre, A., Lluis, F., Gonzalez-Sastre, F., and Mora, J. (2000) A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. *Int J Cancer*, **85**, 73-7.

Ranaldi, R., Gioacchini, A.M., Manzin, A., Clementi, M., Paolucci, S., and Bearzi, I. (1995) Adenoma-carcinoma sequence of colorectum. Prevalence of K-ras gene mutation in adenomas with increasing degree of dysplasia and aneuploidy. *Diagn Mol Pathol*, **4**, 198-202.

- Rapallo, A., Sciuotto, A., Geido, E., Orecchia, R., Infusini, E., Pujic, N., d'Amore, E.S., Monaco, R., Risio, M., Rossini, F.P., and Giaretti, W. (1999) K-ras2 activation and genome instability increase proliferation and size of FAP adenomas. *Anal Cell Pathol*, **19**, 39-46.
- Redston, M.S., Papadopoulos, N., Caldas, C., Kinzler, K.W., and Kern, S.E. (1995) Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. *Gastroenterology*, **108**, 383-92.
- Rochlitz, C.F., Heide, I., de Kant, E., Bohmer, R., Peter, F.J., Neuhaus, P., Huhn, D., and Herrmann, R. (1993) Position specificity of Ki-ras oncogene mutations during the progression of colorectal carcinoma. *Oncology*, **50**, 70-6.
- Rosty, C., Chazal, M., Etienne, M.C., Letoublon, C., Bourgeon, A., Delpero, J.R., Pezet, D., Beaune, P., Laurent-Puig, P., and Milano, G. (2001) Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. *Int J Cancer*, **95**, 162-7.
- Russo, A., Migliavacca, M., Bazan, V., Maturi, N., Morello, V., Dardanoni, G., Modica, G., Bazan, P., Albanese, I., La Farina, M., and Tomasino, R.M. (1998) Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases. *Cell Prolif*, **31**, 139-53.
- Saito, M., Yamaguchi, A., Goi, T., Tsuchiyama, T., Nakagawara, G., Urano, T., Shiku, H., and Furukawa, K. (1999) Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis. *Oncology*, **56**, 134-41.
- Salbe, C., Trevisiol, C., Ferruzzi, E., Mancuso, T., Nascimbeni, R., Di Fabio, F., Salerni, B., and Dittadi, R. (2000) Molecular detection of codon 12 K-RAS mutations in circulating DNA from serum of colorectal cancer patients. *Int J Biol Markers*, **15**, 300-7.
- Salhab, N., Jones, D.J., Bos, J.L., Kinsella, A., and Schofield, P.F. (1989) Detection of ras gene alterations and ras proteins in colorectal cancer. *Dis Colon Rectum*, **32**, 659-64.
- Sanchez-Cespedes, M., Esteller, M., Hibi, K., Cope, F.O., Westra, W.H., Piantadosi, S., Herman, J.G., Jen, J., and Sidransky, D. (1999) Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. *Clin Cancer Res*, **5**, 2450-4.
- Sasaki, M., Okamoto, M., Sato, C., Sugio, K., Soejima, J., Iwama, T., Ikeuchi, T., Tonomura, A., Miyaki, M., and Sasazuki, T. (1989) Loss of constitutional heterozygosity in colorectal tumors from patients with familial polyposis coli and those with nonpolyposis colorectal carcinoma. *Cancer Res*, **49**, 4402-6.
- Sasaki, M., Sugio, K., and Sasazuki, T. (1990) K-ras activation in colorectal tumors from patients with familial polyposis coli. *Cancer*, **65**, 2576-9.
- Sasaki, M., Watanabe, H., Jass, J.R., Ajioka, Y., Kobayashi, M., and Hatakeyama, K. (1998) Immunoperoxidase staining for cytokeratins 8 and 18 is very sensitive for detection of occult node metastasis of colorectal cancer: a comparison with genetic analysis of K-ras. *Histopathology*, **32**, 199-208.
- Sawyer, E.J., Cerar, A., Hanby, A.M., Gorman, P., Arends, M., Talbot, I.C., and Tomlinson, I.P. (2002) Molecular characteristics of serrated adenomas of the colorectum. *Gut*, **51**, 200-6.
- Schimanski, C.C., Linnemann, U., and Berger, M.R. (1999) Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. *Cancer Res*, **59**, 5169-75.
- Schimanski, C.C., Sutter, C., Linnemann, U., and Berger, M.R. (1999) Sampling technique influences the detection of K-ras mutations in normal appearing mucosa of colorectal cancer patients. *Int J Oncol*, **15**,

- Schmitt, C.A., Thaler, K.R., Wittig, B.M., Kaulen, H., Meyer zum Buschenfelde, K.H., and Dippold, W.G. (1998) Detection of the DCC gene product in normal and malignant colorectal tissues and its relation to a codon 201 mutation. *Br J Cancer*, **77**, 588-94.
- Schneider-Stock, R., Boltze, C., Peters, B., Szibor, R., Landt, O., Meyer, F., and Roessner, A. (2004) Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. *Neoplasia*, **6**, 529-35.
- Sedivy, R., Wolf, B., Kalipciyan, M., Steger, G.G., Karner-Hanusch, J., and Mader, R.M. (2000) Genetic analysis of multiple synchronous lesions of the colon adenoma-carcinoma sequence. *Br J Cancer*, **82**, 1276-82.
- Segura-Uribe, J., Santiago-Payan, H., and Quintero, A. (2003) Transitions and transversions in Ki-ras gene in colorectal cancers in Mexican patients. *Tumori*, **89**, 259-62.
- Shaw, P., Tardy, S., Benito, E., Obrador, A., and Costa, J. (1991) Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. *Oncogene*, **6**, 2121-8.
- Shen, C., Chang, J.G., Lee, L.S., Yang, M.J., Chen, T.C., Lin, K.Y., Lee, M.D., and Chen, P.H. (1991) Analysis of ras gene mutations in gastrointestinal cancers. *J Formos Med Assoc*, **90**, 1149-54.
- Shi, C.Y., Phang, T.W., Ngai, S.S., Wee, A., Li, B., Lin, Y., Lee, H.P., and Ong, C.N. (1994) Characterization of p53 gene mutations in colorectal carcinomas from an Asian population. *Anticancer Res*, **14**, 2811-6.
- Shirasawa, S., Urabe, K., Yanagawa, Y., Toshitani, K., Iwama, T., and Sasazuki, T. (1991) p53 gene mutations in colorectal tumors from patients with familial polyposis coli. *Cancer Res*, **51**, 2874-8.
- Shitoh, K., Furukawa, T., Kojima, M., Konishi, F., Miyaki, M., Tsukamoto, T., and Nagai, H. (2001) Frequent activation of the beta-catenin-Tcf signaling pathway in nonfamilial colorectal carcinomas with microsatellite instability. *Genes Chromosomes Cancer*, **30**, 32-7.
- Shitoh, K., Koinuma, K., Furukawa, T., Okada, M., and Nagai, H. (2004) Mutation of beta-catenin does not coexist with K-ras mutation in colorectal tumorigenesis. *Dig Dis Sci*, **49**, 1631-3.
- Shitoh, K., Konishi, F., Miyaki, M., Iijima, T., Furukawa, T., Tsukamoto, T., and Nagai, H. (2000) Pathogenesis of non-familial colorectal carcinomas with high microsatellite instability. *J Clin Pathol*, **53**, 841-5.
- Slebos, R.J., Baas, I.O., Clement, M., Polak, M., Mulder, J.W., van den Berg, F.M., Hamilton, S.R., and Offerhaus, G.J. (1996) Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. *Br J Cancer*, **74**, 165-71.
- Smith, D.R., Elnatan, J., Myint, T., and Goh, H.S. (1995) Association of activated proto-oncogenes ras and myc in colorectal carcinomas. *Ann Acad Med Singapore*, **24**, 393-8.
- Smith, D.R., Khine, K., and Goh, H.S. (1995) Allelic loss of the p53 gene in colorectal cancer. *Ann Acad Med Singapore*, **24**, 399-402.
- Soh, K., Yanagisawa, A., Hiratsuka, H., Sugano, H., and Kato, Y. (1993) Variation in K-ras codon 12 point mutation rate with histological atypia within individual colorectal tumors. *Jpn J Cancer Res*, **84**, 388-93.
- Span, M., Moerkerk, P.T., De Goeij, A.F., and Arends, J.W. (1996) A detailed analysis of K-ras point

mutations in relation to tumor progression and survival in colorectal cancer patients. *Int J Cancer*, **69**, 241-5.

Sparks, A.B., Morin, P.J., Vogelstein, B., and Kinzler, K.W. (1998) Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. *Cancer Res*, **58**, 1130-4.

Sugai, T., Habano, W., Nakamura, S., Yoshida, T., Uesugi, N., Sasou, S., Itoh, C., and Katoh, R. (2000) Use of crypt isolation to determine loss of heterozygosity of multiple tumor suppressor genes in colorectal carcinoma. *Pathol Res Pract*, **196**, 145-50.

Suh, J.H., Lim, S.D., Kim, J.C., Hong, S.H., and Kang, G.H. (2002) Comparison of clinicopathologic characteristics and genetic alterations between microsatellite instability-positive and microsatellite instability-negative sporadic colorectal carcinomas in patients younger than 40 years old. *Dis Colon Rectum*, **45**, 219-28.

Tanaka, M., Omura, K., Watanabe, Y., Oda, Y., and Nakanishi, I. (1994) Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. *J Surg Oncol*, **57**, 57-64.

Tannergard, P., Liu, T., Weger, A., Nordenskjold, M., and Lindblom, A. (1997) Tumorigenesis in colorectal tumors from patients with hereditary non-polyposis colorectal cancer. *Hum Genet*, **101**, 51-5.

Tortola, S., Marcuello, E., Gonzalez, I., Reyes, G., Arribas, R., Aiza, G., Sancho, F.J., Peinado, M.A., and Capella, G. (1999) p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. *J Clin Oncol*, **17**, 1375-81.

Tortola, S., Steinert, R., Hantschick, M., Peinado, M.A., Gasterer, I., Stosiek, P., Lippert, H., Schlegel, W., and Reymond, M.A. (2001) Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. *J Clin Oncol*, **19**, 2837-43.

Toyooka, S., Tsukuda, K., Ouchida, M., Tanino, M., Inaki, Y., Kobayashi, K., Yano, M., Soh, J., Kobatake, T., Shimizu, N., and Shimizu, K. (2003) Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. *Oncol Rep*, **10**, 1455-9.

Tsai, M.H., Yang, Y.C., Chen, K.H., Jiang, J.K., Chou, S.J., Chiang, T.C., Jan, H.S., and Lou, M.A. (2002) RER and LOH association with sporadic colorectal cancer in Taiwanese patients. *Hepatogastroenterology*, **49**, 672-7.

Tsao, J. and Shibata, D. (1994) Further evidence that one of the earliest alterations in colorectal carcinogenesis involves APC. *Am J Pathol*, **145**, 531-4.

Tsunoda, A., Iijima, T., Tsunoda, Y., Nakao, K., Miyaki, M., and Kusano, M. (2004) Association of K-ras mutations with liver metastases from colorectal carcinoma. *Anticancer Res*, **24**, 2471-6.

Uchida, H., Ando, H., Maruyama, K., Kobayashi, H., Toda, H., Ogawa, H., Ozawa, T., Matsuda, Y., Sugimura, H., Kanno, T., and Baba, S. (1998) Genetic alterations of mixed hyperplastic adenomatous polyps in the colon and rectum. *Jpn J Cancer Res*, **89**, 299-306.

Umetani, N., Sasaki, S., Masaki, T., Watanabe, T., Matsuda, K., and Muto, T. (2000) Involvement of APC and K-ras mutation in non-polypoid colorectal tumorigenesis. *Br J Cancer*, **82**, 9-15.

Umetani, N., Sasaki, S., Watanabe, T., Shinozaki, M., Matsuda, K., Ishigami, H., Ueda, E., and Muto, T. (1999) Genetic alterations in ulcerative colitis-associated neoplasia focusing on APC, K-ras gene and microsatellite instability. *Jpn J Cancer Res*, **90**, 1081-7.

- van den Broek, M.H., Jhanwar, S.C., Fodde, R., Chaganti, R.S., and Meera Khan, P.M. (1993) p53 mutations in colorectal cancers in the patients of Metropolitan New York. *Anticancer Res*, **13**, 1769-72.
- van Wyk, R., Slezak, P., Hayes, V.M., Buys, C.H., Kotze, M.J., de Jong, G., Rubio, C., Dolk, A., Jaramillo, E., Koizumi, K., and Grobbelaar, J.J. (2000) Somatic mutations of the APC, KRAS, and TP53 genes in nonpolypoid colorectal adenomas. *Genes Chromosomes Cancer*, **27**, 202-8.
- Vortmeyer, A.O., Lubensky, I.A., Merino, M.J., Wang, C.Y., Pham, T., Furth, E.E., and Zhuang, Z. (1997) Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. *J Natl Cancer Inst*, **89**, 1448-53.
- Voskuil, D.W., Kampman, E., van Geloof, W., Grubben, M., Kok, F., van Muijen, G., Nagengast, F., Vasen, H., and van't Veer, P. (2000) No major difference in K-ras and p53 abnormalities in sporadic and hereditary nonpolyposis colorectal adenomas. *Dig Dis Sci*, **45**, 2187-94.
- Wadler, S., Bajaj, R., Neuberg, D., Agarwal, V., Haynes, H., and Benson, A.B. (1997) Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the eastern cooperative oncology group (EST 2292). *Cancer J Sci Am*, **3**, 284-8.
- Wang, J.Y., Hsieh, J.S., Chen, F.M., Yeh, C.S., Andersen, K., Huang, T.J., Chen, D., and Lin, S.R. (2003) High frequency of activated K-ras codon 15 mutant in colorectal carcinomas from Taiwanese patients. *Int J Cancer*, **107**, 387-93.
- Wang, L., Cunningham, J.M., Winters, J.L., Guenther, J.C., French, A.J., Boardman, L.A., Burgart, L.J., McDonnell, S.K., Schaid, D.J., and Thibodeau, S.N. (2003) BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. *Cancer Res*, **63**, 5209-12.
- Watari, J., Saitoh, Y., Obara, T., Fujiya, M., Maemoto, A., Ayabe, T., Ashida, T., Yokota, K., Orii, Y., and Kohgo, Y. (2002) Natural history of colorectal nonpolypoid adenomas: a prospective colonoscopic study and relation with cell kinetics and K-ras mutations. *Am J Gastroenterol*, **97**, 2109-15.
- Wistuba, I., Behrens, C., Albores-Saavedra, J., Delgado, R., Lopez, F., and Gazdar, A.F. (2003) Distinct K-ras mutation pattern characterizes signet ring cell colorectal carcinoma. *Clin Cancer Res*, **9**, 3615-9.
- Yamamoto, H., Itoh, F., Kusano, M., Yoshida, Y., Hinoda, Y., and Imai, K. (1998) Infrequent inactivation of DCC gene in replication error-positive colorectal cancers. *Biochem Biophys Res Commun*, **244**, 204-9.
- Yamamoto, T., Konishi, K., Yamochi, T., Makino, R., Kaneko, K., Shimamura, T., Ota, H., and Mitamura, K. (2003) No major tumorigenic role for beta-catenin in serrated as opposed to conventional colorectal adenomas. *Br J Cancer*, **89**, 152-7.
- Yamamura-Idei, Y., Satonaka, K., Fujimori, T., Maeda, S., and Chiba, T. (1994) p53 mutations in flat- and polypoid-type colorectal tumors detected by temperature-gradient gel electrophoresis. *Dig Dis Sci*, **39**, 2043-8.
- Yamashita, N., Minamoto, T., Ochiai, A., Onda, M., and Esumi, H. (1995) Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. *Gastroenterology*, **108**, 434-40.
- Yamashita, N., Minamoto, T., Ochiai, A., Onda, M., and Esumi, H. (1995) Frequent and characteristic K-ras activation in aberrant crypt foci of colon. Is there preference among K-ras mutants for malignant progression? *Cancer*, **75**, 1527-33.
- Yang, Y., Forslund, A., Remotti, H., Lonnroth, C., Andersson, M., Brevinge, H., Svanberg, E., Lindner, P., Hafstrom, L., Naredi, P., and Lundholm, K. (2001) P53 mutations in primary tumors and subsequent liver

metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. *Cancer*, **91**, 727-36.

Young, J., Simms, L.A., Biden, K.G., Wynter, C., Whitehall, V., Karamatic, R., George, J., Goldblatt, J., Walpole, I., Robin, S.A., Borten, M.M., Stitz, R., Searle, J., McKeone, D., Fraser, L., Purdie, D.R., Podger, K., Price, R., Buttenshaw, R., Walsh, M.D., Barker, M., Leggett, B.A., and Jass, J.R. (2001) Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. *Am J Pathol*, **159**, 2107-16.

Yuan, P., Sun, M.H., Zhang, J.S., Zhu, X.Z., and Shi, D.R. (2001) APC and K-ras gene mutation in aberrant crypt foci of human colon. *World J Gastroenterol*, **7**, 352-6.

Yun, K., Merrie, A.E., Gunn, J., Phillips, L.V., and McCall, J.L. (2000) Keratin 20 is a specific marker of submicroscopic lymph node metastases in colorectal cancer: validation by K-RAS mutations. *J Pathol*, **191**, 21-6.

Zauber, N.P., Sabbath-Solitare, M., Marotta, S.P., and Bishop, D.T. (2003) The characterization of somatic APC mutations in colonic adenomas and carcinomas in Ashkenazi Jews with the APC I1307K variant using linkage disequilibrium. *J Pathol*, **199**, 146-51.

Zauber, N.P., Sabbath-Solitare, M., Marotta, S.P., Zauber, A.G., and Bishop, D.T. (2001) Molecular changes in the Ki-ras and APC genes in colorectal adenomas and carcinomas arising in the same patient. *J Pathol*, **193**, 303-9.

Zauber, N.P., Wang, C., Lee, P.S., Redondo, T.C., Bishop, D.T., and Goel, A. (2004) Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients' survival. *J Clin Pathol*, **57**, 938-42.

Zauber, P., Sabbath-Solitare, M., Marotta, S.P., and Bishop, D.T. (2003) Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. *Mol Pathol*, **56**, 137-40.

Zhang, H., Arbman, G., and Sun, X.F. (2003) Codon 201 polymorphism of DCC gene is a prognostic factor in patients with colorectal cancer. *Cancer Detect Prev*, **27**, 216-21.

Zhang, H., Nordenskjold, B., Dufmats, M., Soderkvist, P., and Sun, X.F. (1998) K-ras mutations in colorectal adenocarcinomas and neighbouring transitional mucosa. *Eur J Cancer*, **34**, 2053-7.

Zhang, J.S., Caplin, S., Bosman, F.T., and Benhantar, J. (1997) Genetic diversity at the p53 locus between primary human colorectal adenocarcinomas and their lymph-node metastases. *Int J Cancer*, **70**, 674-8.

Zhou, X.P., Loukola, A., Salovaara, R., Nystrom-Lahti, M., Peltomaki, P., de la Chapelle, A., Aaltonen, L.A., and Eng, C. (2002) PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. *Am J Pathol*, **161**, 439-47.